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Psychotic symptoms occur in approximately 40% of patients with Alzheimer’s 
disease (AD) and have been linked with striatal dopamine (D2/3) receptor function.  
The first component of the thesis aims to investigate the neuropsychological profile 
accompanying psychotic symptoms in AD, and establish whether cognitive and 
motor tasks which have a documented association with dopaminergic function might 
be markers of psychotic symptoms and delusional subtypes in AD. Dopamine D2/3 
receptor occupancy studies have been instrumental in guiding antipsychotic 
prescribing in schizophrenia. The second part of the thesis aims to adapt 
[
18
F]fallypride imaging for use in healthy older people and in dopamine (D2/3) 
receptor occupancy studies in AD.  
Methods 
Neuropsychology: 70 AD subjects aged between 65 and 95 years were categorised 
into psychotic (n=34) and non-psychotic (n=36) groups, based on carer-rated scales, 
and then compared using a hypothesis-driven test battery.  
Imaging: Eight healthy older (>65 years) adults were scanned twice, 4-6 weeks 
apart. [
18
F]fallypride binding potential (BPND) was determined and test-retest 
variability and intraclass correlation coefficient (ICC) values were calculated. A 
further six subjects with AD were recruited prior to commencing amisulpride 
treatment. [
18
F]fallypride BPND pre/post 2-8 weeks of amisulpride treatment and 
D2/3 occupancy was measured.  
Results 
Neuropsychology: Subjects with psychotic symptoms, in particular misidentification 
phenomena, had significantly poorer sustained attentional and visuoperceptual 
function.  
Imaging: The adapted [
18
F]fallypride scanning protocol showed high reproducibility 




Neuropsychology: Sustained attention deficits may act as a marker of psychotic 
symptoms in AD due to associations with dopaminergic function in the associative 
striatum. Visuoperceptual deficits may indicate additional pathology in the ventral 
visual stream, which could characterize the misidentification subgroup.  
Imaging: The feasibility of an adapted scanning protocol was demonstrated in AD 
subjects and represents the first step towards defining a ‘therapeutic window’ of 
D2/3 occupancy to guide antipsychotic prescribing in AD. 
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Chapter 1: Introduction   
This thesis investigates psychotic symptoms in Alzheimer’s disease (AD), with a 
focus on neuropsychology and imaging. The first component of the thesis aims to 
investigate the neuropsychological profile of psychotic symptoms in AD, and 
establish if test performance measures which have an established association with 
dopaminergic function might act as ‘cognitive markers’ of psychotic symptoms in 
AD. The second component aims to adapt [
18
F]fallypride Positron Emission 
Tomography (PET) imaging for use in healthy older people and in dopamine (D2/3) 
receptor occupancy studies in AD. This chapter is structured as follows: 
1.1 The first section provides a general overview of AD, including epidemiology, 
diagnostic criteria, and cognitive and non-cognitive changes associated with 
the disease. 
1.2 The second section discusses the general anatomy of the dopaminergic 
system, including corticostriatal neurocircuitry, and the classification and 
distribution of receptor subtypes. 
1.3 The third section details the role of dopamine in cognition, motor function 
and psychotic symptoms in AD. 
1.4 The fourth section outlines the aims for the neuropsychological component of 
this thesis. 
1.5 The fifth section discusses the heightened sensitivity to antipsychotic drugs in 
AD, and the use of PET imaging in guiding treatment strategies. 
1.6 The final section outlines the aims for the imaging component of this thesis. 
 
1.1 Alzheimer’s Disease 
1.1.1 Epidemiology 
Dementia is an umbrella term used for a range of neurodegenerative diseases, which 
result in deterioration of cognitive abilities. AD is the most common type of 
dementia, accounting for 50-60% of all cases (Blennow et al., 2006). The prevalence 
of AD demonstrates an almost exponential increase with age; below 1% of those 
aged 60-64 are affected, in comparison to a prevalence of between 24% and 33% in 
those aged above 85 years in the western world (Ferri et al., 2005). In 2010 it was 
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estimated that 36 million people were suffering with dementia globally. Due to the 
anticipated increase in life expectancy, this number is predicted to almost double in 
the next 20 years, and more than triple to an estimated 115 million by 2050 (World 
Alzheimer Report 2012). AD is characteristically a progressive illness, resulting in 
death after 10-15 years from the time of onset, and a median of 6 years from the time 
of diagnosis (Waring et al., 2005). The progressive deterioration in both cognitive 
function and the accompanying non-cognitive symptoms are the pre-requisite for 
growing demands on the health and social care system, causing a large economic 
burden. The World Alzheimer Report 2010 estimated the total worldwide costs of 
dementia to amount to $604 billion (US), with an annual cost of £23 billion in the 
UK alone (Alzheimer’s Society Dementia 2012 report). Costs accumulate due to 
informal care, social care and direct medical expenses. 
 
1.1.2 Diagnostic Criteria 
Attempts to establish diagnostic criteria for AD began in 1952, with the release of 
the first Diagnostic and Statistical Manual (DSM-1) (American Psychiatric 
Association (APA), 1952). In this first edition, AD was not specified, but instead 
referred to as an ‘organic brain syndrome’, which included all neurodegenerative 
disorders causing dementia. It was not until 1980, with the release of the third 
revision of the DSM (DSM-III), that the term AD was included to describe the main 
cause of ‘senile’ age-related dementia (APA, 1994). Subsequent revisions led to the 
widely used DSM-IV criteria, with the fifth and most recent edition published earlier 
this year (May 2013). Another diagnostic manual was devised by the World Health 
Organisation (WHO, 1992), named the International Classification of Diseases 
(ICD). The ICD was developed alongside the DSM, with largely similar codes being 
used for the two manuals (summarised in Table 1.1). The ICD is currently in its tenth 
edition (ICD-10), with international survey results suggesting it is more commonly 
used for clinical diagnosis, in contrast to the DSM which is more valued for research 
purposes. The most commonly used criteria for research however, is that developed 
by the combined efforts of the National Institute of Health (NIH), the National 
Institute of Neurological and Communicative Disease and Stroke (NINCDS) and the 
Alzheimer’s Disease and Related Disorders Association (ADRDA) (McKhann et al., 
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1984) (Table 1.2). This criterion is more detailed than those mentioned above, 
differentiating between possible, probable and definite AD. In 2011, the NINCDS-
ADRDA was revised for the first time in 27 years, to outline new guidelines for both 
the clinical diagnosis of, and research into, AD (McKhann et al., 2011). In contrast 
to the original criteria which only described the later stages of the disease, the new 
guidelines cover the full spectrum of the illness, differentiating between three stages; 
preclinical, mild cognitive impairment, and a final stage of AD. In addition, the new 
guidelines recognise the importance of biomarkers (measures in blood, fluid, or 
imaging) to detect the preclinical stages of the disease, prior to the onset of 
symptoms. The revised criteria were developed by the National Institute of Aging 
(NIA) and the Alzheimer’s Association (AA). 
 
Table 1.1: Summary of ICD-10 and DSM-IV Diagnostic Criteria for AD  
Fulfil criteria for dementia syndrome: 
 multiple cognitive deficits, which must include amnesia 
 functional impairment 
 clear consciousness 
 change from previous level of functioning 
 long duration (at least 6 months)                                                         
Insidious Onset 
Gradual progression 
Absence of focal neurological signs 
Absence of systemic or brain disease sufficient to cause dementia 
(APA 1994; WHO 1992) 
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Table 1.2: Summary of NINCDS-ADRDA Diagnostic Criteria for Probable AD 
Dementia  
(established by clinical examination and documented by the Mini-Mental Test, Blessed 
Dementia Scale, or some similar examination and confirmed by neuropsychological tests) 
Deficits in two or more areas of cognition 
Progressive worsening of memory and other cognitive functions (such as language, motor 
skills and perception) 
No disturbance of consciousness 
Onset between age 40 and 90 
Absence of systemic disorders or other brain diseases that in and of themselves could 
account for progressive deficits in memory and cognition 
Note: Patients who meet the above criteria (McKhann et al., 1984) would also meet the revised 
NINCDS-ADRDA criteria for probable AD (McKhann et al., 2011). 
 
A clinical diagnosis of AD is generally made following a referral by a general 
practitioner to a specialist service, where a cognitive and functional assessment will 
be carried out, together with a physical examination. A detailed, focused history is 
also obtained from an informant. Blood tests are routinely carried out to exclude 
other potentially reversible causes of memory loss, such as vitamin B12 deficiency 
or hypothyroidism. Structural imaging in the form of CT (Computerised 
Tomography) or MRI (Magnetic Resonance Imaging) is also performed to exclude 
the presence of a stroke, normal pressure hydrocephalus, or space occupying lesion. 
The screening measures most widely used in the assessment procedure include the 
Mini-Mental State Examination (MMSE) (Folstein et al., 1975), which is a global 
measure of cognition including five domains: orientation, language, memory, 
attention and praxis. The test is scored out of 30, with scores of 26 suggesting a 
questionable dementia, 21-26 a mild dementia, 11-20 a moderate dementia, and 
below 10 a severe dementia (Folstein et al., 2001). Non-cognitive symptoms are 
rated by an informant, using scales such as the Neuropsychiatric Inventory (NPI) 
(Cummings et al., 1994), which measures the frequency and severity of 12 
behaviours commonly associated with AD, including neuropsychiatric symptoms: 
delusions, hallucinations, apathy, agitation, disinhibition, depression, irritability, 
elation, anxiety, and aberrant motor behaviour; and neurovegetative symptoms: night 
time behaviour and appetite. Additional screening measures include: The Functional 
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Assessment Questionnaire (FAQ) (Pfeffer et al., 1982), used to assess the ability to 
carry out tasks of daily living, and the Global Deterioration Scale (GDS) (Reisberg et 
al., 1982) and Clinical Dementia Rating scale (CDR) (Berg 1988), both of which 
measure the progression of the disease and include cognitive, functional and 
neuropsychiatric domains. 
 
1.1.3 Cognitive Deficits 
AD is characterised by pathology in the medial temporal lobe (e.g. hippocampus, 
and entorhinal cortex), a region critical for episodic memory (Braak & Braak 1991). 
Therefore, impaired episodic memory, characterised by a reduced ability to 
remember new information, is the most prominent symptom of AD, and is listed in 
both the DSM-V and ICD-10 diagnostic criteria (WHO 1992; APA 1994). Such 
symptoms typically occur early in the disease course (Butters et al., 1987; Salmon & 
Bondi 2009), and can include frequent repetition of questions, forgetting names and 
appointments, or mislaying household items. In contrast, distant memories are 
relatively well preserved in mild AD (Beatty et al., 1988). As the disease progresses 
however, memory loss broadens to include older events, and other cognitive domains 
begin to show impairments, including semantic memory, language, attention, 
executive function and visuospatial abilities, discussed below. 
Attention and executive function are well characterised symptoms of AD (Perry & 
Hodges 1999), and have been reported to be the first non-memory domains to 
manifest in AD (Binetti et al., 1996; Lafleche & Albert 1995). Advances in research 
have led to the fractionation of attention into separate components, which include 
‘selective attention’ (the ability to attend to relevant stimuli, whilst screening out 
irrelevant stimuli), ‘divided attention’ (the ability to attend to more than one stimuli 
simultaneously) and ‘sustained attention’ (the ability to focus on one task for 
unbroken periods of time) (Posner & Petersen 1990). Whilst research has shown 
impairments in both divided and certain aspects of selective attention (mainly set-
shifting and response selection) in mild AD, there is a general consensus that 
sustained attention remains fairly intact, at least in the early stages (Perry & Hodges 
1999). This is supported by the normal performance of patients with mild AD on 
tests of immediate attention span, compared with supra-span tests (Cherry et al., 
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2002). However this is not agreed by all, with some reporting increased vigilance 
decrements in mild AD compared to healthy controls (Berardi et al., 2005). 
Executive function involves higher order cognitive processes, which help to plan and 
monitor sequences of actions. Executive deficits are apparent in AD in the form of 
difficulties with everyday tasks such as planning and cooking a meal, travelling to a 
new location, or choosing the appropriate clothes to wear. Neuropsychological tests 
of executive function are difficult to interpret, as many involve aspects of attention. 
However, impairments in performance on several tasks thought to measure executive 
function to a greater degree (Patterson et al., 1996), such as the Porteus Maze test 
(requiring foresight and planning), and part B of the trail-making test (requiring 
concurrent manipulation of information), provide evidence of executive deficits early 
in the course of AD (Grady et al., 1988). Other tests involving the problem solving 
aspect of executive function, such as the Tower of London puzzle (Lange et al., 
1995) and the modified Wisconsin Card Sorting Task (Bondi et al., 1993), are also 
impaired in mild AD patients compared to healthy age-matched controls. 
Specifically, the greatest executive deficits in AD are reported in tasks which involve 
set-shifting and sequencing and monitoring of information, for which the 
simultaneous processing of information is required (Lafleche & Albert 1995). 
Another component of executive function is ‘working memory’, which refers to a 
process whereby information that is the immediate focus of attention is temporarily 
held in a limited-capacity immediate memory buffer, while being manipulated by a 
‘central executive’ (Baddeley 2003). Studies of working memory performance in AD 
suggest deficits are initially mild, perhaps disrupting the central executive only, and 
not the immediate memory. However, as the disease progresses, both components of 
the working memory system are disrupted, resulting in more severe deficits 
(Baddeley et al., 1991; Collette et al., 1999). 
Language deficits are reported in AD and appear to progress in parallel with disease 
severity (Emery 2000). Semantic impairment occurs early in the disease course, 
affecting performance on confrontational naming tasks and verbal fluency (Groves-
Wright et al., 2004). A deterioration of semantic memory is thought to result in many 
of the language difficulties seen in AD, such as word finding difficulties, reduced 
number of words, and content word substitutions or omissions in written language 
(Henderson et al., 1992; Horner et al., 1988; Neils et al., 1989). Support for the 
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involvement of semantic impairment in the early stages of the disease is provided by 
the ability of a word fluency task (semantic) to differentiate between mild-AD and 
healthy controls (Groves-Wright et al., 2004). Phonological difficulties and simpler 
grammatical structures are reported as the disease progresses, together with a 
worsening in spelling performance (Hughes et al., 1997; Kemper et al., 1993; 
Kempler et al., 1998). In a study comparing a range of language abilities between 
healthy controls and patients with mild-AD and moderate-AD, the moderate AD 
group were significantly worse than both other groups on all tasks of written and 
verbal language, and showed greater variability in performance. These results 
suggest that language deficits predominantly occur later in the disease course, and 
individuals are affected with different profiles of deficits (Groves-Wright et al., 
2004).  
Visuospatial deficits are also reported to occur in AD, and can be observed in 
various tasks such as drawing (Ober et al., 1991), copying (Brouwers et al., 1984) 
and construction (Johnson et al., 1997). It has been suggested that visuoperceptual 
abilities are impaired in early AD (Alegret et al., 2009; Binetti et al., 1998), while 
constructional impairments become apparent later in the disease course (Binetti et 
al., 1998).  
Other common cognitive deficits in AD include apraxia; the inability to carry out 
complex motor tasks (Dumont et al., 2000), and agnosia; the inability to recognise 
objects or faces (Goudour et al., 2011).  
 
1.1.4 Neuropsychiatric Deficits 
The non-cognitive symptoms of AD are generally classified into two domains; 
neuropsychiatric symptoms, which include agitation, apathy, disinhibition, 
irritability, aberrant motor behaviour, psychosis, depression, anxiety and elation; and 
neurovegetative symptoms, which relate to sleep and appetite disturbances. The 
umbrella term ‘Behavioural and Psychological Symptoms of Dementia’ (BPSD) 
(Finkel et al., 1996) is typically used to describe the non-cognitive symptoms of 
dementia, which occur in an estimated 90% of patients (Lyketsos et al., 2002). In the 
past, such symptoms have received less attention than the well documented cognitive 
deficits. However, their importance is becoming increasingly recognised given the 
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association with increased carer distress (Deimling & Bass 1986), earlier 
institutionalisation (Steele et al., 1990), more rapid cognitive decline (Ropacki & 
Jeste 2005), and poorer quality of life for the patient and carer (Banerjee et al., 2006; 
Matsui et al., 2006). In addition, BPSD contribute significantly to the overall costs of 
dementia care (Beeri et al., 2002; Herrmann et al., 2006).  
It has been observed that BPSD tend to occur in clusters rather than in isolation, and 
a number of broad groupings have been identified by factor analytical studies which 
have used rating scales designed to measure such symptoms. Comparison between 
studies is difficult however, especially given that many did not differentiate between 
the different aetiologies of dementia. Factor analysis of BPSD in AD has shown 
several distinct factors relating to aggression, affect, psychotic symptoms, and 
frontal lobe dysfunction (disinhibition and activity disturbance) (Cerejeira et al., 
2012). Many of the studies are limited by their small sample sizes and are difficult to 
compare due to differences in assessment measures and study design. Nevertheless, a 
certain degree of concordance between studies does exist, particularly in relation to 
delusions and hallucinations, which have been grouped into a ‘psychosis factor’ in 
all factor analytical studies using the NPI (a rating scale used to assess BPSD). The 
grouping of delusions and hallucinations is supported by the existence of a separate 
diagnostic criteria, which identifies psychosis as a distinct syndrome in AD (Jeste & 
Finkel 2000). It is thought that by identifying discrete subgroups of neuropsychiatric 
symptoms in AD, the recognition of such symptoms and clinical treatments could be 
improved, based on the fact that the co-occurrence of symptoms may represent 
discrete biological underpinnings. The present thesis addresses psychotic symptoms 
in AD, with a particular focus on the role of the neurotransmitter dopamine as a 
possible biological substrate. 
 
1.1.5 Neurobiological changes contributing to cognitive and non-cognitive 
deficits in AD 
Since the 1970s, the ‘cholinergic hypothesis’ has been the predominant theory 
underlying the cognitive symptoms in AD. The cholinergic hypothesis was derived 
from post-mortem studies of AD patients, which found a significant reduction in the 
activity of enzymes involved in the synthesis and degradation of acetylcholine 
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(Bowen et al., 1976; Davies & Maloney 1976). The theory attributes the marked 
memory and learning deficits in AD to acetylcholine loss. Later, lesion and 
pharmacological challenges in experimental animals showed a crucial effect of 
cholinergic neurotransmission on other cognitive symptoms of AD, including 
attentional performance, discrimination learning and avoidance learning and 
habituation (Collerton 1986; Sutherland et al., 1982; Wishaw IQ 1985). More 
recently, pharmacological studies using Cholinesterase Inhibitors (ChEI) in patients 
with AD have shown improved performance on a choice reaction time task and 
visual selective attention task, compared to those taking placebo (Caramelli et al., 
2004; Foldi et al., 2005; Gorus et al., 2007; Sahakian & Coull 1993; Vellas et al., 
2005). 
In 1998, Cummings and Back suggested that the cholinergic hypothesis may also 
underpin BPSD, in particular psychotic symptoms (Cummings & Back 1998). This 
theory is predominantly based on pharmacological studies, which have demonstrated 
a reduction/amelioration of delusions following treatment with ChEIs or muscarinic 
agonists (Bodick et al., 1997; Cummings et al., 1993; Kaufer et al., 1996; Paleacu et 
al., 2002; Raskind et al., 1997). Further evidence for a role of cholinergic 
neurotransmission in psychosis is provided by the fact that delusions correlate with 
regions showing marked cholinergic deficits, including the temporal and frontal 
lobes (Kotrla et al., 1995; Mentis et al., 1995; Starkstein et al., 1994; Sultzer et al., 
1995; Procter et al., 1988).   
However, some authors argue that cholinergic deficits alone may not be enough to 
explain the cognitive and non-cognitive symptoms of AD, and suggest that 
perturbation of the dynamic balance between acetylcholine and other 
neurotransmitters, such as serotonin (Garcia-Alloza et al.,  2005), and/or dopamine  
(Cummings et al., 2011), may play a crucial role (Dringenberg 2000; Cummings et 
al, 2011; Garcia-Alloza et al., 2005). 
The present thesis will focus on the role of dopamine as a possible biological 
substrate of motor, cognitive and neuropsychiatric control in AD. In AD, dopamine 
transmission is relatively preserved (Cummings et al., 2011, Piggott et al., 1999) in 
contrast to the well documented cholinergic deficits (reviewed by Francis et al., 
(1999)). Therefore, dopamine is likely to maintain its role in motor control and 
cognition, and may contribute to the formation of psychotic symptoms. An overview 
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of the dopaminergic system is given in Section 1.2, followed by a description of its 
role in motor control, cognition and psychotic symptoms in Section 1.3.  
 
1.2 The Dopaminergic System 
1.2.1 Neuroanatomy of Corticostriatal Neurocircuitry 
The striatum receives the densest dopaminergic innervation in the mammalian brain, 
with afferents arising from neurons in the substantia nigra and the ventral tegmental 
area of the midbrain (Andén et al., 1966; Björklund et al., 1984). Initially, the role of 
dopamine in the striatum was thought to be limited solely to motor control, given the 
movement deficits observed in Parkinson’s disease (PD) following nigrostriatal 
dopaminergic denervation (Hornykiewicz & Kish 1987). The role of the basal 
ganglia in motor control soon became apparent, with early evidence suggesting that 
the basal ganglia received striatal inputs from the entire cerebral cortex, which were 
integrated via the ventrolateral thalamus, and projected back to the motor cortex 
(Allen & Tsukahara 1974; Evarts & Thach 1969; Kemp & Powell 1971). However, 
later evidence suggested that two distinct loops pass through the basal ganglia, one 
‘motor’ loop, which receives inputs from the sensorimotor cortex and projects to 
premotor areas, and one ‘association’ loop, which receives inputs from the 
association areas and projects to portions of the prefrontal cortex (DeLong & 
Georgopoulos 1981). Further research led to the suggestion of four additional 
circuits organised in parallel with the motor circuit. Each circuit engages specific 
regions of the cerebral cortex, which project through the basal ganglia to the 
thalamus, and back to a specific region of the cortex. The five proposed basal 




Figure 1.1: Parallel Loop Model  
 
 
(Postuma & Dagher 2006) 
 
The existence of multiple closed loop circuits was confirmed by Middleton and 
Strick, who used the retrograde transneuronal transport of the herpes simplex virus 
type 1 (HSV1) to trace the circuitry of the central nervous system (CNS) in primates, 
and therefore map the basal ganglia projections (Middleton & Strick 2000). The 
anatomy of the fronto-striato-thalamic loops supports a role for dopamine in 
cognitive and emotional processes, as well as motor control, and is discussed later in 
this chapter.  
There are differing views as to the organisation of corticostriatal connectivity. Some 
authors have suggested that each cortical region is projected in a strict topographical 
manner to the striatum, and that each striatal region receives projections from the 
nearest cortical area (Kemp & Powell 1970). However, given that non-adjacent 
cortical areas (e.g. prefrontal and parietal cortices) project to adjacent striatal 
territories (Selemon & Goldman-Rakic 1985), others have argued against a 
topographical organisation and instead proposed a tripartite functional division of the 
striatum into motor, associative, and limbic areas (Parent 1990). The 3 subdivisions 
include: associative striatum (consisting of the rostral putamen and most of the head 
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of the caudate), which receives its densest input from the dorsolateral prefrontal 
cortex; sensorimotor striatum (consisting of the caudal and dorsolateral putamen and 
dorsolateral rim of the caudate), which receives input from motor and premotor 
cortices; and limbic striatum (consisting of the ventral caudate and putamen, 
including the nucleus accumbens), which receives projections from the orbital and 
medial frontal cortex. The differences in anatomical connections reflect the distinct 
functional subdivisions of this model, whereby the associative striatum is involved in 
attention and executive control (Selemon & Goldman-Rakic 1985), the sensorimotor 
division is involved in motor control and coordination (Flaherty & Graybiel 1994), 
and the limbic striatum plays a role in motivational and reward processes (Kunishio 
& Haber 1994). The tripartite subdivision model is consistent with the parallel loop 
theory (Alexander et al., 1986), which proposed multiple segregated circuits 
conveying either sensorimotor (motor and oculomotor loops), associative 
(dorsolateral prefrontal and lateral orbitofrontal loops) or limbic (anterior cingulate 
loop) information (Alexander & Crutcher 1990). However, the tripartite functional 
organisation of the cortico-striatal projections does not imply further functional 
subdivisions within each striatal region, as proposed by the parallelist view. 
 
1.2.2 Classification of Dopamine Receptors 
Adenosine 3',5'-monophosphate (cyclic AMP) is a second messenger molecule, 
involved in intracellular signal transduction, and is activated by the enzyme adenylyl 
cyclase (McAfee et al., 1971). Dopamine receptors were initially thought to exist as 
two discrete subtypes, one which is positively coupled to adenylyl cyclase, and one 
independent of cAMP. The two subtypes were identified as D1 and D2 receptors, 
respectively (Kebabian & Calne 1979). After about a decade, the introduction of 
gene cloning procedures identified three new subtypes of receptors, which were 
named D3 (Sokoloff et al., 1990), D4 (Van Tol et al., 1991) and D5 (Sunahara et al., 
1991). However, it was later suggested that all the receptor subtypes fall into the two 
initial classifications, referred to as D1-like (D1, D5) and D2-like (D2, D3, D4) 
(Missale et al., 1998). There are significant structural and ligand binding 
characteristics within each receptor family, for example a 75% homology between 
the transmembrane domains of D2 and D3 receptors (Missale et al., 1998). This is 
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reflected in reports from pharmacological studies which demonstrate D3 receptors to 
bind to D2-selective ligands with relatively high affinity (Seeman & Van Tol 1994). 
An example of this would be the use of D2-selective radiotracers used in PET 
imaging, which are unable to differentiate between the two receptors. As a result, 
such tracers are referred to as D2/3 receptor tracers, and the possibility of D3 binding 
cannot be excluded in the interpretation of results. 
 
1.2.3 Distribution of Dopamine Receptors 
Given the absence of ligands specific to each receptor subtype, the distribution of 
dopamine receptor messenger (m)RNA has been studied using in situ hybridisation. 
D2 receptor mRNA is present in all major brain regions receiving dopaminergic 
projections, but is predominantly expressed in the striatum (Bouthenet et al., 1991). 
D2 receptor mRNA is highly expressed in the cell bodies of dopamine neurons in the 
substantia nigra and ventral tegmental area. This suggests an additional role of D2 
receptors in modulating dopaminergic transmission through pre-synaptic 
autoreceptors, and is supported by studies of mice lacking the D2 receptor gene 
(Dickinson et al., 1999; Mercuri et al., 1997). In contrast to the widespread 
distribution of D2 dopamine receptors, D3 receptors have a more restricted 
distribution, with mRNA primarily being expressed in limbic regions, in particular 
the nucleus accumbens (ventral striatum) (Bouthenet et al., 1991). D3 receptor 
mRNA is poorly expressed in the dorsal striatum. The different distributions of the 
two receptors may help to interpret data from imaging studies which have used D2/3 
receptor radiotracers.  
Of the other receptor subtypes, D1 receptors are the most widely distributed and the 
most abundant of the receptor subtypes, with the highest levels of mRNA detected in 
the caudate, putamen, nucleus accumbens, and olfactory tubercle. Cells expressing 
D1 receptor mRNA were also detected in the cerebral cortex, limbic system, 
hypothalamus, and thalamus (Fremeau et al., 1991).  
D4 receptor mRNA is found in many brain regions, including the frontal cortex, 
amygdala, hippocampus, hypothalamus, pituitary and the retina (Cohen et al., 1992; 
Van Tol et al., 1991), albeit at lower levels than D1 and D2 receptors. The 
32 
distribution of D5 receptors has been more difficult to measure, due to the 
similarities between dopamine D1 and D5 sequences (Sunahara et al., 1991).  
 
1.3 Dopaminergic Control of Movement, Cognition and Psychosis in AD 
1.3.1 Role of Dopamine in Motor Control 
Overview 
The role of the dopaminergic system in movement control has been well documented 
since the initial finding that nigrostriatal dopamine loss was responsible for the 
motor deficits seen in patients with PD (Bernheimer & Hornykiewicz 1965). Of the 
basal ganglia-thalamocortical circuits, the motor loop has been the most extensively 
studied, due to its importance in motor disorders, such as PD and Huntington’s 
disease (Wichmann & DeLong 1996). Research has identified two pathways in the 
control of movement through the basal ganglia; the direct and indirect pathways 
(illustrated in Figure 1.2). Dopaminergic input from the substantia nigra pars 
compacta (SNc) induces excitation in the direct pathway, via activation of dopamine 
D1 receptors, and inhibition in the indirect pathway via D2 receptors. The direct 
pathway facilitates movement by decreasing inhibitory output from the internal 
globus pallidus (GPi) to the thalamus, while the indirect pathway suppresses 
movements by increasing the inhibitory outputs of the basal ganglia. Disruption of 
the dopaminergic system therefore deregulates the circuit, resulting in movement 
disorders. At the level of the striatum, the motor circuit is largely controlled by the 
putamen (Kunzle 1975), supporting the functional subdivisions of the striatum 
described earlier. The role of the D2 receptor in motor control is supported by the 
extrapyramidal side effects of antipsychotic drugs (tremor and bradykinesia), which 
antagonise D2 receptor sites. 
 
Dopamine and Motor Control in AD 
In AD, nigrostriatal dopamine is relatively preserved (Piggott et al., 1999). However, 
extrapyramidal symptoms (EPS) (bradykinesia and rigidity) are reported to emerge 
in 35-40% of patients (Murray et al., 1995). Evidence regarding the dopaminergic 
contribution to such symptoms is unclear, with some studies reporting reduced 
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markers of nigrostriatal  dopamine function post-mortem (Joyce et al., 1998; Murray 
et al., 1995; Sahlberg et al., 1998) and in vivo (Rinne et al., 1998), while others 
report little or no abnormalities in nigrostriatal dopaminergic function in those with 
EPS (Piggott et al., 1999; Tyrrell et al., 1990). The latter studies suggest that 
extranigral factors may be contributing to the bradykinesia and rigidity observed in 
patients with AD. Only one study to date has directly assessed the role of D2/3 
receptors in motor control in AD. This study used PET imaging to demonstrate a 
significant association between higher striatal D2/3 receptor availability and 
increased motor speed (Reeves et al., 2010). The association was most marked in the 
sensorimotor striatum, consistent with the corticostriatal circuitry described in 
Section 1.2.1, whereby the sensorimotor striatum receives its densest input from 
motor and premotor cortices (Flaherty & Graybiel 1994). 
 
Figure 1.2: The Direct and Indirect Pathways of Motor Control 
 
 





1.3.2 Role of Dopamine in Cognitive Control 
Overview  
Cognitive deficits are frequently reported in a range of neurological disorders in 
which dopamine has been implicated, including schizophrenia, attention deficit 
hyperactivity disorder (ADHD), and PD (Nieoullon 2002). Such observations, 
together with awareness that the basal ganglia project to several non-motor areas, 
support the role of dopamine in influencing a broad range of behaviours (Alexander 
et al., 1986). One of the most established findings of the role of dopamine in 
cognition came from the work of Goldman-Rakic’s research group, who reported 
that specific cortical depletion of dopamine by 6-Hydroxydopamine (6-OHDA) 
impaired performance on a working memory task in monkeys (Brozoski et al., 
1979). In humans, pharmacological agents which reduce dopamine transmission by 
either antagonising dopamine receptors, or depleting dopamine precursors, such as 
tyrosine and phenylalanine, have resulted in impaired performance on a range of 
executive tasks such as working memory, planning, and attentional set shifting 
(Harmer et al., 2001; Mehta et al., 1999). 
In vivo evidence of the role of D2/3 receptors in cognition is provided by PET and 
single photon emission computerised tomography (SPECT) studies, which report 
decreased striatal binding to be associated with tasks of working memory and other 
executive functions (Backman et al., 2000; Lawrence et al., 1998; Reeves et al., 
2005; Volkow et al., 1998; Yang et al., 2004). The recent development of higher 
affinity D2/3 radiotracers such as [
11
C]FLB-457, has enabled the role of D2/3 
receptors outside the striatum to be investigated, and studies have suggested a role of 
hippocampal D2/3 receptors in memory. Other tasks requiring executive processes 
were also associated with hippocampal D2/3 receptor availability, a finding which 
the authors explained by a postulated hippocampal-prefrontal pathway (Takahashi et 
al., 2007; Takahashi et al., 2008).  
 
Dopamine and Cognitive Control in AD 
Few studies have looked directly at the impact of dopaminergic function upon 
cognition in AD. A single study proposed that hippocampal D2/3 receptors 
contribute to performance on tasks of memory and naming in AD (Kemppainen et 
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al., 2003). This suggestion was based on two findings: firstly, D2 receptor 
availability was reduced by 34% and 14% in the right and left hippocampus 
respectively in AD patients compared to healthy controls; and secondly, the 
magnitude of binding was positively associated with verbal memory performance 
and picture naming. Further support for the role of dopamine in cognition is provided 
by a study which demonstrated that increased striatal dopamine synthesis capacity in 
AD was associated with higher scores on the MMSE (Itoh et al., 1994). Most 
recently, the D2/3 radiotracer [
11
C]raclopride was used to examine the association 
between striatal D2/3 receptor availability and cognition. This study found higher 
striatal D2/3 receptor availability to correlate with sustained attentional performance, 
with the most marked correlation occurring in the associative striatum. This finding 
is consistent with the corticostriatal neurocircuitry described in Section 1.2.1, 
whereby the associative striatum receives its densest input from the prefrontal cortex 
and has a primary role in attention and executive function (Selemon & Goldman-
Rakic 1985). The same study also showed a trend-level association between striatal 
D2/3 receptor availability and verbal episodic memory (Reeves et al., 2010).  
 
1.3.3 Role of Dopamine in Psychosis 
Overview 
In addition to cognitive and motor control, dopamine has also been strongly 
implicated in psychosis. Perhaps one of the most widely researched roles of 
dopamine is in relation to schizophrenia, a disorder with positive symptoms 
(hallucinations, delusions), negative symptoms, and formal thought disorder. The 
first direct evidence of a dopaminergic underpinning to schizophrenia came about in 
the 1970s, following observations of a high correlation between the antipsychotic 
potency of neuroleptic drugs and their affinity for binding to dopamine receptors 
(Creese et al., 1976; Seeman et al., 1975). Subsequent studies using neuroimaging 
techniques provided further evidence of the role of dopamine in psychosis, reporting 
an increased striatal density of D2 receptors in drug-naïve schizophrenic patients 
(Wong et al., 1986), and excessive striatal dopamine release in psychotic patients in 
response to amphetamine challenge (Laruelle et al., 1996). Such studies provided 
direct evidence that psychotic symptoms were promoted by excessive D2 receptor 
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stimulation. Contemporary theories of psychosis have integrated the dopamine 
hypothesis of schizophrenia with data on motivational salience, to suggest that 
aberrant signalling of salience due to excessive striatal dopamine activity plays a key 
role in delusion formation (Kapur 2003). The pre-synaptic dopamine system has also 
been implicated in psychosis. Studies have demonstrated increased striatal dopamine 
synthesis capacity (Howes et al., 2007), and increased responsivity of presynaptic 
striatal dopamine neurones to psychostimulant challenge (Breier et al., 1997) in 
young adults with schizophrenia compared to their healthy counterparts. 
 
Dopamine and Psychosis in AD 
Psychotic symptoms are common in AD, with their prevalence increasing from 
approximately 25% in mild-AD (MMSE score 21-25) to 50% in those with severe 
cognitive impairment (MMSE score 10 or below) (Ropacki & Jeste 2005). 
Contemporary theories suggest that disruption of the cholinergic/dopaminergic axis 
plays a central role in the formation of delusions in AD (Cummings 1992) (discussed 
in Chapter 3, Section 3.1.2). This theory, reviewed by Reeves et al. (2012), overlaps 
with that of Kapur et al. (2003), whereby relative hyperdopaminergia leads to 
misinterpretation of the environment (Kapur 2003). In support of these theories is 
evidence that cholinergic denervation in rodents increases striatal dopamine release 
in response to amphetamine challenge, and subsequently results in psychotic-like 
behaviour (Mattsson et al., 2007; Mattsson et al., 2004). A dopaminergic 
contribution to psychotic symptoms in AD is supported by in vitro research, which 
suggests a 70% increase in D3 receptor density in AD patients with a history of 
psychosis, compared to their non-psychotic counterparts (Sweet et al., 2001). The 
involvement of dopamine receptors in psychosis is also supported by genetic studies, 
which have shown variations in the genes encoding D1 and D3 receptors to be 
associated with hallucinations and delusions, respectively, in AD (Holmes et al., 
2001). More recently, in vivo evidence has emerged showing increased striatal D2/3 
receptors in those with delusions in AD, compared to those without delusions 
(Reeves et al., 2009).  
In summary, dopamine has been implicated in motor control, cognition and 
psychotic symptoms in AD, and this has been recently demonstrated in vivo by 
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Reeves and colleagues (Reeves et al., 2009; Reeves et al., 2010) in a sample of 
patients with mild to moderate AD. These findings raise questions as to whether 
cognitive and motor tasks associated with dopaminergic function could perhaps act 
as markers of psychotic symptoms in AD. However, the small sample size (N = 23; 7 
psychotic) in these studies meant that it was not possible to meaningfully compare 
psychotic and non-psychotic groups in terms of test performance. The present thesis 
aims to address this question, and will be discussed in further detail in Chapter 3.  
 
1.4 Aims of Thesis: Part 1  
Neuropsychological Assessment 
 To test the hypothesis that performance on tests with a demonstrated link 
with dopamine (striatal D2/3 receptor) function will differ in psychotic versus 
non-psychotic patients with AD, after controlling for differences in age, 
education and MMSE.  
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1.5 Treatment of Psychotic Symptoms in AD 
1.5.1 Antipsychotic Medication: Mechanism of Action  
Antipsychotic medication is prescribed across a range of disorders for the treatment 
of psychotic symptoms (delusions and hallucinations). The primary mechanism of 
action of antipsychotic drugs is antagonism at D2/3 receptor sites. However, due to 
the crucial role of the dopaminergic system in motor control (Section 1.3.1), motor 
side effects known as extrapyramidal symptoms (EPS) commonly occur, and include 
bradykinesia, tremor and rigidity. Such side effects are a serious concern when 
treating psychotic disorders.  
 
1.5.2 Use of PET Imaging to Guide Antipsychotic Prescribing 
PET imaging has been instrumental in guiding treatment strategies in schizophrenia, 
through the investigation of the relationship between drug dose, blood levels and 
central D2/3 occupancy. Studies carried out in the early 1990s established that there 
is a ‘therapeutic window’ of D2/3 receptor occupancy, within which symptom 
reduction is accompanied by minimal EPS. In vivo imaging of dopamine D2/3 
receptors was first achieved by Wagner and colleagues in 1983 (Wagner et al., 
1983). Following this, several studies used PET imaging techniques to study the role 
of D2 receptors in antipsychotic response, and reported high D2/3 occupancy in 
patients treated with antipsychotic drugs (Cambon et al., 1987; Farde et al., 1986; 
Smith et al., 1988). In 1988, Farde et al. reported 65-85% occupancy of D2/3 
receptors in patients treated with 11 chemically distinct antipsychotics (Farde et al., 
1988). These studies provided direct in vivo evidence that antipsychotic effects were 
mediated by D2/3 receptors. In 1992, Farde et al. was the first to measure the 
correlation between D2/3 receptor occupancy and the clinical effects of antipsychotic 
treatment (Farde et al., 1992). In an open study of 22 patients with schizophrenia, the 
authors observed a uniformly high D2/3 occupancy of 70-89% at conventional doses, 
and that occupancy was higher in patients exhibiting EPS. These results were 
supported by Nyberg and colleagues, who reported a threshold for antipsychotic 
effects at about 70%, and a distinct threshold for EPS at 80%. Based on these 
findings, the authors postulated a ‘therapeutic window’ of 70-80% D2/3 occupancy, 
illustrated in Figure 1.3 (Nyberg et al., 1995). Two double blinded studies supported 
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the observation of a ‘therapeutic window’, and in particular the threshold of 80% 
occupancy for EPS. However, both studies suggested a lower threshold of 60-65% 
for antipsychotic effects (Kapur et al., 2000; Nordström et al., 1993). Taken together, 
these studies led to the suggestion of a ‘therapeutic window’ of 60-80% D2/3 
occupancy in young adults, in order to achieve adequate antipsychotic response with 
low or minimal side effects (Kapur 1998). A direct application of the above findings 
is observed in studies which have reduced the recommended daily dosage of 
antipsychotic drugs, based on D2/3 occupancies falling within the ‘therapeutic 
window’. For example, D2/3 occupancy data suggest 4mg of risperidone as the 
optimal starting dose in schizophrenic patients, as opposed to 6mg (previously 
suggested as the standard dose), which caused unnecessarily high D2/3 occupancy 
and resulted in EPS (Nyberg et al., 1999). Similarly, 2-3mg of haloperidol is 
recommended, in contrast to 10-20mg advised in previous studies (Kapur et al., 
2000). This imaging paradigm has led to huge clinical advances, not only in terms of 
guiding treatment strategies of schizophrenia in young adults, but also in the 
development and evaluation of new antipsychotics (de Greef et al., 2011), the 
comparison of existing antipsychotics (Kapur et al., 1999), and also in developing 
clinically comparable animal models for the testing of antipsychotic medication 
(Kapur et al., 2003). The ‘therapeutic window’ of antipsychotic drug action is now 
widely accepted and has been the subject of several review articles (de Greef et al., 
2011; Nord & Farde 2011; Pani et al., 2007). 





C]FLB-457 have allowed D2/3 receptor availability to be measured in extrastriatal 
regions, where receptors are present at a much lower density compared to the 
striatum. This has enabled the role of extrastriatal D2/3 receptors in antipsychotic 
treatment response to be investigated. Such studies have shown atypical 
antipsychotics to have higher occupancies in the temporal cortex compared to the 
striatum (Bigliani et al., 2000; Pilowsky et al., 1997; Xiberas et al., 2001b). 
Additional studies have implicated temporal cortical D2/3 receptor occupancy in 
response but not adverse effect profile (Stone et al., 2009). Exploration of the clinical 
relevance of extrastriatal D2/3 receptor occupancy by antipsychotic drugs is an on-
going focus of research (discussed in Chapter 4). 
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In contrast to the abundance of data on D2/3 occupancy in young adults, this area has 
been largely neglected in the older population, including those with AD, who are 
highly sensitive to antipsychotic side effects and would benefit from the optimisation 
of antipsychotic dosing regimens. 
 





(Nord & Farde 2011)  
 
1.5.3 Antipsychotic Sensitivity in AD 
Current prescribing of antipsychotics in AD is associated with a range of side effects 
including: EPS (bradykinesia, tremor), sedation, postural hypotension, falls, 
cerebrovascular events (stroke, transient ischemic attacks) and increased mortality 
(Ballard & Howard 2006). In a meta-analysis of placebo controlled trials of atypical 
antipsychotics (Ballard & Howard 2006), AD patients treated with risperidone were 
twice as likely to experience EPS compared to those taking placebo, even at low 
doses of 1-2mg. Use of risperidone was also associated with fever and peripheral 
oedema, while both risperidone and olanzapine significantly increased drowsiness. 
Both antipsychotics were also reported to cause a 3 fold increase in serious 
cardiovascular events compared to placebo. Out of a total of 17 placebo controlled 
trials, using a range of antipsychotics in elderly patients with AD, 15 studies 
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demonstrated numerical increases of approximately 1.7 fold for the risk of mortality 
in the drug treated group, compared to those taking placebo. These studies enrolled 
over 5000 patients in total and were analysed by several groups (Schneider et al., 
2005). Examination of the deaths revealed that the majority were caused by 
cardiovascular events or infections (mostly pneumonia). These findings led to the 
FDA issuing a black box warning in 2005 against the use of antipsychotics in AD 
(Leon et al., 2010). As a result, the majority of antipsychotics are not licensed to 
treat neuropsychiatric symptoms of dementia. However, despite the risks, many are 
still prescribed off-label due to the lack of alternative pharmacological treatments for 
behavioural or psychotic symptoms. 
The reasons for the heightened sensitivity to antipsychotic drugs observed in the 
elderly are poorly understood. Several theories have been proposed (illustrated in 
Figure 1.4) including: the peripheral pharmacokinetic theory, whereby a higher drug 
plasma level is reported for a given dose; the central pharmacokinetic theory, which 
proposes higher D2/3 occupancies for a given dose of drug; and the 
pharmacodynamic theory, which postulates that an age-related reduction in D2/3 
receptor reserve results in a greater functional outcome for a given D2/3 receptor 
occupancy (Uchida et al., 2009b) (discussed in Chapter 5).  
However, no studies have directly assessed the contribution of each of these theories 
to the heightened antipsychotic sensitivity observed in AD. To date, there have been 
no studies of D2/3 receptor occupancy in patients with AD, nor any research into the 
clinical relevance of extrastriatal D2/3 receptors to therapeutic response in this 
population. There is an urgent clinical need for both lines of research in the AD 
population, in order to improve efficacy and reduce adverse effects with 
antipsychotic drugs. One reason for the lack of research in older adults is the fact that 
many scanning protocols require lengthy periods of time in the scanner, which is 
particularly difficult for patients with cognitive impairment. Adapting the scanning 
procedure to reduce the time spent in the scanner could enable the advancement of 
research in this field. This issue is addressed in further detail in Chapter 4.  
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1.6 Aims of Thesis: Part 2 
PET Imaging 
1. To determine the test-retest reliability of regional binding of the PET 
dopamine D2/3 receptor radiotracer [
18
F]fallypride in eight healthy older 
(>65 years) adults, using a protocol that has been specifically adapted to 
minimise the amount of time spent in the scanner, thus making it feasible for 
use in the older population. 
2. To further adapt and optimise [18F]fallypride imaging for use in D2/3 







Figure 1.4: Mechanisms of Antipsychotic Sensitivity in the Elderly 
 
 
(Uchida et al., 2009b) 
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Chapter 2: Overview of Methodology  
This chapter provides a general overview of the methodology employed in the 
present thesis. There are three experimental studies in this thesis, one which 
evaluates neuropsychological tests and two which involve PET imaging. This 
chapter has been divided into two parts, in order to deal with the neuropsychology 
and imaging components separately. Part 1 details the methodology relating to 
neuropsychological testing and Part 2 details the methodology used for the PET 
imaging studies. The structure within each part is outlined below. 
 
Part 1: Neuropsychological Testing 
2.1 Methodology used to establish the neuropsychological profile of psychotic 
 symptoms in AD. This includes study design, subject criteria, informed 
 consent procedure, ethical approval, and sample size considerations. 
2.2 Rationale provided for the choice of neuropsychological tests and carer-
 rated measures, and details of how these tests were administered. 
2.3 Data analysis.  
 
Part 2: PET Imaging 
2.4 Overview of methodology associated with PET. This includes the principles 
 of PET imaging, PET quantification and choice of radioligand. 
2.5 Methodology used to establish the test-retest reliability of an adapted 
 [
18
F]fallypride PET imaging protocol in older people. This includes study
 design, subject criteria, informed consent procedure and the scanning 
 protocol. 
2.6 Methodology used to optimise [
18
F]fallypride PET imaging for D2/3 receptor 
 occupancy studies in AD. This includes study design, subject criteria, 
 informed consent procedure, scanning protocols, and a description of the 
 cognitive and  motor tests used for baseline and follow up assessments. 
2.7 General methodology common to both experiments including: ethical 
 approval, sample size and general data analysis. 
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2.1 Neuropsychological Profile 
2.1.1 Summary of Study Design 
Subjects with AD (Group 1 with psychotic symptoms, Group 2 without psychotic 
symptoms) were recruited to the study with the aim of establishing the 
neuropsychological profile of psychotic symptoms in AD. Subjects completed a 
neuropsychological test battery over two visits (1 week apart). The test battery 
included computerised and pen-and-paper measures that assessed performance in 
different cognitive domains. Carer-rated scales of symptom severity were used to 
determine the frequency and severity of psychotic symptoms (delusions and 
hallucinations). 
 
2.1.2 Recruitment and Screening 
Inclusion Criteria 
Patients were included in the study if they were aged between 65 and 95 years and 
fulfilled NINCDS-ADRDA criteria for AD (McKhann et al., 1984) (described in 
Chapter 1, Section 1.1.2). 
 
Exclusion Criteria 
Patients were excluded from taking part on the basis of medical, psychiatric and 
medication history. In terms of medical history, exclusion criteria included a history 
of epilepsy, substance misuse, traumatic brain injury or addiction (which was 
confirmed with the referring medical practitioner). The Geriatric Depression Scale-
15 (described in Section 2.2.1) was administered with a cut off score of <6 out of 15 
to exclude those with depression, which may have affected performance on the test 
battery. Patients were also excluded on the basis of past or current psychiatric illness 
(confirmed with the referring medical practitioner). A detailed medication history 
was taken and patients were excluded if they were prescribed psychotropic 
medication (including antidepressants and anxiolytics), or other medication that 
might interfere with dopamine function. A modified version of The Unified 
Parkinson’s Disease Rating Scale (Ballard et al., 1997) (described in Section 2.2.1) 
was used to screen for the presence of overt motor symptoms (bradykinesia, rigidity, 
facial masking or tremor). Patients with a score of >8 were excluded, in order to rule 
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out the potential confounding influence of motor symptoms upon striatal 
dopaminergic indices, and to avoid the potential for inclusion of patients with Lewy 
Body Dementia (DLB). Patients with other symptoms suggestive of a possible 
diagnosis of DLB (frequent falls/syncope, prominent visual hallucinations, or 
marked fluctuation in cognitive ability) were also excluded. A score of <10 on the 
MMSE (described in Section 2.2.1) was also a cause for exclusion in order to avoid 
floor effects on the neuropsychological tests. 
 
Recruitment Procedure 
Subjects were recruited from the Institute of Psychiatry Dementia Case Register (n = 
3, described in Section 2.5.2), memory clinics (n = 66), and community mental 
health teams for older adults (n = 11) within the catchment area of the South London 
and Maudsley NHS Foundation Trust (SLaM). The researcher attended weekly team 
meetings at the Croydon Memory Service to identify potential candidates for the 
study. In an attempt to facilitate recruitment further, permission was obtained from 
Consultant Psychiatrists and keyworkers within each of the teams, to search their 
caseloads on the Electronic Patient Records System for potential subjects. Once the 
keyworkers consented to their patients being contacted, the researcher made initial 
contact with the patients via the telephone. After obtaining verbal consent, a one-
page summary leaflet and more detailed information sheet were sent in the post to 
the patients and their caregivers, respectively. A follow-up phone call was made to 
the patients to confirm participation and arrange the first visit. This procedure 
allowed patients to digest the information provided to them before giving informed 
consent to participate. The summary leaflet and information sheet used for this study 
are detailed in Appendix 7.1.1. Recruitment took place between January 2011 and 
November 2012. 
 
Informed Consent Procedure 
Written informed consent from each subject was obtained upon recruitment to the 
study (see Appendix 7.1.1 for the consent form).  
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2.1.3 Ethical Approval 
This study was approved by The Joint South London and Maudsley and Institute of 
Psychiatry NHS Research Ethics Committee (written approval is listed in Appendix 
7.2). 
 
2.1.4 Sample Size Considerations 
Sample size was determined using previous data on AD patients, where the standard 
deviation (SD) of motor speed was 20% and mean motor speed was found to be 11% 
higher in the psychotic (n = 7) compared to non-psychotic (n = 16) group (Reeves et 
al., 2010). To detect a between-group difference of 11% in mean motor speed, a 
sample size of 50 in each group would be required (power = 0.8, alpha = 0.05; 
independent samples t-test); and a sample size of 35 in each group would allow 
differences of 13.6% to be detected. 
 
2.2 Neuropsychological Testing 
2.2.1 Screening Tools 
Delusions and Hallucinations 
A modified version of The Neuropsychiatric Inventory (NPI) (Cummings et al., 
1994) was used as a screening tool to identify patients with delusions and 
hallucinations (see Appendix 7.3). The NPI is a caregiver rated scale that evaluates 
12 areas of psychopathology in dementia, 10 neuropsychiatric symptoms (delusions, 
hallucinations, agitation, depression/ dysphoria, anxiety, euphoria/elation, apathy, 
disinhibition, irritability and aberrant motor behaviour) and two neurovegetative 
symptoms (sleep and appetite). Caregivers are first asked a screening question to 
determine whether or not the symptom is present. If the answer to the screening 
question is yes, the caregiver is asked about the symptom in further detail and asked 
to rate the frequency and severity with which it occurs. The NPI has been shown to 
have good validity and reliability (Cummings et al., 1994). 
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The screening tools below were used in order to control for the confounding effects 
of global cognitive functioning, intellectual functioning, level of affect, and 
dopaminergic function, on other neuropsychological test measures. 
 
Brief Cognitive Screening 
The Mini-Mental State Exam (MMSE) (Folstein et al., 1975) was used to briefly 
assess global cognitive functioning. The MMSE consists of five subtests in the 
domains of orientation, language, memory, attention and praxis. It is scored out of a 
total of 30 points, higher scores indicating better performance.  
 
Premorbid Intellectual Functioning 
The National Adult Reading Test (NART) (Nelson 1982) was used to provide an 
estimation of premorbid intellectual functioning. The number of NART errors was 
used to predict Performance Intelligence Quotient scores (Wechsler 1955), based on 
regression equations presented by Nelson (1982). The test consists of 50 short words 
of irregular pronunciation (e.g. deny, prelate). Subjects are asked to read each word 
out aloud, and the total number of pronunciation errors (out of 50) is recorded.  
 
Geriatric Depression Scale-15 
The Geriatric Depression Scale-15 (GDS-15) (Yesavage et al., 1982) which is 
specifically designed for use in the older population, was used as a screening tool for 
depression. The test consists of 15 ‘yes’ or ‘no’ questions regarding the subject’s 
mood. The simplicity of the questionnaire enables its use in those with cognitive 
impairment.  
 
Unified Parkinson’s Disease Rating Scale 
The Unified Parkinson’s Disease Rating Scale (UPDRS) (Motor Examination) 
(Ballard et al., 1997) was used to screen for the presence of parkinsonian symptoms, 
and hence disruption to the dopaminergic system. The modified version used in the 
present study focused solely on overt motor symptoms including bradykinesia, 
rigidity, facial masking, resting tremor, and action or postural tremor. Each symptom 
was rated on a scale from 0 (no symptom) to 4 (marked symptoms) and added 
together to give a total score out of 20.  
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2.2.2 Hypothesis-Driven Tests 
Two neuropsychological tests were chosen on the basis of demonstrated links with 
dopaminergic function, and are described in further detail below. 
 
Rapid Visual Information Processing (RVP) 
The RVP task is a test of visual sustained attention and forms part of the Cambridge 
Neuropsychological Test Automated Battery (CANTAB, Cambridge Cognition, UK) 
(Robbins et al., 1994). There is robust evidence to support a role of corticostriatal 
dopaminergic neurocircuitry in the control of attention maintenance (Grafton et al., 
1995; Graybiel 1995; Jueptner et al., 1997a; Jueptner et al., 1997b). The RVP was 
chosen in preference to other attentional tasks because it has been adapted for use in 
the AD population (Egerhazi et al., 2007; Jones et al., 1992), and performance 
accuracy has been shown to correlate negatively with striatal D2/3 receptor 
availability (Reeves et al., 2010).  
During the test, a white box appears in the centre of the computer screen, inside 
which single digits from two to nine appear in a pseudorandom order at a rate of 100 
digits per minute. The original version of the test requires subjects to press a button 
whenever specific three-digit sequences (‘357’, ‘246’ or ‘468’) appear on the screen, 
over a 3 minute test period. In the AD population, the test has been modified such 
that subjects are required to recognize only one sequence (‘357’), thus reducing the 
working memory component of the task (Jones et al., 1992). 
In the present study, the RVP was carried out using a touch screen computer and a 
button box. Prior to starting the test, subjects were familiarised with the apparatus 
and asked to practice pressing the button whilst simultaneously looking at the screen. 
Once this had been mastered, subjects were given a 2 minute ‘practice’ session, 
during which the task requirements were made clear. A maximum of two practice 
runs were allowed before commencing the test, which ran over 3 minutes. Correctly 
detected sequences (‘hits’) and false identifications (‘misses’) were recorded in 
addition to the response time for each ‘hit’. For the purposes of the current analysis, 
the accuracy of test performance was indexed by the number of hits, with a 
maximum achievable score of 24 (recorded in three blocks, with eight target 
sequences in each). 
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Simple Reaction Time (SRT) 
The SRT task is a test of motor speed which forms part of the CANTAB. There is 
strong evidence to support the role of corticostriatal dopamine function in 
visuomotor control (Jueptner et al., 1997a). This test was chosen as a more accurate 
measure of motor speed than the motor screening test (MOT), which was previously 
found to correlate positively with D2/3 receptor availability (Reeves et al., 2010). 
During the task, a white box appears in the centre of the computer screen. The 
subject is asked to press a button as quickly as they can when the white box appears 
on the screen. In the present study, the SRT was carried out using a touch screen 
computer and a button box. Prior to starting the test, subjects were familiarised with 
the apparatus and asked to practice pressing the button whilst simultaneously looking 
at the screen. Once this had been mastered, subjects were given a ‘practice’ session 
containing 24 trials, during which the task requirements were made clear. Cues on 
the screen guided the subject if they were responding too soon or too late to the 
stimulus. After the practice session there was a pause to ensure the subject 
understood the instructions and was comfortable using the computer. The pause was 
followed by two blocks of assessed trials, with a brief pause between the two. Each 
block contained 50 trials. The average response time over the two assessed trials was 
recorded.  
 
2.2.3 Neuropsychological Test Battery 
Neuropsychological tests were grouped into separate cognitive domains, in order to 
identify if discrete functional networks are associated with psychotic symptoms in 
AD. The tests used within each domain are described below, together with their 
psychometric properties. Many of the tests used are taken from The Consortium to 
Establish a Registry for Alzheimer’s Disease (CERAD) (Morris et al., 1989). This is 
a global scale of cognition, however the individual subtests are commonly used as 
standalone measures of specific aspects of cognition, and have demonstrated good 
inter-rater and test-retest reliability (Morris et al., 1989; Welsh-Bohmer & Mohs 
1997). Validity of the tests has also been demonstrated by both cross-sectional and 
longitudinal studies showing a progressive decline in performance with disease 
severity (Fillenbaum et al., 2008; Morris et al., 1993).  
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Memory 
Immediate verbal recall: measured using the immediate word list task from the 
CERAD. Subjects read aloud a list of 10 words, after which they are asked to 
immediately recall as many words as they can remember. They are shown the word 
list three times in total. For the purpose of the current study, the total number of 
words recalled over the three trials was measured.  
 
Delayed verbal recall: measured using the word list recall task from the CERAD. 
Subjects are asked to recall as many words as they can remember from the above 
task, after a short delay. During the delay, the subjects are distracted by continuing 
with other tasks from the CERAD. Performance is measured by the number of words 
correctly recalled. The total score is measured out of 10.  
 
Delayed verbal recognition: measured using the word list recognition task from the 
CERAD. After a delay, subjects are shown the words seen earlier, together with 10 
new words, and are asked to identify which of the words were shown previously. 
The number of words correctly identified as previously present or absent is recorded. 
The total score is measured out of 20.  
 
Delayed visual recall: measured with the constructional praxis recall task from the 
CERAD. After a delay, subjects are required to recall shapes copied earlier in the 
assessment procedure. The accuracy of the drawings is scored out of a total of 11 
points.  
  
Delayed visual recognition: measured using the Camden Short Recognition Memory 
Test for Faces (Warrington 1996). Subjects are shown 25 different faces, and asked 
to judge whether each face is ‘pleasant’ or ‘unpleasant’. They are then shown two 
faces per page and asked to identify which they have seen previously. Performance is 
measured by the number of faces correctly identified. This test was developed to 
provide a short and quick recognition memory test. Validation studies have been 
performed and the discriminative power of the test has been established by assessing 
patients with dementing illnesses (Warrington 1996). 
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Executive Function 
Digit Span: taken from the Wechsler Adult Intelligence Scale-III (WAIS-III) 
(Wechsler & Corporation 1997). Subjects are asked to repeat a string of digits either 
forwards or in reverse order, ranging from two to nine numbers. Performance is 
measured by the total number of sequences correctly repeated. High test-retest 
reliability has been reported for the digit span test (Iverson 2001). The validity of 
WAIS-III has been demonstrated by high correlations with its predecessor, the 
WAIS-R, and other tests of intellectual function including the Dementia Rating Scale 
(Strauss et al., 2006). 
 
Semantic and Phonemic Fluency (Benton 1976): subjects are given 1 minute to 
retrieve as many words as possible that start with a specific letter (C, F, L: Phonemic 
Fluency), or belong to a certain semantic category (animals, fruits, vegetables: 
Semantic Fluency). The total number of words is used as the outcome measure. 
Verbal fluency tasks have high test-retest reliability (0.79 and 0.80 for Semantic and 
Phonemic Fluency respectively), and validity is demonstrated by the sensitivity of 
the tasks to distinguish between patients with frontal lesions and healthy controls 
(Homack et al., 2005). 
 
Motor Inhibition: measured using the Go/No-Go task (Rubia et al., 2001). This task 
measures the ability to inhibit a motor response and selective attention. A motor 
response has to be selectively executed or inhibited depending on whether a ‘go’ or 
‘no-go’ stimulus appears on a computer screen. This particular version of the task 
was originally designed for use in children with ADHD. The ‘go’ stimulus, an image 
of an aeroplane, appeared 77.4% of the time, and the ‘no-go’ stimulus, an image of a 
green ‘enemy planet’ appeared in 22.6% of trials. The task was administered twice, 
once with each hand, to assess for laterality effects. Each round of the task consisted 
of 150 trials, with the first five serving as a practice run. The interstimulus interval 
(ISI) was 1 second. Instructions were to respond as fast as possible to the ‘go’ 
stimulus (aeroplanes), but not to respond to the ‘no-go’ stimulus (enemy planets). 
The validity of this version of the Go/No-Go task to measure impulsivity is 
demonstrated by the impaired performance of children with a specific phenotype of 
ADHD, compared to psychiatric, and healthy, controls (Rubia et al., 2001). 
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Verbal Inhibition: measured using the Hayling Sentence Completion task (Burgess et 
al., 1997). This task measures response initiation and response suppression, and 
involves inhibiting prepotent responses. The researcher reads aloud a list of 
sentences which have the last word missing. Subjects must complete each sentence 
with a relevant word in part 1. In part 2, the word used to complete the sentence must 
have no association to the sentence. The outcome measures in the current study 
included total time to respond in part 2 (‘Hayling inhibition time’), and total number 
of errors made. The test-retest reliability for the ‘Hayling inhibition time’ score is 
adequate (0.78), however a lower reliability is reported for the total number of errors 
(0.52) (Burgess et al., 1997). The validity of the test has been demonstrated by 
reports of impaired performance in those with frontal lobe lesions (Burgess et al., 
1997) and in a variety of conditions in which executive dysfunction has been 
implicated, including AD (Collette et al., 2002; Salmon et al., 2000). 
 
Language 
Boston Naming Task: taken from the CERAD. Subjects are asked to name 15 
pictures ranging from high frequency objects (e.g. house, bed), to low frequency 
objects (e.g. hammock, sugar tongues). Performance is measured by the total number 
of correctly named pictures.  
 
Praxis 
The Clock Drawing Task (Shulman et al., 1986): subjects are presented with a large 
printed circle and asked to draw the numbers in the circle so as to resemble a clock 
face. They are then asked to set the hands on the clock to ‘ten past eleven’. 
Performance is scored on a scale of 1-6 using the Schulman scoring system, whereby 
a score of 1 is given to a drawing with perfect resemblance to a clock, and a score of 
6 when the drawing has no representation of a clock. The Shulman scoring system 
shows good inter-rater and test-retest reliability, a high correlation with other 
cognitive measures e.g. MMSE, and good concurrent and predictive validity for 
detecting cognitive change (Shulman 2000). 
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Constructional Praxis: measured using a task from the CERAD, which involves 
subjects copying four pictures of increasing complexity. Accuracy of drawings is 
scored out of a total of 11. 
 
Visuoperceptual Function 
The Visual Object and Space Perception Battery (VOSP) (Warrington & James 
1991): the VOSP consists of eight individual subtests, however only four were used 
in the current study. Descriptions of the tasks are as follows, the first two measuring 
object perception and latter two measuring space perception: (i) Incomplete Letters - 
subjects are asked to identify 20 letters which are 70% obliterated; (ii) Object 
Decision - subjects are presented with 20 arrays, each of which displays 2D 
silhouettes of one real object and three distractors, and are asked to point to the real 
object; (iii) Number Location - subjects are asked to identify the number 
corresponding to the position of a dot; (iv) Cube Analysis - subjects are asked to 
count the number of solid bricks illustrated. Each of the subtests have been well 
validated, through studies demonstrating the ability of the tasks to distinguish 
between patients with right and left hemisphere lesions and medical controls 
(Warrington & James 1991). Data on the reliability of the tests is limited however, 
with one study reporting specificities ranging from 71.2% (Number Location) to 
98.2% (Incomplete Letters), and test-retest reliabilities ranging from 0.54 
(Incomplete Letters) to 0.84 (Number Location) (Bonello et al., 1997). 
 
2.2.4 Procedure for Administration of Neuropsychological Tests 
Subjects completed a neuropsychological test battery over two visits, in order to 
avoid fatigue effects. The visits were separated by approximately 1 week. During the 
first visit, subjects completed all screening measures, tasks from the CERAD, the 
Digit Span Test and the computerised SRT and RVP tasks. The NPI was also 
administered to the informants on this visit. During the second visit, the remaining 
tests were completed. This order of test administration was chosen to ensure the two 




All statistical analyses were carried out using SPSS 19 (www.spss.com). Between-
group differences in demographic data were analysed using independent samples t-
tests, with the presence of psychotic symptoms as the grouping variable. Separate 
MANCOVAs (multivariate analysis of covariance) were performed for multiple 
dependent variables in specific cognitive domains, and ANCOVAs (analysis of 
covariance) were carried out where there was only one dependent variable in a 
cognitive domain. Age, MMSE score and years of education were controlled for in 
each analysis (unless otherwise stated). Further detail of the analysis procedure is 
provided in Chapter 3, Section 3.2.4. 
 
2.4 Part 2: PET Imaging 
2.4.1 Basic Principles of PET Imaging 
PET is a non-invasive imaging technique which measures the spatial and temporal 
distribution of radiotracers labelled with positron emitters in the body or brain of 
human subjects. There are several steps involved in a typical PET scan. Firstly, 
positron emitting radionucleotides are produced by nuclear reactions using charged 
particle beams. This takes place in a cyclotron. The radionucleotides are then 
chemically incorporated into receptor specific ligands. The radiotracer (ligand and 
radioactive isotope) is then intravenously injected into the peripheral circulation of 
the patient, who is located within the bore of the PET scanner. The tracer will then 
accumulate in regions where the specified receptor is present. Once injected, the 
unstable radionucleotides undergo positron decay, whereby a nucleus with too low a 
neutron-to-proton ratio converts a proton (p) to a neutron (n), emitting a positron (e
+
) 
and a neutrino (ν) which carries off excess energy. This is described by the equation: 
p = n + e
+
 + ν. The emitted positron will travel a short distance before it collides with 
an electron. Both positron and electron annihilate creating two 511 KeV gamma 
rays. The gamma ray photons are emitted 180° apart from one another and are 
detected by scintillation crystals in the scanner, creating a burst of light inside the 
crystal. The scintillators are coupled to photomultiplier tubes, which convert the light 
photons to a measurable electrical pulse, which is then sent to a computer. The two 
gamma-rays must be detected simultaneously, or within a very narrow time window 
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(a few nanoseconds) in order for this technique to work. The source of the photons is 
then able to be localised along a straight line (coincident line), due to the gamma 
photons being emitted at 180° to one another. Data of thousands of coincident lines 
are collected at different angles and different time points, and can be reconstructed to 
form an image of the distribution of radioactivity in a subject’s brain. For the 
purpose of the current thesis, the regional levels of radioactivity are assumed to 
indicate available receptor density. The process described above is illustrated in 
Figure 2.1. 
When gamma rays are given off from a person, scatter occurs within the brain and 
their progress is impeded (‘attenuated’) by skull, tissue and other brain structures. In 
order to correct for this in each individual, a CT scan (taken over 30 seconds) is 
carried out prior to the main (dynamic) scan, to measure individual attenuation. With 
attenuation correction and scatter correction calculated for the individual, a PET 
scanner is thus able to produce quantitative images, in that the activity per pixel can 
be measured in absolute terms, Becquerel (Bq) per pixel (Paans et al., 2002). The 
spatial resolution achievable on a standard scanner reflects the finite range of the 
emitted positron and the technical limitations of the scanner.  
 






2.4.2 Neuroreceptor Quantification  
PET techniques allow the quantification of critical components of neurotransmission 
through the use of radiotracers that target specific (most commonly receptor) sites on 
pre- or post-synaptic neurones. The total measured activity recorded by the scanner 
reflects specifically bound, non-specifically bound and unbound (free) radiotracer 
(Slifstein & Laruelle 2001) in the tissue, plus a small contribution from activity in 
the blood in the capillaries (typically 5% in the brain). Several factors influence the 
profile of this activity, including peripheral clearance, regional cerebral blood flow 
and blood brain barrier (BBB) transport. In order to control for the extraneous factors 
and relate the measured activity to receptor density, mathematical modelling of the 
PET data is required. A variety of modelling approaches exist to quantify receptor 
binding with radioligand imaging, with the choice of model depending on various 
factors, such as characteristics of the ligand and infusion techniques. However, 
despite their differences, all models rely on the use of equations with rate constants 
to determine the movement of the radioligand through the body. By fitting the model 
to the PET data obtained, the rate constants can be derived, resulting in a quantitative 
outcome measure, for example the Binding Potential (BP).  
BP is the most common outcome measure in neuroreceptor imaging. It is essentially 
a measure of the available receptor density and the affinity of the ligand for the 
receptor. The simplest form of deriving BP is explained by in vitro radioligand 
binding assays, from which tracer kinetic models used in PET studies originated. 
  
2.4.3 Compartmental Models 
Compartmental models describe the transfer or exchange of radiotracer between 
different compartments, via first order kinetics or rate constants. The rate constants 
determine the fractional rate of change of tracer concentration between 
compartments over time (Lammertsma & Hume 1996). 
 
Radioligand Binding Assays 
A two compartmental model is used for radioligand binding assays. Homogenous 
tissue, together with the radioligand is incubated in buffer solution. The first 
compartment includes the buffer solution, and the second compartment reflects 
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receptor rich tissue. A radioligand enters the model in the buffer solution and can 
then transfer directly into the second compartment by binding to receptors. 
Association and dissociation to the receptor are measured by the rate constants kon 
and koff respectively. Over time, the reversibly binding radioligand reaches 
equilibrium concentrations in buffer solution and tissue. At equilibrium, the rate 
constants can be simplified to form an 'equilibrium dissociation constant', Kd 
(koff/kon). The total number of receptors is referred to as Bmax, and so BP is derived 
by determining the ratio of bound radioligand concentration to free radioligand 
concentration at equilibrium (Bmax/Kd) (Ichise et al., 2001). In vivo tracer kinetic 




In vivo PET studies differ from in vitro binding assays because of additional factors 
affecting the flow of the radiotracers, i.e. blood flow, radioligand clearance from 
plasma, and number and affinity of available receptors (Ichise et al., 2001). PET 
imaging studies primarily use a three compartmental model (Figure 2.2). The three 
compartments include the arterial blood or plasma, the free compartment and a 
specifically bound ligand compartment. A fourth compartment, containing non-
specifically bound ligand also exists, and exchanges with the free compartment. 
However, for most radioligands, the exchange between these two compartments is in 
rapid equilibrium, and so the free and non-specifically bound compartments are 
treated as one (referred to as the non-displaceable compartment). This reduces the 
number of estimated parameters in the model. The specifically bound ligand 
compartment consists of high-affinity receptors. The transfer rate of radiotracer 
across the BBB into the non-displaceable compartment is determined by rate 
constants K1 and k2. The movement of radiotracer between the non-displaceable and 
specific binding compartments is measured by k3 and k4, which reflects the 




Figure 2.2: The Three Compartment Model 
 
 
Adapted from Ichise et al. (2001) 
 
Measuring the ratio of the rate constants in the compartmental model can achieve the 
BP outcome measure. However, several variations have been used in recent years in 
an attempt to reflect the true in vitro Bmax/Kd measurement. The discrepancy in 
deriving BP outcomes is due to different reference concentrations being used to 
measure the non-specific/free binding. Innis et al. (2007) has produced a consensus 
nomenclature in order to differentiate between BP values derived from different 
reference concentrations. BP is described as the ratio at equilibrium of specifically 
bound radioligand to that of free radioligand in tissue (BPF), total parent radioligand 
in plasma (BPP) and non-displaceable radioligand in tissue (BPND). The first two 
require arterial blood sampling, and the latter uses a reference region approach to 
estimate the non-specific binding. The current thesis uses a reference tissue approach 
(described below) and will therefore use BPND as the outcome measure (Innis et al., 
2007).  
 
Assumptions of Compartmental Analysis 
Compartmental analysis relies on several assumptions in order to reduce the number 
of estimated parameters and to produce as close an estimate as possible to the true in 
vitro BP. Primary assumptions include the following: the radioligand comes from a 
single source i.e. arterial blood plasma; there is free movement of the radioligand 
between arterial plasma and the free compartment; first order kinetics can describe 
the exchange of radioligand between compartments; non-specifically bound 
radioactivity in the second compartment equilibrates with free tissue radioactivity, 
allowing the free and non-specific binding compartments to be merged; and that the 
kinetic parameters are constant during the study (Ichise et al., 2001). 
 
 60 
Reference Tissue Model 
As mentioned above, movement of a radiotracer through the body or brain is affected 
by cerebral blood flow and peripheral clearance. Since the concentration of free 
radiotracer in the brain cannot be measured directly, arterial blood sampling is used 
to provide a tracer input function (concentration for ‘arterial blood’ compartment in 
Figure 2.2), a metabolite-corrected measurement of the free concentration of the 
radiotracer in the plasma. This involves arterial cannulation and technical demands. 
In order to avoid the invasive procedure involved in arterial blood sampling, 
alternative methods have been devised which rely on the presence of a reference 
tissue, which is devoid of the specific binding site. The time course of radioligand 
uptake in the region of interest is measured against the rate of uptake in a specified 
reference region. This is known as the reference tissue model (Hume et al., 1992; 
Lammertsma & Hume 1996). The reference region is assumed to reflect the ‘non-
displaceable’ compartment in Figure 2.2, where no specific binding occurs.  
The advantages of the reference tissue approach include less complicated scanning 
protocols and data analysis procedures, and the fact that no arterial cannulation is 
needed. It also removes the labour-intensive task of correcting samples for 
metabolites.  
As with most mathematical models there are several assumptions. For example, the 
level of free and non-specific binding is assumed to be the same in the target and 
reference region, and it is assumed that the reference region is not affected by the 
pathology under study (Lammertsma & Hume 1996). The reference region must be 
chosen carefully, as specific binding in the reference region will underestimate BP 
(Gunn et al., 1997). 
 
Simplified Reference Tissue Model 
In an attempt to improve the reference tissue model, a simplified model was devised, 
which reduced the large standard errors associated with the parameters in the 
previous method, and increased convergence rates. The simplified reference tissue 
model has been shown to yield BP values which are highly correlated to those of the 
original reference tissue model (Lammertsma & Hume 1996), and will be used for 
the current study. 
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2.4.4 Radioligand Selection: [
18
F]fallypride 
The receptor of interest in the current thesis is the D2 dopamine receptor. However, 
as mentioned in Chapter 1, the 75% homology of D2 and D3 receptor domains 
makes it difficult for D2 selective tracers to differentiate between the two receptors 
(Missale et al., 1998). The remainder of the thesis will thus refer to the target 









F]fallypride. Of these, 
only the latter two have a sufficiently high affinity to measure extrastriatal D2/3 
receptors, which exist at a density 10-100 fold lower than in the striatum (Kessler et 
al., 1993). In order to meet the aims of this study, to devise a suitable scanning 
protocol for imaging D2/3 receptor occupancy in response to antipsychotic treatment 
in older adults, it is important that we are able to image extrastriatal D2 receptors, 
given their proposed involvement in antipsychotic treatment response in young 
adults with schizophrenia (Bigliani et al., 2000; Stone et al., 2009; Xiberas et al., 
2001a; Xiberas et al., 2001b). 
[
18
F]fallypride has been selected for use in the present thesis due to its unique ability 
to image both striatal and extrastriatal regions in a single scan (Mukherjee et al., 
2002). In contrast to the short half-life of carbon 11 (20 minutes) used in the high 
affinity tracer [
11
C]FLB-457 (Olsson & Farde 2001), fluorine-18 has a much longer 
half-life (110 minutes), which enables tracer uptake to achieve a plateau in the 
striatum, where D2/3 receptor density is greatest (Bouthenet et al., 1991). The use of 
[
18
F]fallypride in the quantification of striatal and extrastriatal D2/3 receptors has 
been well validated by test-retest studies (Cropley et al., 2008; Mukherjee et al., 
2002; Siessmeier et al., 2005), and is a well-established tool for measuring D2/3 
receptor occupancy (Kegeles et al., 2008; Kessler et al., 2005; Kessler et al., 2006; 
Riccardi et al., 2008). 
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2.5 Methodology for Chapter 4: Establishing the Test-Retest Reliability of an 
Adapted [
18
F]fallypride Imaging Protocol for Use in Older People  
2.5.1 Summary of Study Design 
A two-scan approach was used to test the reliability of an adapted scanning protocol, 
used to measure striatal and extrastriatal dopamine D2/3 receptor availability. 
Subjects were scanned twice at rest, 4-6 weeks apart. The adapted protocol aimed to 
minimise the time spent in the scanner. It consisted of three scanning sessions, each 
lasting 30 minutes, over a total duration of 4 hours.  
 
2.5.2 Recruitment and Screening 
Inclusion Criteria 
Eight healthy volunteers were recruited to the study. Participants were included in 
the study if they were aged between 65 and 90 years. Eligibility for the study was 
assessed by a clinician conducting a brief screening of the individual’s medical 
history and current medications. The MMSE and GDS-15 (described in Section 
2.2.1) were used as screening tools for this study. Participants had to score >26 out 
of 30 on the MMSE to rule out a diagnosis of dementia (Folstein et al., 2001), and 
<6 out of 15 on the GDS-15 to rule out a clinical diagnosis of depression. 
 
Exclusion Criteria 
Participants were excluded from taking part on the basis of medical, psychiatric and 
medication history. In terms of medical history, exclusion criteria included a history 
of epilepsy, substance misuse, traumatic brain injury, addiction and neuro-
degenerative disease. Additional exclusion criteria included the presence of 
conditions that might affect a person’s ability to tolerate a brain scan such as 
significant respiratory or cardiac disease, or severe kyphosis. Participants were also 
excluded on the basis of past or current psychiatric illness or needle phobia (the latter 
because the scan required intravenous cannulation). Structural imaging (T1-weighted 





Participants were recruited from the Institute of Psychiatry Dementia Case Register. 
This database holds information on healthy and cognitively impaired adults 
interested in research. It was set up within the NHS trust using a grant from the 
National Institute of Health Research. All subjects on the Register have given 
consent to being approached about on-going research projects. Access of researchers 
to the Register is carefully monitored by a manager and a core team of three people, 
who ensure that potential subjects are not involved in more than one project at a 
time. Subjects are contacted following their participation in individual projects to 
ascertain whether they would be willing to be contacted again. In order to facilitate 
the recruitment procedure, a one-page summary leaflet was distributed to the Case 
Register team, in order to provide potential volunteers with basic information. If 
permission was given, contact was then made by the researcher via telephone, and a 
more detailed information sheet was provided (see Appendix 7.1.2). Recruitment 
took place between December 2010 and June 2011. 
 
Informed Consent Procedure 
Written informed consent from the subjects was obtained upon recruitment to the 
study. The information sheets and consent forms used to obtain agreement for the 
current study are included in Appendix 7.1.2.  
 
2.5.3 Scanning Protocol 
The scanning times post injection were: 0-30 minutes, to provide an input function to 
model a reference region approach; 60-90 minutes, to measure the peak tracer 
binding within extrastriatal regions; and 210-240 minutes, to ensure that tracer 
binding achieves a plateau in the striatum of all subjects. These optimal time frames 
were determined using data from a previous pilot study (Dunn, 2008-preliminary 
data), and data from receptor occupancy studies using [
18
F]fallypride in young adults 
(Kegeles et al., 2008; Kessler et al., 2006). There have been studies which have used 
protocols requiring a shorter total scanning time, for example 120 minutes 
(Mukherjee et al., 2002) and 180 minutes (Vernaleken et al., 2011), however the 
time-activity curve from the former study shows uptake in the striatum to still be 
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climbing towards a plateau at the end of the final scanning session (see Figure 2.3), 
and the latter study reported that tracer may take up to 210 minutes to achieve 
equilibrium in a small proportion of people. Therefore, the total scan duration of 240 
minutes was chosen in the current study to ensure tracer uptake in the striatum had 
reached equilibrium. The time frames of the adapted protocol allow investigation 
into the effect of shorter scan durations without reducing the total uptake time, which 
could lead to inaccuracies in the quantification of striatal BPND. 
 
Figure 2.3: Regional Time-Activity Curve of [
18




(Mukherjee et al., 2002) 
 
2.5.4 Statistics 
A paired t-test was used to compare the administered dose of [
18
F]fallypride between 
test and retest scans. BPND values for test and retest scans were determined, and the 
absolute variability of test-retest reproducibility was calculated. The intraclass 
correlation coefficient (ICC) (Fisher 1958) was also calculated to measure the 
reliability of the test-retest BPND values for each region of interest. Further details of 
the statistical analysis are provided in Chapter 4, Section 4.2.4. 
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2.6 Methodology for Chapter 5: Optimising [
18
F]fallypride Imaging for D2/3 
Receptor Occupancy Studies in AD 
2.6.1 Summary of Study Design 
A two-scan approach was used to test the feasibility of an adapted scanning protocol 
used to measure striatal and extrastriatal D2/3 receptor availability. Subjects were 
scanned twice, at rest, using interrupted scanning protocols designed to reduce the 
time spent in the scanner. The first (baseline) scan was carried out prior to 
commencing amisulpride treatment and was used to provide a baseline for 
comparison with post-treatment scans. The second scan took place after 2-8 weeks of 
amisulpride treatment (50-200mg daily), when a therapeutic response (symptom 
reduction of >25%) had been achieved. The protocol consisted of two scans of 20 
minutes and one scan of 40 minutes, over a total duration of 2.5 hours.  
Neuropsychiatric symptoms were assessed prior to baseline and post-treatment scans 
using the NPI, and motor side effects were measured with the Simpson-Angus Scale 
(SAS) (Simpson & Angus 1970) (both assessments are detailed further in Section 
2.6.5). Other side effects, including falls and sedation, were also recorded. 
 
2.6.2 Recruitment and Screening 
Inclusion Criteria 
Patients were included in the study if they were aged between 65 and 90 years, 
fulfilled the NINCDS-ADRDA criteria for AD (McKhann et al., 1984) (described in 
Chapter 1, Section 1.1.2), and were eligible to receive amisulpride treatment for 
behavioural or psychotic symptoms, but had not yet commenced medication. Clinical 
assessment included the MMSE (described in Section 2.2.1) to determine the 
severity of dementia (27 = normal, 21-26 = mild, 11-20 = moderate, <10 = severe) 
(Folstein et al., 2001). 
 
Exclusion Criteria 
Exclusion criteria are similar to those described for healthy control subjects in 
Section 2.5.2. In addition, a detailed medication history was taken and patients were 
excluded if they were prescribed psychotropic medication that might interfere with 
dopamine function. A modified version of the UPDRS was used to screen for the 
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presence of overt motor symptoms (bradykinesia, rigidity, facial masking or tremor). 
Patients with a score of >8 were excluded in order to rule out the potential for 
inclusion of patients with DLB. Patients with other symptoms suggestive of a 
possible diagnosis of DLB (frequent falls/syncope, prominent visual hallucinations, 
or marked fluctuation in cognitive ability) were also excluded.  
 
Recruitment Procedure 
Subjects were recruited from inpatient units (n = 2) and community mental health 
teams for older adults (n = 6) within the catchment area of the South London and 
Maudsley NHS Foundation Trust (SLaM). Researchers established links with 
Consultants and keyworkers working within the teams, who were then responsible 
for identifying and referring patients who might be suitable to take part in the study. 
In order to facilitate this, a one-page summary leaflet was distributed to each team to 
provide potential volunteers with basic information. If permission was given, contact 
was then made by the researcher via telephone, and a more detailed information 
sheet was provided (the leaflet and information sheet used for this study are detailed 
in Appendix 7.1.3). Recruitment took place between April 2012 and January 2013. 
 
Informed Consent Procedure 
Initially, written informed consent was required from all subjects. However, given 
the fact that antipsychotics were being prescribed most commonly in people with 
moderate to severe AD, the ethics committee approved a substantial amendment 
request which enabled consent to be obtained from the carer on the patients behalf 
(see Appendix 7.2.1). Subsequently, verbal and written informed consent was 
obtained from subjects who were able to give fully informed consent (n = 3), or from 
the carer, who acted in the capacity of a personal legal representative and gave 
consent on his/her behalf (n = 5). The consent form used in the current study is 
detailed in Appendix 7.1.3. 
 
2.6.3 Scanning Protocol 
The baseline scanning protocol is identical to that used in the reliability study, 
detailed in Section 2.5.3. The original scanning protocol for the post-treatment scan 
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consisted of two scanning sessions at 0-60 minutes and 110-150 minutes post-
injection. However, a substantial amendment was made to the protocol in order to 
further reduce the first 60 minute scanning session (see Appendix 7.2.2). The reason 
for this amendment was to improve the tolerability of the scanning protocol in 
subjects who were physically frail and/or more severely cognitively impaired than 
was anticipated when the study was originally designed. The amended scanning 
times post-injection were as follows: 0-20 minutes, to provide an input function to 
model a reference region approach; 40-60 minutes, to measure peak tracer binding 
within extrastriatal regions; and 110-150 minutes, to measure peak tracer binding 
within the striatum. The total scanning time for the post-treatment scan is shorter 
than the baseline scan due to a reduced number of D2/3 receptor sites available for 
tracer binding following antipsychotic medication. Therefore, [
18
F]fallypride uptake 
achieves an earlier plateau. Optimal time frames for the post-treatment scan were 
derived from previous occupancy studies using [
18
F]fallypride in young adults, 
which show tracer uptake to plateau between 2-3 hours (Kegeles et al., 2008; Kessler 
et al., 2006). 
 
2.6.4 Amisulpride Dose-Titration  
After the baseline scan, amisulpride was commenced at a starter dose of 25mg or 
50mg, depending on the preference of the prescribing clinician. Follow-up 
assessments were carried out every 14±7 days, with the aim of assessing symptom 
and side effect profile through amisulpride dose titration up to a maximum of 200mg 
daily. This dose range was based on data from open-label trials in elderly patients 
with AD (Lim et al., 2006; Mauri et al., 2006). One study began prescribing at 
50mg/day, and titrated upwards to a maximum dose of 400mg/day. The mean dose 
prescribed was 85±53.3mg/day, which resulted in >50% reduction in NPI scores in 
80% of subjects. Of those that developed EPS, 67% were taking >100mg/day of 
amisulpride. However, another study showed doses up to 200mg/day were tolerated 
by patients with moderate-severe AD, and resulted in a significant decrease in NPI 
score in all patients, with no significant motor effects. Data from the two studies 
together support a dose range of 50-200mg daily of amisulpride. 
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In our sample, medication was administered in the evening by a carer in all but one 
subject, who lived alone and in whom compliance was facilitated through the use of 
a blister pack. Subjects were scanned when a reduction in total symptom ratings 
(summed total of delusions, agitation and hallucinations domains) of 25% or more 
had been achieved.  
Amisulpride was chosen because of its favourable side effect profile compared to 
other atypical drugs, including a reduced sedative effect, lower risk of weight gain 
and metabolic disturbance, and no reports of excess cerebrovascular mortality 
(Coulouvrat & Dondey-Nouvel 1999). In addition, amisulpride selectively targets 
D2/3 receptors, which allows investigation into the ‘therapeutic window’ of D2/3 
receptor occupancy, one of the main objectives of the current thesis (Coukell et al., 
1997). The low affinity of amisulpride for plasma proteins, and the fact that it 
undergoes primarily renal excretion (hepatic metabolism is negligible) reduces the 
potential for drug interactions, making it suitable for use in elderly patients who do 
not have significant renal impairment (Rosenzweig et al., 2002). Furthermore, 
amisulpride was commonly prescribed within the Trust for the treatment of 
behavioural and psychotic symptoms in dementia at the time the study was designed, 
which meant that participation in the study would not be at odds with the standard 
approach used by prescribers. 
 
2.6.5 Monitoring Neuropsychiatric Symptoms and Motor Side Effects 
Neuropsychiatric Inventory  
For the purposes of this study, three specific symptom domains from the NPI 
(described in Section 2.2.1) were assessed - delusions, hallucinations and agitation – 
with the aim of specifically focusing on symptoms which necessitate the use of 
antipsychotic medication. Live-in caregivers were asked about symptoms over the 
preceding month, both at baseline and prior to the post-treatment scan. For each 
domain, carers were asked a screening question to determine whether or not the 
symptom was present. If the answer was negative a rating of 0 was given, and if 
positive, carers were then asked to rate the frequency (1-4) and severity (1-3) of the 
symptom. The frequency and severity scores were multiplied to give a score from 0 
(symptom absent) to 12 (symptom continuously present and a major source of 
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disruption) for each symptom. The NPI is the standard measure used to assess global 
psychopathology in clinical trials (Birks 2006).  
 
Simpson Angus Scale 
The Simpson-Angus Scale (SAS) (Simpson & Angus 1970) was used to monitor 
clinically significant motor side effects. The scale includes 10 items: one which 
measures gait (hypokinesia), six which measure rigidity (arm dropping, shoulder 
shaking, elbow rigidity, wrist rigidity, leg pendulousness, and head dropping), and 
three others measuring glabella tap, tremor and salivation. Each item is rated on a 5-
point scale, with a score of 0 meaning the complete absence of the condition, and 4 
indicating an extreme form of the symptom is present. The total score of the scale is 
obtained by adding the items together and dividing by 10. Final scores of up to 0.3 
are considered within the normal range. The Simpson-Angus Scale has been shown 
to have good validity and reliability (Simpson & Angus 1970), and is the most 






F]fallypride BPND values were determined for pre- and post-treatment 
scans and used to calculate D2/3 receptor occupancy. Further details of the statistical 
analysis are provided in Chapter 5, Section 5.2.6.  
 
2.7 Methodology Common to Chapters 4 and 5 
2.7.1 Ethical Approval 
Both the reliability and feasibility components of this study were approved by The 
Joint South London and Maudsley, and Institute of Psychiatry NHS Research Ethics 
Committee (see Appendix 7.2). Permission to administer [
18
F]fallypride was given 
by the Administration of Radioactive Substances Advisory Committee (ARSAC).  
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2.7.2 Sample Size Considerations 
A sample size of eight was needed for both the reliability and the feasibility study. 
The sample size is comparable to a previous reliability study of [
18
F]fallypride, 
carried out in healthy young adults (N = 6) (Mukherjee et al., 2002), and is a 
standard sample size used to establish the test-retest error of PET radiotracers. 
 
2.7.3 PET Protocol 
Subjects were scanned twice at rest on a GE VCT Discovery PET-CT camera 
(FWHM 5mm), at St Thomas’ PET Centre. A moulded head rest and straps were 
used to minimise head movement and an external webcam was used to detect 
significant head movements that could degrade the quality of image data. 
[
18
F]fallypride was administered via a single bolus intravenous injection of 250MBq. 
Each scanning session consisted of three dynamic scans in 3D mode, each preceded 
by a low dose CT scan for attenuation correction. Details of the different scanning 
protocols are discussed in the relevant results chapter. 
 
2.7.4 General Data Analysis 
Data were analysed using a simplified reference tissue model (Lammertsma & Hume 
1996), with the cerebellum (excluding the vermis) as a reference region. This method 
has been validated by a previous study using [
18
F]fallypride, which reported a 
significant correlation of BP values derived from quantification models requiring 
arterial blood sampling and those using the cerebellar reference region approach 
(Siessmeier et al., 2005). Furthermore, the reference region approach has been used 
in previous test-retest publications using [
18
F]fallypride (Cropley et al., 2008; 
Mukherjee et al., 2002). 
 
Pre-processing 
Statistical Parametric Mapping, SPM 8 (www.fil.ion.ucl.ac.uk/spm/software/spm8/) 
was used for pre-processing, and all other analyses were performed using Matlab 
(www.mathworks.com). Non-attenuation corrected (NAC), fully 3D iteratively 
reconstructed PET scans (GE ‘VuePoint’ reconstruction algorithm, 4 iterations, 28 
subsets, 4.8mm Hanning 3D filter) were used for frame-by-frame realignment. The 
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absence of attenuation correction results in a less biased distribution of tracer, 
providing a visibly clearer image of the brain, especially around the scalp, whilst the 
iterative algorithms provide good signal to noise ratios. Frames within the first 
scanning session (0-30 minutes) were realigned to frame 21, and frames from the last 
two sessions were aligned to the first frame in that session. A mean image within 
each scanning session was created, and all frames within the scanning session were 
aligned again to the mean image. The mean image was then recalculated. This 
process was performed for each of the three scanning sessions independently. 
Between-sessions realignment was performed using the co-register routine in SPM. 
The mean images from the last two scanning sessions were realigned to the mean 
image from the first session, and those parameters were then applied to all the frames 
in the corresponding session. This realignment approach ensures all frames, in all 
sessions, are aligned together.  
These transformations were then applied to attenuation corrected (AC) filtered back 
projected (FBP, fourier-rebinned 2D reconstruction, with geometric, deadtime, 
scatter and random correction, 4.8 Hanning Transaxial filter) PET images, which 
were used for quantification in order to avoid bias from the AC-iterative images. The 
transformations were also applied to AC-iterative PET images (4 iterations, 28 
subsets, 4.8mm Hanning 3D-filter), which were used for warping atlases, due to their 
good signal to noise ratio and good contrast between brain structures. All images 
were reconstructed to 128 x 128 x 47 voxels with dimensions 2 x 2 x 3.27mm. The 
pre-processing procedure is illustrated in Figure 2.4. 
 
Defining the Regions of Interest  
Region of Interest (ROI) analysis is a standard approach to the analysis of PET data. 
A computer is used to draw a region around a contiguous set of pixels in the add-
image (a summated PET image), using image analysis software (Analyze; 
Biomedical Imaging
 
Resource, Mayo Foundation). For example, a standard template 
for the caudate nucleus is generally defined by 5mm x 7mm ellipse. Time-activity 
curves are then produced that plot the mean radioactivity value in a ROI across a 
sequence of PET images (i.e. across time). An alternative approach is to use ROI 
templates that have been defined on a magnetic resonance (MRI) scan positioned in 
standard Montreal Neurological Institute (MNI) space (Meyer et al., 1999), and to 
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spatially transform this to the individual space for each scan, using an automated 
(spatial normalisation) procedure. This standardizes the image analysis and removes 
any subjectivity in the placing of ROIs. The latter approach was used for the current 
study. Details of the specific ROIs will be discussed in the relevant results chapters. 
In general, the cerebellar reference region was defined using the Automated 
Anatomical Labelling Atlas (Tzourio-Mazoyer et al., 2002) due to its clearer 
definition of the cerebellum without the vermis, and the Tziortzi Atlas (Tziortzi et 
al., 2011) was used to define the caudate, putamen and specified extrastriatal regions 
(detailed in Chapters 4 & 5). An additional atlas was used to define the striatal 
subdivisions (as discussed in Chapter 1, Section 1.2.1). 
 
Defining the Striatal Subdivisions 
Recent advances in the spatial resolution of PET cameras have enabled imaging 
techniques to differentiate between anatomical subregions of the striatum, as 
opposed to analysing the striatum as a whole. This technique was first demonstrated 
in a study which showed increased amphetamine-induced dopamine release in the 
ventral striatum (nucleus accumbens, ventromedial caudate, and anteroventral 
putamen) compared to the dorsal caudate, in both baboons and humans (Drevets et 
al., 2001; Drevets et al., 1999). The consistency of these findings with microdialysis 
data in non-human primates (Di Chiara et al., 1993) supports the ability of PET 
imaging to quantify binding in subregions of the striatum. The adaptation of data 
from detailed neuroanatomical studies in experimental animals (Haber et al., 2000) 
for use in PET (Mawlawi et al., 2001) have now made it possible to quantify tracer 
binding in the striatum in terms of its functional connections - limbic, associative, 
and sensorimotor regions - referred to as the functional subdivisions. The feasibility 
and validity of such techniques have been evaluated (Martinez et al., 2003; Mawlawi 
et al., 2001), and a gradient of D2/3 receptor binding consistent with post-mortem 
studies has been reported. The greatest BPND is reported in the sensorimotor striatum 
and the lowest values in the limbic striatum (Mawlawi et al., 2001). The same 
gradient has also been reported in an AD sample (Reeves et al., 2009). Imaging of 
the striatal functional subdivisions could enable us to further explore the underlying 
pathophysiology of psychotic symptoms in AD, and the contribution of regional 
D2/3 occupancy to therapeutic response. 
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The template used in the current study for the three striatal subdivisions was 
originally defined on a magnetic resonance (MRI) scan positioned in standard MNI 
space (Hammers et al., 2003; Meyer et al., 1999), using the same anatomical 
landmarks described by Mawlawi et al. (2001). This template has been previously 
used to quantify [
11
C]raclopride BPND in people with AD (Reeves et al., 2009), and 
is shown in Figure 2.5. The boundary between the ventral (limbic) striatum 
(inferiorly) and dorsal caudate and dorsal putamen (superiorly) was defined using the 
anterior commissure-posterior commissure (AC-PC) transaxial plane. The ventral 
(limbic) striatum was sampled from the anterior boundary of the striatum to the level 
of the anterior commissure coronal plane. The transaxial AC-PC plane was used to 
subdivide the dorsal caudate and putamen into associative (caudate and putamen 
rostral to the anterior commissure and the caudate caudal to the anterior commissure) 
and sensorimotor (putamen caudal to the anterior commissure) striatum.  
 
Warping via PET Image 
The next stage in the analysis involved warping the atlases to subject space via a 
previously constructed PET [
18
F]fallypride template in standard (MNI) space. The 
current study chose not to co-register MRI with PET data, as the specific aim was to 
establish the most widely applicable analysis method that would be suitable for use 
in older, cognitively impaired individuals, in whom MRI may be contraindicated or 
difficult to tolerate. The [
18
F]fallypride template was created from six healthy young 
subjects (Dunn et al., 2010) using structural MRI data which had been spatially 
normalised to MNI space using the unified segmentation algorithm in SPM. The 
transformations were applied to each of the co-registered summed (3-30 minutes) 
AC-iterative PET images, as these reconstructions have a good signal to noise ratio, 
and show a clear distribution of [
18
F]fallypride across the brain during the first 30 
minutes. A mean [
18
F]fallypride template was calculated by scaling each transformed 
PET image by the subject global mean, and then taking the mean of the six PET 
images.  
Add-images for the current study were created, summating frames 21-47 for the pre-
treatment protocol, and 21-37 for the post-treatment scan. The [
18
F]fallypride 
template was warped to these add-images using the SPM normalisation routine, and 
the warp parameters were then applied to the atlas.  
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Model Fitting 
Time-activity curves for individual regions (left and right hemispheres combined) 
were extracted from regions defined by the warped atlases in the realigned and co-
registered PET images, and used to estimate tracer kinetic parameters based on the 
simplified tissue reference model (Lammertsma & Hume 1996). Mathematical 
modelling was used to estimate the three parameters; relative delivery (R1), the target 
region clearance constant (k2), and BP (the parameter of interest). 
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Figure 2.5: Delineation of Striatal Functional Subdivisions  
 
 
Right-sided sensorimotor (shown in red), associative (shown in yellow) and limbic (shown in green) regions-of-interest, defined on a magnetic 
resonance (MRI) scan, have been superimposed upon a [
11
C]raclopride (dynamic) image positioned in standard Montreal Neurological Institute 
(MNI) space. From left to right: transverse view, sensorimotor striatum and associative striatum; coronal view, associative striatum and limbic 
striatum; sagittal view, associative striatum and limbic striatum. 
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Chapter 3: Establishing the Neuropsychological Profile of Psychotic Symptoms 
in AD 
3.1 Introduction 
3.1.1 Prevalence and Phenomenology 
Psychotic symptoms (delusions and hallucinations) were amongst the first 
neuropsychiatric symptoms to be described in AD. In his initial case report, Alois 
Alzheimer described a 51 year old lady who presented with fixed, false ideas that 
staff were trying to harm her and steal from her (persecutory delusions) and 
complained of ‘seeing things’ (visual hallucinations) in the context of marked 
cognitive dysfunction (Alzheimer 1907). It was not until the 1980s that the 
phenomenology of psychotic symptoms in AD was explored in more depth and 
symptoms categorised as three principal domains; paranoid delusions, 
misidentifications, and hallucinations (Figure 3.1, Rubin et al., 1988). Paranoid 
delusions most commonly involve ideas of ‘theft’ or ‘suspiciousness’ regarding the 
intentions of others, but may also manifest as morbid jealousy (belief that one’s 
spouse is having an affair), or beliefs about ‘abandonment’. Misidentification 
phenomena mostly involve the belief that there is an intruder in the house (phantom 
boarder syndrome), confusion regarding the identity of one’s reflection in the mirror 
(Mirror sign), confusion regarding the TV (TV sign), believing that a spouse or 
relative is an imposter (Capgras syndrome), and not recognising one’s house as one’s 
own. Hallucinations are primarily visual or auditory in nature and rarely involve 
modalities. Table 3.1 elaborates on the content of persecutory and misidentification 
delusions (Reeves et al., 2012). Subsequent studies have largely concurred with this 
classification (Burns et al., 1990a; Merriam et al., 1988; Reisberg et al., 1987; Teri et 
al., 1988). Prevalence studies (reviewed by Ropacki & Jeste, 2005) have reported the 
median prevalence of psychotic symptoms in AD to be 41% (range = 12.2%–
74.1%). This includes 36% presenting with delusions, mostly persecutory (reported 
in 50.9% of studies), and 18% with hallucinations (predominantly visual in nature). 
Psychotic symptoms in patients with AD are associated with substantial morbidity, 
including a poorer quality of life (Banerjee et al., 2006; Matsui et al., 2006), an 
increased frequency of co-morbid agitation (Gilley et al., 1991), verbal and physical 
aggression (Kotrla et al., 1995) and anxiety (Schneider et al., 2003). Non-cognitive 
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symptoms of dementia are major contributors to the higher distress observed in 
patients and caregivers (Deimling & Bass 1986). They are also associated with early 
institutionalisation (Steele et al., 1990), worse prognosis, and increased costs 
(Herrmann et al., 2006). It is suggested that an estimated 30% of the financial burden 
in AD is directly attributable to management of non-cognitive symptoms (Murman 
& Colenda 2005). 
 




Adapted from Rubin et al. (1988) 
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Table 3.1: Description of Delusional Content in AD 
Paranoid delusions Misidentification phenomena 
‘Theft’ – others are stealing from him/her 
‘Harm’ – others are trying to hurt or harm 
‘Morbid jealousy’ – spouse is having an 
affair 
‘Abandonment’ – family/spouse/carer is 
planning to abandon him/her 
‘Phantom boarder’ – real or imagined people 
are staying in the house 
‘Mirror sign’ – inability to recognise oneself 
in the mirror 
‘TV sign’ – inability to differentiate between 
the TV and reality 
‘Picture sign’ – inability to differentiate 
between a picture/photograph and reality 
‘Capgras’ – carer has been replaced by an 
imposter 
‘House is not one’s home’ – inability to 
recognise one’s home environment 
‘Dead person is alive’ – calls out, looks for 
dead spouse or family member  
(Adapted from Reeves et al., 2012) 
 
3.1.2 Pathophysiology of Psychotic Symptoms in AD 
In the 1980s, an increasing awareness of the prognostic implications of psychotic 
symptoms in AD led to an exploration of the underlying pathophysiology of 
delusions and hallucinations. Cummings and Victoroff (1990) discussed four 
possible theories, which attributed psychotic symptoms in AD to: (i) efforts to 
understand the environment within the context of cognitive deficits, (ii) mood 
changes, (iii) coincidence, and (iv) neurobiological changes. The first of these 
theories originated from suggestions that delusions may reflect the patient’s efforts 
to explain misplaced possessions (Rabins et al., 1982). However, this explanation is 
challenged by reports of delusions occurring prior to identifiable cognitive deficits in 
AD, although this may be due to a lack of sensitivity of neuropsychological tests to 
detect subtle changes in cognition. Nevertheless, the poor correlation of dementia 
severity with the presence of delusions also argues against the first theory 
(Cummings et al., 1987). Furthermore, the lack of correlation between the intensity 
of mood changes and the occurrence of delusions in AD is inconsistent with the 
theory that mood disturbance underlies psychotic symptoms (Cummings et al., 
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1987). Both the high prevalence of psychotic symptoms in AD compared to healthy 
older adults and reports of dementia as the greatest risk factor for psychosis in the 
elderly, challenge the assumption that psychotic symptoms in AD occur as a 
coincidence of old age (Cummings et al., 1987; Miller & Lesser 1988). 
Neurobiological theories quickly predominated and have been elaborated over the 
past two decades. Several theories have been suggested, indicating structural (Bruen 
et al., 2008; Geroldi et al., 2000), neuropathological (Farber et al., 2000; Zubenko et 
al., 1991), and genetic (Nacmias et al., 2001; Sweet et al., 2010) underpinnings to 
psychotic symptoms in AD. 
The most influential model was proposed by Cummings et al. (1992), which 
combined anatomical and biochemical explanations, and proposed that limbic 
dysfunction was a crucial ‘common factor’ across a range of neurological diseases in 
which psychotic symptoms featured. The limbic dysfunction described was 
underpinned by a range of insults, including lesions in the temporal lobe or caudate 
nuclei, or by disruption of the cholinergic/dopaminergic axis. In AD, dopaminergic 
transmission is relatively preserved in the context of a severe deficiency in 
cholinergic function, resulting in an imbalance of the two neurotransmitters. 
Cholinergic deficiency in AD is most severe in limbic regions (Procter et al., 1988), 
hence the proposed disruption to this region in the formation of psychotic symptoms. 
Figure 3.2 describes the model, in which a disruption to the limbic surveillance 
mechanism leads to environmental misperception and interferes with the assessment 
of environmental threats; incorrectly perceiving danger and threatened behaviour. 
These perceptual disturbances manifest as the persecutory and misidentification 
delusions commonly seen in AD. The precise content of the delusions is influenced 
by an individual’s repertoire of experiences. Support for the 
cholinergic/dopaminergic theory has come from studies involving anticholinergic 
agents or amphetamine, which indicate that either cholinergic hypofunction or 
dopamine excess play a role in delusions (Dysken et al., 1978; Janowsky & Risch 
1979). This theory also overlaps with contemporary theories (Kapur 2003), which 
propose that hyperdopaminergia leads to the ‘aberrant assignment of salience to 











Further support for the dopaminergic theory of psychotic symptoms has come from 
neuroimaging techniques such as PET, which are able to visualise striatal D2/3 
receptors in vivo. The majority of research in this area has focused upon young 
adults with schizophrenia, and has provided evidence of increased striatal D2/3 
receptor density, independent of the effects of antipsychotic medication (Kestler et 
al., 2001; Laruelle 1998; Zakzanis & Hansen 1998). This area of research has been 
largely neglected in people with dementia. In one study, PET imaging using 
[
11
C]raclopride showed increased striatal D2/3 receptor availability to be associated 
with psychotic symptoms (predominantly mild, transient delusions) in AD (Reeves 
et al., 2009). This study observed a 14% increase in tracer binding in the striatum of 
delusional patients compared to those without delusions (Figure 3.3), consistent with 
data on young adults with schizophrenia (Kestler et al., 2001; Laruelle 1998; 
Zakzanis & Hansen 1998). The findings are also consistent with a study which 
compared psychotic and non-psychotic patients with bipolar disorder (Pearlson et al., 
1995), and are supported by several post-mortem studies which showed an increase 
in D3 receptor availability in those with psychotic symptoms in AD (Sweet et al., 
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2001), and in schizophrenia (Gurevich et al., 1997). Taken together, these findings 
are supportive of a shared dopaminergic aetiology of delusions, and warrant further 
exploration (reviewed by Reeves et al. (2012) – discussed in Chapter 6, Section 
6.3.1). 
 












(Reeves et al., 2009) 
 
3.1.3 Cognitive Correlates of Psychotic Symptoms in AD 
Studying the neuropsychological correlates of psychotic symptoms in AD provides 
an additional method of gaining a more thorough understanding of the underlying 
pathophysiology. It may help to identify markers that may herald the onset or predict 
progression of psychotic symptoms, and may potentially identify discrete functional 
networks involved in the pathophysiology of these symptoms. Defining a 
neuropsychological profile for psychotic symptoms in AD has, however, proved 
challenging due to the many inconsistencies reported in the literature. Many studies 
have reported more severe cognitive impairment in those with psychotic symptoms 
compared to those without, based on MMSE score (Bassiony & Lyketsos 2003; 
Fischer et al., 2006; Gilley et al., 1991; Jeste et al., 1992; Mizrahi et al., 2006). 
However, this is a global measure of cognition and in order to determine the 
underlying pathology of such psychotic symptoms, more specific cognitive profiling 
must occur.  
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Confounding factors such as age, education level and dementia severity (as measured 
by a global cognitive measure such as the MMSE) need to be carefully controlled for 
when comparing neuropsychological test performance. If not already controlled for 
in the recruitment stage (e.g. matched case-control designs), confounding variables 
such as these must be taken into account during the analysis stage in order to prevent 
the misinterpretation of results. The importance of controlling for these effects is 
demonstrated by studies in which impairments in verbal fluency in the psychotic 
group fail to remain significant after controlling for dementia severity (Chen et al., 
1998; Perez-Madriñan et al., 2004). Such results suggest that the differences seen 
between psychotic and non-psychotic groups were due to differing levels of global 
cognitive decline, rather than executive functioning per se. Focusing solely on those 
studies which have controlled for potential confounding effects, executive function 
deficits have been reported in those with psychotic symptoms, as measured by the 
Clock Drawing Task (Heinik et al., 2001), and a Frontal Assessment Battery (FAB; 
tests of conceptualisation, mental flexibility, inhibitory control, motor programming 
and sensitivity to interference) (Nagata et al., 2009). In contrast, improved 
attentional performance on the attention/calculation subset of a modified MMSE has 
been reported in those with psychotic symptoms in AD, compared to those without 
(Bylsma et al., 1994). Delusions have also been associated with episodic 
confabulation, a falsification of memory typically associated with frontal lobe 
dysfunction (Fischer et al., 1995; Johnson et al., 1997; Moscovitch & Melo 1997), 
both in a group who exhibited delusions and aggression (Lee et al., 2007), and in 
those with delusions alone (Lee et al., 2009). However, in contrast to the above 
studies, much of the literature reports negative findings on the association of 
psychotic symptoms with tasks of executive function, memory, language, and 
visuospatial function (Migliorelli et al., 1995; Mizrahi et al., 2006; Perez-Madriñan 
et al., 2004; Starkstein et al., 1994). 
Another potentially confounding factor in the analysis of neuropsychological test 
performance is the use of past or present psychotropic medication. Only two of the 
above studies adequately controlled for this, either by excluding subjects who had 
taken psychotropic medication within the 3 weeks prior to assessment (Chen et al., 
1998), or by excluding subjects on the basis of past or present psychotropic use 
(Mizrahi et al., 2006). In contrast, Nagata et al. (2009) excluded patients taking 
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Cholinesterase Inhibitors (ChEI), however made no mention of psychotropic 
medication (Nagata et al., 2009). The inconsistencies amongst studies makes it 
difficult to compare results and to reach any substantial conclusions about the 
cognitive correlates of psychotic symptoms in AD, given that psychotropic 
medication may interfere with cognition and/or dopamine transmission.  
One way of improving the consistency of reported neuropsychological correlates of 
psychotic symptoms in AD may be to use a more hypothesis-driven approach to the 
choice of cognitive domains tested. After finding an association between increased 
striatal D2/3 availability and delusions in AD (Figure 3.3), Reeves et al. (2010) used 
the same sample to demonstrate that increased striatal dopaminergic D2/3 receptor 
activity (as measured by [
11
C] RAC binding) was also associated with specific 
aspects of cognitive and motor function, including increased motor speed and poorer 
attentional performance (recorded as the number of accurate responses on a task of 
Rapid Visual Processing (RVP)). These results are illustrated in Figures 3.4 & 3.5, 
respectively. The findings suggest that specific aspects of neuropsychological test 
performance may differ between psychotic and non-psychotic patients with AD 
because of their inherent links with dopaminergic neurotransmission. If this were 
found to be the case, such tests may be more sensitive markers of psychotic 
symptoms in AD than standard neuropsychological test performance measures, and 
could potentially be utilised to monitor the functional consequences of D2/3 
antagonism by antipsychotic medication. Given that the entire sample of the above 
study experienced persecutory as opposed to misidentification delusions, it is unclear 
whether or not the tests may be cognitive markers of the psychosis phenotype or 
more specifically persecutory delusions, prompting a discussion of psychotic 
subtypes later in this chapter. 
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Figure 3.4: Scatter Plot Showing Correlation Between Striatal [
11
C] RAC Binding 
(i.e. measure of D2/3 receptor availability) and Performance on Motor Latency Task 
 
 
Figure 3.5: Scatter Plot Showing Correlation Between Striatal [
11
C] RAC Binding 
and Performance on RVP Task (higher score indicates better attentional 
performance) 
  
   
(Reeves et al., 2010) 
 
Regression analysis is a common method used to determine whether certain 
cognitive tasks are sensitive markers of psychotic symptoms in AD. For example, 
regression models, such as logistic regression, allow the researcher to determine the 
effects of multiple independent variables on an outcome measure, and hence are 
widely used to determine predictor variables, whilst controlling for several 
potentially confounding variables. Previous studies which have used this technique 
have identified the total score on the FAB (Nagata et al., 2009), a task of executive 
function (Hopkins & Libon 2005), and the total MMSE score (Mizrahi et al., 2006), 
as predictors of psychotic symptoms in AD. Performing regression analysis on 
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hypothesis-driven neuropsychological tests would provide additional information 
regarding the suitability of specific tests to act as cognitive markers of psychotic 
symptoms in AD.  
 
3.1.4 Psychosis Versus Delusional Subtypes 
Following the initial report of psychotic symptoms in AD (Alzheimer 1907), the 
literature classified such symptoms as ‘senile psychosis’, which referred to psychosis 
in elderly patients with dementia (Jeste & Finkel 2000). An abundance of research 
was seen in this area in subsequent years, providing clear evidence that the psychotic 
symptoms and associated features seen in AD were different to those of other 
dementias and brain disorders with psychotic symptomatology. For example, 
compared to the complex and bizarre delusions reported in schizophrenia, the 
delusions reported in AD are more simple and typically of the paranoid type, whilst 
hallucinations are predominantly visual in AD compared to a high frequency of 
auditory hallucinations in schizophrenia (Jeste & Finkel 2000). Such differences, 
together with the distinct phenotype associated with psychotic symptoms in AD, i.e. 
more rapid cognitive and functional decline, and increased liability to aggressive 
behaviour (Ropacki & Jeste 2005; Scarmeas et al., 2005), led to psychosis in AD 
being classified as a distinct syndrome, with individual diagnostic criteria (Jeste & 
Finkel 2000). In support of a distinct phenotype, several studies reported a 
suggestive genetic link underlying the presence of psychotic symptoms in AD 
(Sweet et al., 2010; Sweet et al., 2003).  
However, in contrast to the global view of psychotic symptoms, some authors view 
delusions and hallucinations as distinct phenotypes with separate clinical correlates 
(Ballard et al., 1995; Bassiony & Lyketsos 2003; Bassiony et al., 2000). Clinical 
factors such as older age, depression, aggression and poorer general health have been 
associated with delusions (Bassiony & Lyketsos 2003; Bassiony et al., 2000), while 
factors such as visual impairment, less education, more severe dementia, longer 
duration of illness, and falls have been linked to hallucinations (Ballard et al., 1995; 
Bassiony et al., 2000). Separate neurobiological correlates have also been reported, 
for example the involvement of the occipital lobes helps to distinguish visual 
hallucinations from other psychotic symptoms (Casanova et al., 2011).  
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Others argue, however, for distinct subtypes of delusions, given the diversity of false 
beliefs reported in AD. As mentioned previously, psychotic phenomena were 
initially classified into three broad domains; paranoid delusions, misidentification 
delusions and hallucinations, based on qualitatively similar content (Drevets & 
Rubin 1989; Rubin et al., 1988). Research into whether these classifications form 
distinct subtypes of psychotic symptoms in AD is limited, however the low 
correlation (0.12) reported between paranoid and misidentification delusions 
(Devanand et al., 1992) is suggestive of independently occurring phenomena.  
More recently, factor and cluster analyses were applied to the psychosis items from 
the CERAD Behavioural Rating Scale (CBRS) (Tariot 1996), in order to identify the 
subtypes of psychotic symptoms in AD (Cook et al., 2003). The results from this 
study suggested that symptoms loaded onto two factors, which the authors described 
as 'paranoid' (persecutory delusions and delusions of abandonment) and 
‘misidentification’ (misidentification delusions and/or visual hallucinations) 
subtypes (Cook et al., 2003). This classification identifies more homogenous groups 
for analysis, and has since been used by a number of researchers examining the 
neurobiological and neuropsychological correlates of psychotic symptoms (Perez-
Madriñan et al., 2004; Wilkosz et al., 2006). Such studies indicate that the two 
subtypes may be characterised by different cognitive trajectories, with frequent 
reports of a lower MMSE score in patients with misidentification delusions and/or 
hallucinations (Devanand et al., 1992) but not persecutory delusions (Burns et al., 
1990a; Perez-Madriñan et al., 2004), when compared to non-psychotic AD patients. 
However, evidence from longitudinal data suggests that lower MMSE scores may 
only predict proneness to misidentification phenomena (Devanand et al., 1997; 
Wilkosz et al., 2006). These findings suggest that the paranoid and misidentification 
subtypes may be both phenomenologically and biologically distinct (Ismail et al., 
2011; Reeves et al., 2012). It is also possible that the two subtypes are part of a 
continuum (discussed by Reeves et al., 2012); persecutory delusions occurring early 
in the course of the disease, hence showing only subtle differences with non-
psychotic groups; and misidentification delusions forming later in the disease 
progression, presenting with more marked cognitive differences compared to the 
non-psychotic group. However, cognitive trajectories in relation to delusional 
subtypes have not yet been explored. 
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Due to the above mentioned inconsistencies in study design and categorisation of 
psychotic symptoms, it is only possible to draw broad conclusions from the existing 
data on the cognitive correlates of psychotic symptoms in AD. Studies which aim to 
identify the cognitive correlates of the psychotic subtypes in AD may support the 
classification of the subtypes as distinct entities, and may enhance further 
investigations of the psychotic symptoms in AD by identifying more homogenous 
groups for genetic, neuroimaging and post-mortem studies. Focusing analyses on 
hypothesis-driven tests, such as those intimately linked with dopaminergic function 
(Reeves et al., 2010) could prove useful in further explaining the pathology 
underlying psychotic symptoms in AD, and determining whether such pathology is 
subtype specific. Such research may result in more accurate treatment and 
monitoring of psychotic symptoms in AD. 
 
3.1.5 Aims 
The primary aims were: 
1. To test the hypothesis that cognitive tests which correlate with dopamine 
function will differ between psychotic and non-psychotic AD patients. 
2. To establish the neuropsychological profile of psychotic symptoms in AD. 
 
The secondary aims were: 
1. To further explore any significant between-group differences in 
neuropsychological test performance in terms of paranoid (persecutory 
delusions) and misidentification (misidentification delusions and/or visual 
hallucinations) subtypes. 
2. To examine whether neuropsychological test performance can predict the 





The sample has been described previously (Chapter 2, Section 2.1.2). 
 
3.2.2 Neuropsychological Tests 
The neuropsychological test battery has been described previously (Chapter 2, 
Section 2.2.3). Tests of motor speed (simple reaction time, SRT) and sustained 
attention (rapid visual processing, RVP) were analysed first. These tests were 
separated from their cognitive domains in order to carry out a more focused, 
hypothesis-driven, investigation of tests with demonstrated links to dopaminergic 
function (Reeves et al., 2010). In order to establish a full neuropsychological profile 
of psychotic symptoms in AD, the remaining neuropsychological test measures were 
organised into the following cognitive domains: executive function, memory, 
language, constructional praxis and visuoperceptual function.  
 
3.2.3 Procedure 
The procedure has been described previously (Chapter 2, Section 2.2.4). 
 
3.2.4 Statistics 
All data were analysed using IBM SPSS Statistics 19. Prior to statistical analysis, 
data outliers were identified as those values which exceeded 1.5 x the interquartile 
range for each group for a particular variable, and were replaced with the nearest 
value for that group. This resulted in 1.3% of values being replaced in the non-
psychotic group, and 0.8% of values being replaced in the psychotic group. The 
alternative procedure of dealing with outliers by deleting the subject’s data-point was 
not used due to the small sample size in the current study. 
Prior to performing the analysis, data were checked for normality: skewness and 
kurtosis z score between -1.96 and 1.96 (Ghasemi & Zahediasl 2012; Kim 2013), 
homogeneity of variance (Levene’s statistic), homogeneity of regression, and 
linearity between dependent variables and covariates. Data submitted to MANCOVA 
were also assessed for homogeneity of variance covariance matrices (Box’s M Test). 
 90 
Data which violated both the assumption of normality and homogeneity of variance 
were transformed to fulfil at least one assumption (Olejnik & Algina 1984). 
Transformations were as follows, where x represents the test score: MMSE = x
4
; 
Delayed Visual Recall = log10(x+1); Incomplete Letters = x
2
. The transformed scales 
were used in the analysis, and the means and standard errors (SE) of these variables 
are reported in the transformed scale. The mean is also reported in the original scale 
(back-transformed) to enable ease of interpretation and comparison with other test 
variables in the respective cognitive domains. However, the SE cannot be back-
transformed in this way and has therefore not been presented in the original scale 
(Jørgensen & Pedersen 1998). For comparison, the transformed and untransformed 
means and SE have been reported in Appendix 7.4.1. Data which violated the 
assumption of homogeneity of variance were analysed using a stricter alpha level 
(p<0.025; Tabachnick & Fidell, 2012). Data which violated the assumption of 
homogeneity of regression were omitted from the analysis.  
Between-group differences in demographic data were analysed using independent 
samples t-tests, with the presence of psychotic symptoms as the grouping variable. 
Separate MANCOVAs were performed for multiple dependent variables in specific 
cognitive domains, and ANCOVAs were carried out where there was only one 
dependent variable in a cognitive domain. The result of each MANCOVA was 
determined using the Pillai criterion, which is more robust than other options to 
unequal sample sizes and violations of homogeneity of covariance (Tabachnick & 
Fidell 2012). Where a MANCOVA resulted in a significant main effect (p<0.05), 
data were submitted to separate ANCOVAs. Significant differences were determined 
using a Bonferroni adjusted alpha level, and Fisher’s Least Significant Difference 
test (LSD), to correct for multiple pairwise comparisons. Logistic regression was 
then applied to tests which showed significant between-group differences, in order to 
evaluate the extent to which test performance can predict psychotic symptoms. 
Data were first analysed using a global approach to psychotic symptoms i.e. those 
with delusions or hallucinations vs. those with no psychotic symptoms, in order to 
allow for comparison with a greater number of studies in the literature, and to 
maximise the sample size in each group. Post-hoc analyses of delusional subtypes 
were only applied to tests which showed significant between-group differences, so as 
to avoid type 1 errors through multiple comparisons. 
 91 
3.3 Results 
3.3.1 Prevalence  
A total of 80 subjects were recruited to this study. However, upon screening, 10 
subjects were excluded on the basis of specified criteria (detailed in Chapter 2, 
Section 2.1.2): three subjects had an MMSE score of less than 10, one scored above 
6 on the GDS-15, three were taking antidepressants at the time of assessment, one 
had significant cerebrovascular pathology, and two were clinically diagnosed with 
psychiatric disorders other than AD. Of the remaining 70 subjects, 34 (48.6%) had 
experienced a psychotic symptom since the onset of memory difficulties. 82% (n = 
28) of this group were still presenting with the symptoms at the time of assessment, 
while 18% (n = 6) reported symptoms as present within the last year.  
Table 3.2 details the phenomenology of psychotic symptoms in the sample. The 
most common occurring delusions were of a persecutory type, primarily involving 
ideas of theft, and were present in approximately 30% of the sample. Hallucinations 






Note: Some subjects experienced multiple delusions within and across each classification. 
1
Content taken from subscales of NPI. 
2
Ever experienced + currently 
experienced (only presented if different from currently experienced).  
 












Persecutory In danger/others are planning to hurt him/her -   1      (1.4)  
 Others are stealing from him/her 3    (4.3) 17    (24.3) 20    (28.6) 
 Spouse is having an affair -   3      (4.3)  
 Family members plan to abandon him/her -   5      (7.1)  
     
Misidentification Unwelcome guests are staying in his/her house 4    (5.7)   6      (8.6) 10    (14.3) 
 His/her spouse or others are not who they claim to be 1    (1.4)   4      (5.7)   5      (7.1) 
 His/her house is not his/her own 2    (2.9)   6      (8.6)   8    (11.4) 
 Television/magazine figures are present in his/her home -   -  
 Any other unusual beliefs 
- Inanimate objects are alive 
- He/she has won an award 
- He/she is part of a police operation 
- He/she is living in the middle of the war and must escape 
-   6      (8.6) 
  2      (2.9) 
  2      (2.9) 
  1      (1.4) 
  1      (1.4) 
 
     
Hallucinations He/she can hear voices -   2      (2.9)  
 Talks to people who are not there -   1      (1.4)  
 Seeing things not seen by others 1    (1.4)   4      (5.7) 5      (7.1) 
 Smells odours not smelled by others -   -  
 Feel things on his/her skin -   -  
 Tastes without known cause -   -  
 Any other unusual sensory experiences -   -  
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Psychotic symptoms were further grouped into two specific subtypes, based on the 
classification described by Cook et al. (2003); Paranoid only and Misidentification 
only. Subjects experiencing both types of delusions were grouped into a third 
subtype; Paranoid and Misidentification. Table 3.3 shows the frequency of each 
subtype within the sample. The highest proportion (20%) of the sample reported only 
the paranoid subtype, while approximately 17% were grouped in the 
misidentification subtype, and only 8 (11.4%) subjects exhibited both subtypes.  
 
Table 3.3: Psychotic Subgroups    
Group Male N Female N Total N (%) 
Non-Psychotic 
 
16 20 36  (51.4) 
Psychotic 
- Paranoid only 
- Misidentification only 
- Paranoid &Misidentification 
16 
  6 
  7 
  3 
18 
  8 
  5 
  5 
34  (48.6) 
14  (20.0) 
12  (17.1) 
  8  (11.4) 
 
Total 32 38 70 
 
3.3.2 Demographics 
Demographic data on psychotic and non-psychotic subjects are described in Table 
3.4. The psychotic group were older (t(68) = -2.67, P = 0.01) and had a lower 
estimated Premorbid IQ (t(68) = 2.34, P = 0.02) than the non-psychotic group, but 
there were no differences in years of education or MMSE (t= 0.31, p = 0.76; t = 1.78, 
p = 0.08 respectively). 
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Note: n = 36 in non-psychotic group and n = 34 in psychotic group. 
t
Data transformed to fulfil 







Significant at p<0.05. 
 
3.3.3 Neuropsychological Test Scores 
Unless stated otherwise, age was included as a covariate in ANCOVAs or 
MANCOVAs. MMSE and number of years of education were also included as 
covariates, in order to control for the potentially confounding effects of global 
cognitive level, and educational level. NART errors (and hence estimated premorbid 
IQ) were not included as a covariate since performance on this test can be affected 
by the severity of dementia (Taylor 2000). The UPDRS was used solely as a 
screening tool, and was not included as a covariate as all participants scored below 
the cut-off score of 8 out of 20. 
Table 3.4: Demographics     
 Group Mean SE T-value P-value 











































 1.78 0.08 
NART errors  



































Adjusted means, standard errors (SE), standard deviations (SD), between-group 
comparisons and estimated effect sizes (ηp
2




The main effect of the presence of psychotic symptoms on motor speed failed to 
reach statistical significance (F(1,64) =  1.40, p = 0.24, ηp
2 




Adjusted mean with constant covariates - age, transformed MMSE and years of education. n = 
33 in psychotic group as one subject was unable to complete this task. Exclusion of subjects not 
currently experiencing psychotic symptoms (n = 6) made no difference to the findings (see Appendix 
7.3.2, Table 2). 
 
Sustained Attention 
There was a significant main effect of the presence of psychotic symptoms on this 
task of sustained attention (F(1,60) = 6.91, p = 0.01, ηp
2
= 0.10). Those with psychotic 
symptoms achieved fewer correct responses compared to the non-psychotic group, 
suggesting poorer sustained attention in the psychotic group. Age was not included 




Adjusted mean with constant covariates - transformed MMSE and years of education. n = 30 in 
psychotic group as four subjects were unable to complete the task, and n = 34 in non-psychotic group 
as two subjects were unable to complete this task. 
*
Significant main effect at p<0.05. Exclusion of 
subjects not currently experiencing psychotic symptoms (n = 6) made no difference to the findings 
(see Appendix 7.3.2, Table 3). 
Table 3.5.1: Motor Speed - Analysis of Covariance 




















1.40 0.24 0.02 
Table 3.5.2: Sustained Attention - Analysis of Covariance 























Neuropsychological Correlates of Psychotic Symptoms in AD 
Adjusted means, standard errors (SE), between-group comparisons and estimated 
effect sizes (ηp
2
) for the executive function, memory, language, praxis and 
visuoperceptual domains are displayed in tables 3.5.3 to 3.5.7 respectively. The SD 
is also reported for analyses which reached statistical significance.  
 
Executive Function 
The main effect of the presence of psychotic symptoms on tasks of executive 
function failed to reach statistical significance (F(1,55) = 0.89, P = 0.51, ηp
2 
= 0.10). 





Adjusted mean with constant covariates - transformed MMSE and years of education. n = 25 in 
psychotic group as nine subjects were unable to complete at least one of the tasks from this cognitive 
domain, and n = 34 in non-psychotic group as two subjects were unable to complete at least one of the 
tasks. Exclusion of subjects not currently experiencing psychotic symptoms (n = 6) made no 
difference to the findings (see Appendix 7.4.2, Table 4). 
Table 3.5.3: Executive Function - Multivariate Analysis of Covariance 


















0.89 0.51 0.10 
Phonemic Fluency 


























   














Hayling total errors 





























The main effect of psychotic symptoms on memory failed to reach statistical 
significance (F(1,65) = 0.88, P = 0.50, ηp
2 




Adjusted mean with constant covariates - age, transformed MMSE and years of education. 
t
Data transformed to fit homogeneity of variance assumption, mean and SE in transformed scale 
log10(x+1). 
b
Back-transformed mean. Exclusion of subjects not currently experiencing psychotic 
symptoms (n = 6) made no difference to the findings (see Appendix 7.4.2, Table 5). 
 
Language 
The main effect of the presence of psychotic symptoms on language failed to reach 






Adjusted mean with constant covariates - age, transformed MMSE and years of education. 
Exclusion of subjects not currently experiencing psychotic symptoms (n = 6) made no difference to 
the findings (see Appendix 7.4.2, Table 6). 
 
 
Table 3.5.4: Memory - Multivariate Analysis of Covariance  





















0.88 0.50 0.07  
Delayed Verbal Recall 

































    
Delayed Verbal 
Recognition 



























Table 3.5.5: Language - Analysis of Covariance 
Test Group Mean SE F-ratio P-value ηp
2
 
Boston Naming Test 











0.42 0.52 0.01 
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Constructional Praxis 
The main effect of the presence of psychotic symptoms on constructional praxis 






Adjusted mean with constant covariates - age, transformed MMSE and years of education. n = 
35 in non-psychotic group as one subject was unable to complete at least one of the tasks in this 
domain. Exclusion of subjects not currently experiencing psychotic symptoms (n = 6) made no 
difference to the findings (see Appendix 7.4.2, Table 7). 
Table 3.5.6: Constructional Praxis - Multivariate Analysis of Covariance 
Test Group Mean SE F-ratio P-value ηp
2
 













1.63 0.20 0.05 
   
Clock Drawing Task 
























Adjusted mean with constant covariates - age, transformed MMSE and years of education. n = 33 in psychotic group as one subject was unable to complete 
at least one of the tasks in this domain. 
*
Significant main effect at p<0.025 as Levene's test was significant (p<0.001) for Incomplete Letters.
 t
Data transformed to 
fit normality assumption, mean and SE in transformed scale. 
b
Back-transformed mean. Exclusion of subjects not currently experiencing psychotic symptoms (n = 
6) made no difference to the findings (see Appendix 7.4.2, Table 8). 
 
 
Table 3.5.7: Visuoperceptual Function – Multivariate Analysis of Covariance 









































    
    
Number Location 































Analysis of each individual dependent variable, using a Bonferroni adjusted alpha 
level of p<0.0125, showed that the presence of psychotic symptoms had a significant 
effect on performance on the Incomplete Letters task (F(1,64) = 9.85, P =0.003, ηp
2  
= 
0.13; Table 3.5.8). 
 
Table 3.5.8: Visuoperceptual Function - Posthoc Pairwise Comparisons 









   0.13 
Object Decision  
(maximum = 20) 
 
3.88 0.053   0.06 
Number Location  
(maximum = 10) 
 
1.56 0.22   0.02 
Cube Analysis  
(maximum = 10) 
0.02 0.90 <0.001 
Note: 
t
Data transformed to fit normality assumption. 
*
Significant at Bonferroni adjusted alpha level, 
p<0.0125. Exclusion of subjects not currently experiencing psychotic symptoms (n = 6) made no 
difference to the findings (see Appendix 7.4.2, Table 9).  
 
3.3.4 Post-hoc Analyses of Psychotic Subgroups 
Given the significant between-group differences observed in a task of sustained 
attention and one of visuoperceptual function, data were further analysed to 
determine the effect of specific subtypes of psychotic symptoms on task 
performance.  
 
Sustained Attention: Subgroup Analysis 
Adjusted means, SE, SD and a between-group comparison of sustained attention are 
shown in Table 3.6.1. There was a significant main effect of the subtype of psychotic 
symptom on sustained attention (F(3,57) = 3.39, p = 0.02, ηp
2 
= 0.15). Post-hoc Fisher's 
LSD pairwise comparisons showed that accuracy rates were significantly lower in 
the misidentification group compared to the non-psychotic group (p = 0.004). No 





Adjusted mean with constant covariates - age, transformed MMSE and years of education. n = 
13 in paranoid group and n = 11 in misidentification group as one subject from each group was unable 
to complete the task. n = 6 in paranoid & misidentification group and n = 34 in non-psychotic group 
as two subjects from each group were unable to complete the task. 
*




Significant mean difference at p<0.05. Multiple comparisons corrected for using Fisher’s LSD.  
 
Visuoperceptual Function: Subgroup Analysis 
Adjusted means, SE, SD and a between-group comparison of visuoperceptual 
function are shown in Table 3.6.3. There was a significant main effect of the subtype 
of psychotic symptom on visuoperceptual function (F(3,62) = 3.54, p<0.001, ηp
2 
= 
0.19). Individual analysis of each dependent variable, using a Bonferroni adjusted 
alpha level of p<0.0125, showed only the Incomplete Letters task to significantly 
differ between psychotic subgroups (F(3,62) = 11.81, p<0.001; Table 3.6.4). Post-hoc 
Fisher's LSD pairwise comparisons showed that the score on the Incomplete Letters 
task was significantly lower in the misidentification subgroup compared to the non-
psychotic group (p<0.001), paranoid group (p = 0.001), and those with both 
misidentification and paranoid subtypes (p<0.001). No other significant between-
group differences were observed (Table 3.6.5). 
Table 3.6.1: Sustained Attention – Subgroup Analysis of Covariance 





























Table 3.6.2: Sustained Attention – Posthoc Pairwise Comparisons 





Non-Psychotic Paranoid  
Misidentification 






























Adjusted mean with constant covariates - age, transformed MMSE and years of education. n = 7 in the paranoid & misidentification group as one subject 
was unable to complete the number location task. 
*
Significant main effect at p<0.025 as Levene's test was significant (p<0.001) for Incomplete Letters.
Table 3.6.3: Visuoperceptual Function – Subgroup Multivariate Analysis of Covariance  
Test Psychotic Subtype Mean SE SD F-ratio P-value ηp
2
 
Incomplete Letters Non-Psychotic  
Paranoid 
Misidentification 





















Object Decision Non-Psychotic  
Paranoid 
Misidentification 


















Number Location Non-Psychotic  
Paranoid 
Misidentification 


















Cube Analysis Non-Psychotic  
Paranoid 
Misidentification 

















































*Significant mean difference at p<0.05. Multiple comparisons corrected for using Fisher’s LSD. 
 
Table 3.6.4: Visuoperceptual Function – Between Subjects Effects 
 Test F-ratio P-Value 











  0.22 
  0.05 
  0.02 
Table 3.6.5: Visuoperceptual Function – Posthoc Pairwise Comparisons 
 Psychotic Subtype Mean difference 
(A-B) 
SE P-value 
Test A                 B 
Incomplete Letters Non-Psychotic Paranoid 
Misidentification 










  0.09 
<0.001 
  0.74 
Paranoid Misidentification 








  0.001 
  0.14 




 1.34 <0.001 
 104 
3.3.5 Logistic Regression 
To further explore between-group differences observed in sustained attention and 
visuoperceptual function, logistic regression analysis was performed to determine 
whether these neuropsychological test measures could act as predictors of psychotic 
symptoms in AD. First, separate univariate analyses were performed to determine 
the relationship of each neuropsychological test on the presence of psychotic 
symptoms, after controlling for age, MMSE score and years of education. Both the 
RVP and Incomplete Letters task had a significant effect on the presence of 
psychotic symptoms (p = 0.03 and p = 0.02, respectively; Table 3.7). Both 
neuropsychological tests were then entered into a multivariate logistic regression 
model, with the presence of psychotic symptoms as the dependent variable, and the 
RVP and Incomplete Letters task as the independent variables. This analysis also 
controlled for potential confounding effects. Table 3.7 shows the results of the 
multivariate logistic regression analysis. A total of 64 cases were analysed and the 
full model was highly significant (chi-squared = 21.34, df = 5, p = 0.001), 
accounting for between 28.4 and 37.9% (Cox & Snell and Nagelkerke R Square, 
respectively) of the variance in psychotic symptoms. The model correctly predicted 
73.4% of cases, with a specificity of 76.5%, and sensitivity of 70%. The Wald 
statistic and P-values demonstrate that performance on the Incomplete Letters task 
made a significant independent contribution to the prediction of psychotic symptoms 
(p = 0.048). However, performance on the RVP task (sustained attention) did not 
reach statistical significance for an independent contribution to the prediction of 
psychotic symptoms in AD (p = 0.14). The odds ratio indicates that for each correct 
response in the Incomplete Letters task, the odds of psychotic symptoms are reduced 
by a factor of 0.76. 
Note: All logistic regression analyses were controlled for age, MMSE and years of education. 
*
Significant at p<0.05 
Table 3.7: Logistic Regression   




Rapid Visual Processing Task 











Multivariate Rapid Visual Processing Task 











The results of the current study showed a statistically significant between-group 
(psychotic vs. non-psychotic) difference on one of the two hypothesis-driven tests 
(sustained attention (RVP), not motor latency (SRT)), and also on a task of 
visuoperceptual function (Incomplete Letters). Post-hoc analyses revealed both 
significant differences to be driven by the misidentification subgroup of delusions, 
and the logistic regression analyses showed only the Incomplete Letters task made a 
significant independent contribution to the prediction of psychotic symptoms. The 
results are discussed below. 
 
3.4.1 Phenomenology 
Of the 34 patients in the psychotic group, 82.4% presented with delusions in the 
absence of hallucinations. Consistent with the literature, the most common 
delusional belief involved ideas of theft (Ropacki & Jeste 2005). Phantom boarder 
syndrome, i.e. the belief that unwelcome guests are in the house, was the most 
frequently reported misidentification delusion, consistent with previous reports 
(Burns et al., 1990b). The phantom boarder was variously described as a relative, an 
unfamiliar individual or somebody who had previously passed away. In the majority 
of cases, the subjects felt that the phantom boarder meant them no harm, and would 
repeatedly ask the caregiver whether the person had left yet. However, one subject 
felt that the phantom boarder intended to harm her and believed she was receiving 
threatening letters from the unfamiliar individual. The other unusual beliefs listed in 
Table 3.2 included beliefs that dolls and teddy bears were alive, which led to the 
subjects talking to and trying to feed the objects. Beliefs from the subjects that they 
had won an award also occurred, with one man taking his wife to the council’s office 
to collect his award, and another convinced that the queen had awarded him a prize 
for his services to the chaplaincy. Hallucinations were reported in 10% of the 
sample, and were predominantly visual (7.1%). The lower prevalence rate of 
hallucinations compared to delusions is well reported in the literature (Ropacki & 
Jeste 2005; Savva et al., 2009; Steinberg et al., 2008; Sweet et al., 2010), as is the 
predominance of visual hallucinations over auditory or other sensory modalities 
(Ropacki & Jeste 2005). 
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Using the classification of psychosis suggested by Cook et al. (2003), 20% of the 
current sample presented with the paranoid subtype, and 17.1% reported the 
misidentification subtype. Both paranoid and misidentification subtypes were present 
in a small proportion of subjects (11.4%). The distribution of the paranoid and 
combined subgroups is comparable to a previous study which aimed to validate 
Cook et al.’s proposed subtypes (Perez-Madriñan et al., 2004). However, the 
prevalence rate of those experiencing misidentification phenomena is much lower in 
the current study's sample (17.1% compared to 26.9%). The increased prevalence of 
misidentification phenomena reported by Perez-Madriñan et al. (2004) may reflect 
differences in disease severity between the samples. The mean MMSE score in the 
psychotic group in the current study was 22.8, compared to a much lower range of 
13.4-16.9 reported by Perez-Madriñan et al. These findings are consistent with 
suggestions that misidentification phenomena occur in the more advanced stages of 
AD (Burns et al., 1990a; Devanand et al., 1992; Harwood et al., 1999; Harwood et 
al., 1998) – reviewed by Reeves et al. (2012).  
 
3.4.2 Hypothesis-Driven Tests  
The primary aim of this study was to test the hypothesis that tasks which correlate 
with dopamine function will differ between psychotic and non-psychotic AD 
patients. The finding that the accuracy of performance on a sustained attentional task 
(RVP) was significantly poorer in the psychotic group is consistent with previous 
studies, which found that higher D2/3 receptor availability in patients with mild to 
moderate AD was associated with both the presence of delusions (Reeves et al., 
2009) and poorer performance on this task (Reeves et al., 2010). This is also 
comparable to studies which report sustained attention deficits in other clinical 
populations in which dopamine has been implicated, including schizophrenia and 
ADHD (Bozikas et al., 2005; Stins et al., 2005). Subgroup analysis of the results 
suggests that the observed differences in test performance between psychotic and 
non-psychotic groups may be underpinned by the misidentification subtype.  
In contrast, the current results are inconsistent with several studies which were 
unable to detect significant differences between those with and without psychotic 
symptoms on tasks measuring attention (Jeste et al., 1992; Lee et al., 2007; 
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Murayama et al., 2009). However, in these latter studies the tests used to assess 
attention were taken from larger global tests of cognition, such as the Dementia 
Rating Scale (DRS) and the Cognitive Abilities Screening Instrument (CASI), where 
the attentional subscales included tasks more specific to working memory (e.g. digit 
span, repetition and subtraction), as opposed to sustained attention. 
Sustained attention has been primarily linked to the prefrontal cortex, with several 
studies reporting increased cortical [
18
F]fluoro-L-dopa (FDOPA) uptake in the 
dorsolateral prefrontal cortex to be associated with attentional performance (Cabeza 
& Nyberg 2000). Evidence for the role of dopamine in this region has been provided 
by pharmacological studies involving stimulant drugs such as amphetamine and 
methylphenidate which act on dopamine transporters to increase dopamine release, 
and are currently used as treatment for ADHD (Volkow et al., 2012). In addition, 
PET imaging studies using [
11
C]FLB-457 (a selective dopamine D2/3 receptor 
radiotracer) have shown increases in dopamine release in the frontal cortex 
(specifically the anterior cingulate cortex) to be associated with sustained attention 
(Aalto et al., 2005). However, the above literature associates increased dopamine 
release with improved attention. This evidence is contrary to the current findings, 
which demonstrated poorer attention in the psychotic group, who have a 
hypothesised hyperdopaminergic state due to cholinergic/dopaminergic imbalance 
(Cummings 1992). The inconsistency of the literature can possibly be explained by 
the inverted U-shaped curve of dopaminergic function and cognitive performance 
(Arnsten 1997; Goldman-Rakic et al., 2000), which suggests that an optimal level of 
dopaminergic D1 activation in the prefrontal cortex is required for performance of a 
given cognitive task. The fronto-striatal-thalamic circuitry of the dopaminergic 
system, specifically the ‘dorsolateral prefrontal’ circuit, may explain the current 
results, whereby a hyperdopaminergic state in the caudate, as is proposed with the 
psychotic group in the current sample, could inhibit the inhibitory projections to the 
thalamus, resulting in an increased excitatory response to the prefrontal cortex. This 
input may be supra-optimal, resulting in the impaired attentional performance seen in 
the present results. Support for the argument that increased striatal dopamine D2 
receptor function may impair rather than improve attentional performance can be 
obtained from lesion studies carried out in experimental animals, which have shown 
that lesions of the striatum may increase the ability to focus upon the relevant 
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dimensions during an attentional task (Crofts et al., 2001; Roberts et al., 1994). 
Pharmacological studies which have shown that D2 receptor antagonists improve 
performance on the stroop task (Williams et al., 1996), and reverse the impairments 
in performance seen following the use of amphetamine (Van Gaalen et al., 2006), or 
following lesions of the prefrontal cortex (Passetti et al., 2003; Pezze et al., 2009), 
are also consistent with the present findings.  
Tasks of sustained attention have been suggested as a marker of vulnerability to 
schizophrenia, with groups at high risk of developing the disorder also showing 
impairments on these tasks, including first degree relatives of patients with 
schizophrenia (Chen et al., 1998), and non-schizophrenic subjects with high 
schizotypy scores (Lenzenweger et al., 1991). In the current study, the psychotic 
symptoms reported were mild and transient, with no need for antipsychotic 
medication. The fact that differences in RVP performance were observed between 
patients with such mild psychotic symptoms suggests that this may be a sensitive 
marker of psychosis-proneness in AD. However, it is unclear whether the RVP could 
be used as a tool to predict the onset of psychotic symptoms in AD, and longitudinal 
studies would be needed to address this issue directly. Furthermore, the logistical 
regression analysis suggests that, although the RVP may be able to predict 
psychosis, the prediction is more likely due to underlying visual aspects of the task, 
rather than sustained attention itself, given the confounding effect of the Incomplete 
Letters task in the logistic regression model (see Section 3.4.4).  
Contrary to one of the study hypotheses, the difference in motor latency (SRT) 
between the psychotic and non-psychotic groups did not reach statistical 
significance. This is at odds with the previously reported finding of an association 
between motor latency and striatal D2/3 receptor availability in AD (Reeves et al., 
2010). The current finding is also inconsistent with the well documented reaction 
time deficits in disorders in which dopamine has been implicated, including PD 
(Gauntlett-Gilbert & Brown 1998) and schizophrenia (Nuechterlein 1977).  
One of the main differences between the current study and that of Reeves et al. 
(2010) is the choice of task used to measure motor latency. Reeves et al. used the 
motor screening test (MOT) from the CANTAB battery (Robbins et al., 1994) as a 
proxy measure of reaction time. In the MOT, 12 crosses appear on the screen in 
different locations and the subject is asked to touch each cross as quickly as possible. 
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In contrast, the current study employed a computerised SRT task, which had the 
stimulus in a consistent location, and subjects responded via a press pad. A key 
difference between the two tasks is that subjects are required to direct their gaze and 
move their finger to a specified location in the MOT, whereas both gaze and hand 
position remains still in the SRT. It could thus be argued that the additional role of 
dopamine in saccadic eye movements (Hikosaka et al., 2000) and more marked 
finger movements enable the MOT to test the role of dopamine in goal directed 
movement more explicitly than the SRT, therefore making the test more sensitive to 
detecting changes in dopaminergic function (Reeves et al., 2010). However, analysis 
of MOT data from the current study (collected as a practice task) showed no 
significant differences in motor speed between the psychotic and non-psychotic 
group (see Appendix 7.4.3). This could have been due to motivational effects, given 
that the subjects knew the MOT was being used as a familiarisation task. However, 
the present findings could also indicate that motor tasks are not a sensitive measure 
of psychotic symptoms in AD. It is possible that age-related sensory deficits or 
osteoarthritis may impact on the ability of motor tasks to measure between-group 
differences, given that several subjects mentioned some discomfort due to 
osteoarthritis during the task. This could therefore have masked any differences due 
to dopaminergic function.  
Alternatively, the lack of consistent evidence of dopaminergic function in SRT could 
explain the present results. Studies reporting no change in SRT performance after 
pharmacological dopaminergic manipulation in patients with PD has led authors to 
suggest that SRT may not be exclusively dopamine dependent (Pullman et al., 1990; 
Starkstein et al., 1989), which is in contrast to the dopaminergic dependence reported 
in choice reaction time tasks (Pullman et al., 1990). One reason for this could be due 
to the recruitment of additional attention-demanding processes during the SRT task, 
which reduces the sensitivity of the task to measure motor latency (Goodrich et al., 
1989).  
However, the above explanation does not account for the fact that differences were 
not detected on the MOT in the current study. Another possible explanation for the 
current results is that motor function and psychotic symptoms in AD are 
differentially controlled by specific functional subdivisions of the striatum. The 
MOT task was previously shown to correlate with D2/3 receptor availability in the 
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sensorimotor striatum, whereas the greatest percentage change in D2/3 receptor 
availability between those with and without delusions in AD occurred in the 
associative striatum (Reeves et al., 2009; Reeves et al., 2010). The present finding 
could therefore imply that tasks associated with dopamine function in the associative 
striatum are more sensitive cognitive markers of psychotic symptoms in AD, 
compared to tasks which are predominantly associated with dopamine receptor 
availability in the sensorimotor striatum. This is supported by the fact that the RVP 
task, which has previously been shown to correlate with D2/3 availability in the 
associative striatum (Reeves et al., 2010), was able to detect differences between the 
psychotic and non-psychotic groups in the current study.  
 
3.4.3 Neuropsychological Correlates of Psychotic Symptoms in AD 
A second aim of this study was to establish the neuropsychological profile of 
psychotic symptoms in AD. Due to the inconsistency of the findings in the literature, 
the analysis was exploratory rather than hypothesis driven. The present study was 
unable to detect significant differences between psychotic and non-psychotic 
subjects on tasks of executive function, memory, language or constructional praxis. 
There was, however, a significant difference between groups on a task of 




The present finding of no significant difference in executive function between the 
psychotic and non-psychotic group is comparable to the negative findings in much of 
the literature which used similar tasks to assess this cognitive domain, including digit 
span (Jeste et al., 1992; Migliorelli et al., 1995; Mizrahi et al., 2006; Perez-Madriñan 
et al., 2004; Staff et al., 1999; Starkstein et al., 1994), and letter and category fluency 
(Jeste et al., 1992; Lee et al., 2007; Mentis et al., 1995; Mizrahi et al., 2006; Nagata 
et al., 2009; Staff et al., 1999; Starkstein et al., 1994). A few studies have reported a 
significant difference between groups on category fluency (Jeste et al., 1992; Perez-
Madriñan et al., 2004) and letter fluency (Chen et al., 1998), however these 
differences did not remain significant after controlling for MMSE. There is limited 
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literature on the tasks of verbal and motor inhibition (Hayling Sentence Completion 
and Go/No-Go task, respectively) in AD, and more specifically in those with 
psychotic symptoms. However, one study which administered the Go/No-Go task as 
part of the FAB to psychotic and non-psychotic patients with AD, found a significant 
between-group difference on the total FAB score, but were unable to detect a 
significant independent contribution of the Go/No-Go task to the observed 
differences (Nagata et al., 2009). 
Well documented deficits in executive control have been reported in 
neuropsychiatric disorders in which dopamine has been implicated, including ADHD 
(Doyle 2006), schizophrenia (Velligan & Bow-Thomas 1999), and PD (Campos-
Sousa et al., 2010). It is therefore unexpected that the difference in executive 
function between those with and without psychotic symptoms in AD failed to reach 
significance in the current study. One possible explanation for this is that differences 
in executive abilities between psychotic and non-psychotic AD groups were too 
subtle to be detected by the tests used in the current study. The executive deficits in 
disorders linked with dopaminergic function noted above have all been measured in 
comparison to healthy controls, which would serve to enhance any between-group 
differences. Alternatively, it is possible that task complexity contributed to the 
current findings, as nine out of 34 subjects in the psychotic group were unable to 
complete at least one of the tasks in the executive function domain. This reduction in 
sample size may have reduced the power of the analysis to detect significant 
differences between groups. 
 
Memory 
The present study failed to detect a significant difference in memory between 
psychotic and non-psychotic groups. This is comparable to the majority of the 
literature examining the cognitive profile of psychotic symptoms in AD (Lee et al., 
2007; Lopez et al., 1991; Mentis et al., 1995; Migliorelli et al., 1995; Mizrahi et al., 
2006; Murayama et al., 2009; Staff et al., 1999; Starkstein et al., 1994). The only 
studies in which significant differences in memory have been reported between 
psychotic and non-psychotic groups are those in which differences in potential 
confounding variables (e.g. MMSE score) have not been accounted for (Jeste et al., 
1992, Perez-Madriñan et al., 2004). 
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Language 
The current results show no difference in language abilities between the psychotic 
and non-psychotic groups, consistent with previous studies, many of which have 
used the Boston Naming Task (Jeste et al., 1992; Lopez et al., 1991; Mentis et al., 
1995; Migliorelli et al., 1995; Mizrahi et al., 2006; Starkstein et al., 1994). Some 
studies have reported impaired naming (Bylsma et al., 1994), expressive language 
(Aalten et al., 2007; Potkins et al., 2003), and receptive language (Lopez et al., 
1991), in psychotic groups in AD. However, once again these studies did not control 




The present finding of no difference in constructional praxis ability between 
psychotic and non-psychotic groups is consistent with previous studies that have 
reported no difference between groups on the clock drawing task (Jeste et al., 1992), 
‘block design’ tasks (Jeste et al., 1992; Migliorelli et al., 1995; Mizrahi et al., 2006; 
Starkstein et al., 1994), and visual construction components from the CASI (Lee et 
al., 2007). However, it is at odds with that of Heinik et al. (2001), who reported 
impairments on the Clock Drawing task in those with paranoid and delusional 
ideation in AD. Several methodological issues could potentially account for this 
discrepancy between studies. For example, the sample in Heinik et al.’s study was 
smaller in size, had a lower mean MMSE score (overall mean = 17) compared to the 
current study (overall mean = 22) and, in addition, failed to fully control for the 
influence of MMSE score on clock drawing performance between the psychotic and 
non-psychotic groups. Also, neither the presence of hallucinations nor the use of 
psychotropic medications were reported by Heinik et al., two factors which might 
have contributed to the discrepancy between the two studies. 
Another factor which might have contributed to the inconsistency of the current 
results with those of Heinik and colleagues is the use of a different scoring system. 
The current study used a 6-point scoring system devised by Shulman et al. (1986) 
(described in Chapter 2, Section 2.2.3), whereas Heinik et al. (2001) used a 15 point 
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scoring system (Freedman et al., 1994), which may have increased the sensitivity of 
the test to detect cognitive differences between the groups.  
 
Visuoperceptual Function 
Visuoperceptual function was measured by four tasks taken from the VOSP: 
Incomplete Letters, Object Decision, Number Location and Cube Analysis. The 
present findings show a significant difference in performance on the Incomplete 
Letters task between the psychotic and non-psychotic group. The psychotic group 
performed worse on this task, suggesting impaired visuoperceptual function is a 
cognitive correlate of psychotic symptoms in AD. A previous study which 
hypothesized visuoperceptual deficits in those with psychosis in AD reported more 
perceptual errors in those with high levels of psychosis compared to those with low 
levels (Hopkins & Libon 2005). This study measured visuoperception in terms of 
perceptual errors on the Boston Naming Task (such as the patient not identifying 
pictures accurately), and whole/part errors (such as the patient identifying only one 
feature or part of the picture). However, the same study failed to show a significant 
difference between those with and without psychotic symptoms in AD. This finding 
was contradictory to the study’s hypothesis, and the authors suggested that the 
failure to detect significant between-group differences may have been due to the 
choice of task - the Boston Naming task may have been insensitive to detect 
differences between psychotic and non-psychotic groups - or the failure to 
differentiate between AD and vascular dementia, in which visuoperception is 
relatively preserved (Sun 2008). There has been other evidence which argues against 
an association between visuoperception and psychotic symptoms in AD (Lopez et 
al., 1991; Mentis et al., 1995; Migliorelli et al., 1995; Perez-Madriñan et al., 2004; 
Staff et al., 1999; Starkstein et al., 1994). However, these studies are limited by 
small sample sizes (n<18 in psychotic group) (Lopez et al., 1991; Mentis et al., 
1995; Staff et al., 1999; Starkstein et al., 1994), and the variety of tasks used, which 
included Ravens Progressive Matrices and visual form discrimination tasks. This 
makes direct comparisons between studies difficult, especially given the 
visuoconstructive component of the drawing tasks.  
The fact that the current results identified a between-group difference on only one of 
the four VOSP tasks (Incomplete Letters) suggests that a specific aspect of 
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visuoperception may be affected in those with psychotic symptoms in AD. The 
VOSP measures two forms of perception; object perception (Incomplete Letters and 
Object Decision tasks), and space perception (Cube Analysis and Number Location 
tasks). The two forms of perception have been shown to be controlled by separate 
neurocircuitry, via the ventral and dorsal visual pathways respectively (Mishkin et 
al., 1983). It could therefore be argued that disruption to the ventral visual pathway 
may underlie the deficits observed in the psychotic group, given that performance 
was significantly impaired on the Incomplete Letters task. However, if this were the 
case, performance would also be impaired on the Object Decision task. The current 
results do in fact show the psychotic group performed more poorly on this task 
compared to the non-psychotic group, with the analysis yielding a trend level 
significance (p = 0.053). The inability to detect a significant between-group 
difference in this task could have been due to statistical power/sample size issues, or 
the fact that the object decision task had a forced-choice format, which may have 
masked visuoperceptual impairments by increasing response rates, which in some 
cases may have been correct by chance. 
Subgroup analysis of the results suggests that the observed differences in test 
performance between psychotic and non-psychotic groups may be mostly accounted 
for by data from individuals with the misidentification subtype. This finding is 
consistent with reports of impaired performance on the Incomplete Letters task in 
patients with delirium and DLB; two disorders in which misperceptions and visual 
hallucinations are frequently reported (Brown et al., 2009; Cagnin et al., 2013). 
These results may indicate specific dysfunction in the ventral as opposed to dorsal 
visual pathway in those with misidentification delusions/hallucinations in AD. The 
ventral visual pathway, otherwise known as the occipito-temporal pathway, has 
strong connections to the limbic system, which controls emotions, and the medial 
temporal lobe, where long-term memories are stored (Suter & Harvey 2011). These 
connections enable recognition of the perceived object. It has been suggested that 
disruptions to the ventral visual pathway and/or its connections with the limbic 
system may be the cause of disorders such as prosopagnosia (the inability to 
recognise faces) and Capgras syndrome (delusional belief that a familiar person is an 
imposter) (Breen et al., 2000). Similar pathophysiology may be underlying the 
misidentification delusions observed in the current sample, given that more marked 
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pathology has been observed in the limbic regions of this group, but not those with 
persecutory delusions (Forstl et al., 1994; Mukaetova-Ladinska et al., 1993; Sweet et 
al., 2000). Given the evidence, it seems plausible that disturbances to the ventral 
visual pathway may underlie the poorer performance of the misidentification group 
on the Incomplete Letters task. However, whether the deficits arise due to 
dysfunction in the ventral visual pathway itself, or its connections with other ventral 
structures, remains unclear. The dysfunction in the ventral visual pathway may be 
neurochemical (as discussed in Chapter 6, Section 6.3.1). However, we cannot rule 
out the possibility that disruption to the ventral visual stream may be caused by 
pathological changes, for example undetected lewy body formation in the temporal 
lobe. 
That visuoperceptual deficits may lead to misidentification delusions has also been 
suggested in literature concerning DLB, based on the frequent co-occurrence of 
visuoperceptual deficits and delusional misidentifications in this disorder (Mori et 
al., 2000). However, in contrast to suggestions of disruption to the ventral visual 
pathway, others have postulated that such symptoms may be underpinned by 
occipital lobe dysfunction, as indicated by neuroimaging studies demonstrating 
reduced metabolism and blood flow in the occipital lobes in patients with DLB with 
visuoperceptual dysfunction (Albin et al., 1996; Imamura et al., 1999; Ishii et al., 
1998). Consistent with suggestions of occipital involvement is the finding of a 
significant normalised glucose hypometabolism in the left medial occipital region in 
those with delusions in AD compared to those without (Hirono et al., 1998), and 
increased occipital atrophy reported in AD patients with visual hallucinations 
(Holroyd et al., 2000).  
However, the present finding is not supportive of occipital lobe dysfunction, as the 
deficits observed are specific to the Incomplete Letters task, as opposed to all tasks 
with visual components. Adding to this, a sensitivity analysis was carried out in 
order to exclude the possibility of visual sensory deficits in the current results. The 
analysis was unable to detect a significant difference between subgroups on the 
VOSP Shape Detection Screening test (a task measuring visual sensory deficits), and 
is therefore unable to explain the low scores occurring predominantly in the 
misidentification subgroup. In addition to this, the between-group differences on the 
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Incomplete Letters task remained significant after co-varying for performance on the 
VOSP screening task (see Appendix 7.4.4 and 7.4.5).  
 
3.4.4 Logistic Regression 
The results of the logistic regression analysis showed that the Incomplete Letters task 
contributed independently to the presence of psychotic symptoms in AD. These 
results strengthen the finding of visuoperceptual deficits in those with psychotic 
symptoms, and suggest a potential use for this task as a cognitive marker of 
psychotic symptoms in AD. However, the present study was unable to determine the 
task's ability in predicting the onset of psychotic symptoms in AD, and future 
research using a longitudinal design should aim to address this. In contrast, 
performance on the RVP task did not contribute independently to the presence of 
psychotic symptoms (as shown by a non-significant effect of RVP when entered into 
the regression model with the Incomplete Letters task). Instead, the results indicate 
that visuoperceptual ability may have contributed to performance on the RVP test. It 
may be that sustained attention would have independently contributed to the 
presence of psychotic symptoms in AD if an auditory sustained attention task had 
been used in the current study. Future research could explore such a hypothesis using 
tests of auditory sustained attention from the Test of Everyday Attention (such as 
Elevator Counting and Lottery subtests). 
 
3.4.5 Limitations 
The present research is not without some limitations, including the possibility of type 
1 errors owing to the number of statistical comparisons that were carried out. 
However, significant differences remained after using a Bonferroni adjusted alpha 
level and Fisher’s LSD to correct for multiple pairwise comparisons. 
Other limitations include not controlling for the potentially confounding effects of 
duration of illness or prescription of ChEI medication. The demographic screening 
assessment included duration of illness, however many subjects were unable to recall 
the length of time they had been experiencing memory difficulties. The duration of 
illness was therefore measured by the date at which the subject first presented to the 
memory clinic. This was deemed unreliable given that symptoms appear at different 
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stages of the illness. The lack of correlation with MMSE score confirmed this 
variable as unreliable, and it was therefore excluded from the analysis. 
Consequently, MMSE was used as a proxy measure of duration of illness, as 
cognitive decline increases during the course of the illness.  
All subjects prescribed past or present psychotropic medication were excluded from 
the analysis, with the exception of those taking ChEIs. In the present study, all but 
11 subjects were receiving cognitive enhancers (donepezil, galantamine, 
rivastigmine and/or memantine). In order to maximise sample size, and therefore 
increase the power of the analysis, all subjects were included. Given the similar 
distribution of those on and off medication in the two groups (off medication: n = 4 
and n = 7 in non-psychotic and psychotic groups respectively), this is unlikely to 
have had a significant effect on the results of the study. Although the most stringent 
method of comparing the two groups would be to exclude patients who are 
prescribed cognitive enhancers from future studies of this type, this is neither 
feasible nor practical.  
In the present study, the total N of 70 was categorised into two groups; Non-
Psychotic and Psychotic. The sample size in each group was adequate to detect 
differences of 13.6% between these groups (see Chapter 2, Section 2.1.4), but not to 
detect differences between subgroups. Therefore, it is likely that a number of the 
subgroup statistical analyses were insufficiently powered to detect a statistically 
significant between-groups effect. A larger sample size with equal subjects in each 
subgroup would benefit future research into the neurocognitive profiles of specific 
psychotic subgroups.  
Another limitation to the current research, and to other research in this field, is the 
challenge involved in diagnosing a delusion or hallucination in AD. Many delusions, 
such as those involving ideas of persecution, infidelity and abandonment, can be 
accurate interpretations of real events, and care must be taken to determine this. It is 
also difficult to distinguish certain delusions from simple forgetting, as it is common 
for patients to confabulate ideas to fill in the gaps missing from memory. 
Hallucinations can also be challenging to diagnose, especially those occurring upon 
falling asleep or awakening. In order to more accurately determine psychotic 
symptoms in AD, one should address the patient’s response to reality testing, and the 
persistence or recurrence of the delusion over time. Other factors adding to the 
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difficulty in diagnosing psychosis in AD include the similarity of the symptoms to 
other psychiatric disorders (e.g. schizophrenia, schizoaffective disorder, delusional 
disorder and mood disorders with psychotic features), and their association with 
episodes of delirium and substance use (drugs of abuse and medications). Given the 
challenges involved in accurately diagnosing psychosis in AD, a set of diagnostic 
criteria have been proposed, which aim to identify the psychotic features of AD, 
while excluding psychotic syndromes caused by other factors (Jeste & Finkel 2000). 
The current sample met all the diagnostic criteria for psychosis in AD, except that 
which states that "symptoms must be severe enough to cause some disruption to the 
patient’s and/or others’ functioning". The delusions and hallucinations reported in 
the current study were predominantly mild, as D2/3 receptor availability had been 
previously shown to increase even with mild, transient delusions (Reeves et al., 
2009). The beliefs described by the present sample caused little disruption to the 
subjects’ functioning, and for this reason the term ‘psychotic symptoms in AD’, as 
opposed to ‘psychosis in AD’, has been used throughout the study. 
In addition to the clinical challenges of diagnosing psychotic symptoms in AD, the 
current research relies on informant-rated responses on the NPI in order to assess the 
presence of psychotic symptoms. Although the NPI was administered to the 
carer/relative who had the most frequent contact with the patient, many informants 
were not living with the patient and therefore found it difficult to respond to 
questions regarding the frequency of psychotic symptoms, or when they last 
occurred. For this reason, all patients who had ever experienced a psychotic 
symptom were included in the analysis, in order to avoid excluding those currently 
experiencing occasional symptoms, which had gone unnoticed due to infrequent 
contact with the carer/informant. This also enabled a larger sample size to be 
included, adding to the reliability of the results. In order to ensure there were no 
significant state vs. trait effects of psychotic symptoms on the current results, a 
sensitivity analysis was carried out after excluding those who were no longer 
experiencing psychotic symptoms (n = 6). This made no difference to the present 
findings (see Appendix 7.4.2). 
To make the present research more accessible for the elderly population, the 
neuropsychological test battery was administered in the home environment of the 
subjects. Although home visits help to maximise recruitment to the study, and can 
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reduce anxiety levels, they also lead to an increased amount of environmental 
disturbances during the assessment. Efforts were made to separate the subject and 
caregiver, in order to avoid them communicating during the testing procedure e.g. 
the subject asking their caregiver for help on certain questions. In addition, subjects 
were asked to turn off audio distractions such as the radio and TV, and to refrain 
from answering the phone/door during the assessment. However, disturbances 
inevitably occurred and the possibility that these distractions may have influenced 
cognitive performance cannot be ruled out.  
 
3.5 Conclusion 
The present study successfully addressed all four aims laid out in the introduction. 
Consistent with the original hypothesis is the finding of impaired sustained attention, 
as measured by the RVP, in subjects with psychotic symptoms in AD. However, 
motor speed did not differ between the two groups. When the neuropsychological 
profile of psychotic symptoms in AD was investigated across a range of cognitive 
domains, only visuoperceptual performance differed between the two groups, as 
measured by the Incomplete Letters task. Subgroup analysis of the significant 
between-group differences in neuropsychological test performance, in terms of 
paranoid (persecutory delusions) and misidentification (misidentification delusions 
and/or visual hallucinations) subtypes, demonstrated that the significant between-
group differences observed in the RVP and Incomplete Letters tasks were driven 
predominantly by the misidentification subgroup. Logistic regression analysis 
showed an independent contribution of the Incomplete Letters task, but not RVP 
performance, to the presence of psychotic symptoms. The lack of independent 
contribution of the RVP to psychotic symptoms may be explained by the fact that 
visuoperceptual processing is a component of the RVP task, in addition to sustained 
attention. The implications of this will be discussed in Chapter 6, Section 6.3.1. 
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Chapter 4: Establishing the Test-Retest Reliability of an Adapted [
18
F]fallypride 
Imaging Protocol for Use in Older People 
 
4.1 Introduction 
Since dopamine D2/3 receptors were first visualised in vivo in man (Farde et al., 
1986), PET tracers that target dopamine D2/3 receptors have provided important 
insights into the pathophysiology and treatment of psychiatric and neurological 
disorders. For example, D2/3 receptor tracers have increased our understanding of the 
human brain changes occurring in addiction, by consistently demonstrating decreased 
striatal D2/3 receptor availability in patients with a wide variety of drug addictions 
(Volkow et al., 2004; Volkow et al., 1999). Such tracers have also been used to 
investigate the mechanisms involved in the pharmacological treatment of ADHD 
(Volkow et al., 2001; Volkow et al., 2002). In addition, imaging of D2/3 receptors has 
generated important insights into the aetiology of schizophrenia, providing in vivo 
support for the ‘dopamine hypothesis’, which attributes dysregulation of dopaminergic 
transmission to be the cause of psychotic symptoms in schizophrenia (Laruelle & Abi-
Dargham 1999). One of the most influential translational achievements of tracers 
which target D2/3 receptors, has been their role in guiding treatment strategies in 
schizophrenia, by establishing a ‘therapeutic window’ of striatal D2/3 receptor 
occupancy by antipsychotic drugs (Kapur 1998) - discussed in Chapter 1, Section 
1.5.2. 
 
4.1.1 Use of High Affinity Radiotracers to Image D2/3 Receptor Occupancy  





C]FLB-457, have enabled the clinical relevance of extrastriatal 
receptors to be explored, where the density of D2/3 receptors is 10-100 times lower 
than in the striatum (Kessler et al., 1993). A PET study using [
11
C]FLB-457 
demonstrated that temporal D2/3 receptors were a common target for both typical and 
atypical antipsychotics (Xiberas et al., 2001b). The same study also demonstrated a 
limbic selectivity of the atypical antipsychotics, whereby D2/3 occupancies were 
higher in the temporal cortex compared to the striatum. This was not the case with the 
 121 
typical antipsychotics, which showed equally high occupancies in both regions. 
Occupancy studies using [
18
F]fallypride have also reported higher D2/3 receptor 
occupancy in temporal compared to striatal regions for several atypical antipsychotics 
(clozapine, quetiapine and aripriprazole) (Grunder et al., 2005; Kegeles et al., 2008; 
Kessler et al., 2005; Kessler et al., 2006). The limbic selectivity of atypical 
antipsychotics, demonstrated using PET imaging techniques, provides support to 
previous results from less sensitive SPECT studies, which showed relatively low 
striatal occupancies compared to occupancies in the temporal cortex e.g. 32 vs. 60.1% 
(quetiapine), 41.3 vs. 82.8% (olanzapine), and 58 vs. 90% (clozapine) (Bigliani et al., 
2000; Pilowsky et al., 1997; Stephenson et al., 2000). Given the evidence that binding 
in the striatum is associated with EPS, and atypical antipsychotics have a lower 
tendency to induce these symptoms, temporal D2/3 receptor occupancy has been 
implicated in response, but not adverse effect, profiles of antipsychotic drugs (Stone et 
al., 2009). The hypothesis that high temporal occupancy, in conjunction with lower 
striatal occupancy, could result in a favourable response/side effect profile for an 
antipsychotic drug is supported by the antipsychotic clozapine. Clozapine blocks D2/3 
receptors in the temporal cortex in excess of striatal receptors, and presents with high 
clinical efficacy and few EPS (Pilowsky et al., 1997). Since the development of the 
high affinity D2/3 radiotracers, the clinical relevance of the corticolimbic D2/3 
receptors has become a fast growing area of research, which could potentially aid the 
development of novel antipsychotics with minimal adverse effects. However, although 
there is evidence that many atypical antipsychotics have higher D2/3 receptor 
occupancy in temporal compared to striatal regions, this is not a universal finding 
(discussed by Kessler et al., 2006), and further exploration of the clinical relevance of 
extrastriatal D2/3 receptors is needed.  
 
4.1.2 Use of High Affinity Radiotracers to Image Endogenous Dopamine Release  
In addition to receptor occupancy studies, high affinity D2/3 radiotracers are also used 
to image endogenous neurotransmitter release, and have enabled the role of 
corticolimbic dopamine release in human behaviour to be explored (Riccardi et al., 
2006; Riccardi et al., 2011). Additionally, high affinity tracers have been used in a 
range of neurological and psychiatric illnesses including schizophrenia-spectrum 
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disorders (Woodward et al., 2011) and PD (Ray et al., 2012). Dopamine release during 
normal human behaviour was imaged for the first time in 1998, using [
11
C]raclopride 
(Koepp et al., 1998). Since then, this phenomenon has been continually explored, with 
many refinements and improvements to the methodology in the past decade. 
Dopamine release studies are based on the ‘occupancy model’, which describes the 
competition between endogenous dopamine and radiotracer for the D2/3 receptor. An 
increase in the level of synaptic dopamine results in a decrease in tracer accumulation, 
and vice versa. Direct dopamine-enhancing challenges, such as amphetamine, have 
been used in both primates (Dewey et al., 1993; Laruelle et al., 1997) and humans 
(Abi-Dargham et al., 1998; Kegeles et al., 1999; Laruelle et al., 1996; Laruelle et al., 
1995; Volkow et al., 1994), to demonstrate the decrease in radiotracer binding. The 
magnitude of changes in BP reported using the occupancy model correlate with the 
magnitude of changes in dopamine level measured with microdialysis, supporting the 
use of non-invasive techniques to measure dopamine neurotransmission (Breier et al., 
1997; Laruelle et al., 1997). Dopamine release studies are an important area of 
research, from which we can investigate the dopaminergic basis of human behaviour 




F]fallypride Imaging: Advantages and Limitations 
[
18
F]fallypride is unique amongst D2/3 receptor tracers, as it can provide stable 
estimates of both striatal and extrastriatal receptor availability within the same 
scanning session (Mukherjee et al., 2002). In contrast, the short half-life of carbon-11 
(20 minutes) limits the use of [
11
C]FLB-457 to imaging extrastriatal regions only, due 
to the length of time needed to reach a plateau of binding in the striatum, where 
receptor density is high. However, despite the advantages of [
18
F]fallypride, the 
techniques currently used to quantify D2/3 receptor binding involve multiple sampling 
periods (each lasting 60-70 minutes) over a total scan duration of 3-4 hours. This is to 
allow tracer uptake to achieve a plateau within the striatum, where D2/3 receptors are 
most densely concentrated (Mukherjee et al., 2002). These imaging protocols are not 
feasible for use in many clinical populations, particularly older, cognitively impaired 
individuals, or those with movement disorders. Previous experience of conducting 
imaging studies in older people (Reeves et al., 2009; Reeves et al., 2005) has shown 
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that scanning sessions longer than 60 minutes are difficult to tolerate, particularly in 
those with cognitive impairment. Suggested reasons as to why longer scans are not 
tolerable include: joint pain, low temperatures in the scanning room, disruption to 
daily routines (e.g. meal times), anxiety due to an unfamiliar environment, and 
confusion due to memory deficits causing patients to forget where they are and for 
what purpose. Adapting [
18
F]fallypride imaging for use in clinical populations who are 
unable to tolerate lengthy scanning sessions would widen its potential for use in 
understanding disease mechanisms, drug occupancy, and dopamine release in response 





The current study has devised an adapted [
18
F]fallypride scanning protocol, which 
minimises the time spent in the scanner. The timings of the current protocol were 
based upon pilot data using [
18
F]fallypride in young adults, and on studies which have 
previously used [
18
F]fallypride to measure D2/3 receptor occupancy in young adults 
with schizophrenia (Kegeles et al., 2008; Kessler et al., 2006). The protocol was 
designed to capture peak binding, with particular emphasis placed on avoiding 
capturing pre-equilibrium binding, which can lead to errors in the estimation of BPND. 
The scanning times of the adapted protocol are: 0-30 minutes, to provide an input 
function to model a reference region approach; 60-90 minutes, to measure the peak 
tracer binding within extrastriatal regions; and 210-240 minutes, to ensure that tracer 
binding has achieved a plateau in the striatum of all subjects. The current study allows 
us to investigate the effect of shorter scan durations rather than total uptake time, 
which has been increased to ensure equilibrium is reached in all striatal regions (in a 
small proportion of people, tracer may take up to 210 minutes to achieve equilibrium 




The broad aims of the study were to adapt [
18
F]fallypride imaging for use in the 
elderly population, and to optimise the technique for use in D2/3 receptor occupancy 
studies in patients with AD. The specific aims of the study were as follows: 
(i) To establish the test-retest reliability (in healthy older adults) of an 
adapted [
18
F]fallypride imaging protocol, which has reduced the length 
of individual scanning sessions to 30 minutes. 
(ii) To investigate whether sampling times could be further reduced to 20 
minute sessions without reducing reliability. 
 
4.2 Methods 
A brief overview of the recruitment/screening procedure and the methodology 
involved in PET imaging is given in Chapter 2 (Sections 2.4 and 2.5). For the purposes 
of this study, the BPND is reported for the region of interest across both hemispheres, 
consistent with previous test-retest studies (Cropley et al., 2008; Mukherjee et al., 
2002). 
 
4.2.1 Scanning Protocol 
The adapted scanning protocol is detailed in Chapter 2, Section 2.5.3, and consists of 
three scanning sessions: 0-30 minutes, 60-90 minutes, and 210-240 minutes. The 
initial 3 minutes of the first scanning session acquired frames with short duration (1 x 
10 seconds, 10 x 5 seconds, 6 x 10 seconds, and 3 x 20 seconds). The remaining 87 
minutes of scanning were acquired using frame lengths of 1 minute. 
 
4.2.2 Optimising the Protocol 
In order to establish whether sampling times could be further reduced to 20 minute 
sessions without reducing the reliability of the protocol, two sets of analyses were 
performed. Data were first analysed using the complete data set from three scanning 
sessions of 30 minutes, and then were reanalysed using only 20 minutes of data from 
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each scanning session. The two sets of analyses are referred to as Method 1: 0-30, 60-
90 and 210-240 minutes; and Method 2: 0-20, 70-90 and 220-240 minutes. 
 
4.2.3 Defining ROIs 
The cerebellar reference region was defined using the Automated Anatomical 
Labelling Atlas (Tzourio-Mazoyer et al., 2002), and the Tziortzi Atlas (Tziortzi et al., 
2011) was used to define the caudate, putamen and extrastriatal regions (thalamus, 
amygdala, hippocampus, middle and inferior temporal gyri, orbitofrontal cortex and 
anterior cingulate cortex). These regions were chosen to allow comparison with 
previous test-retest studies using [
18
F]fallypride (Cropley et al., 2008; Mukherjee et 
al., 2002). The striatal subdivisions were defined using a template which was 
originally defined using the same anatomical landmarks as Mawlawi et al. (2001), 
described in Chapter 2, Section 2.7.4. 
 
4.2.4 Statistics 
A paired t-test was used to compare the administered dose of [
18
F]fallypride between 
test and retest scans. The ICC (Fisher 1958) was calculated to measure the reliability 
of the test-retest BPND values for each region of interest. The absolute variability of 
test-retest reproducibility was calculated as follows: [|test−retest|/(test+retest)/2]×100. 
The variability between mean BPND values for Methods 1 and 2 was determined by: 
(|Method1_test–Method2_test|/Method1_test)×100 and expressed as the mean and 
standard deviation (SD) across subjects. The coefficient of variation (COV) was 
calculated for each subject’s BPND for the individual ROIs, and is presented as the 
mean % across subjects. ‘PS’ software was used to perform power calculations 
(Dupont & Plummer 1990). The regional percentage change in [
18
F]fallypride BPND 
detectable in a typical within-subjects comparison (sample size = 15; paired t-test) was 
calculated using a probability (power) of 0.8, and an associated type I error probability 





Administered dose of [
18
F]fallypride was 244.1 ± 7.3 MBq. There were no significant 
differences in administered dose between test and retest scans (mean difference = 0.5 
±10.8 MBq, p = 0.90). 
 
4.3.1 Mapping of PET images to ROI  
Figures 4.1 and 4.2 show the accuracy with which the ROIs were mapped onto an 
individual’s PET scan, by warping the atlas via a [18F]fallypride template. The 
alignment of the ROIs with the individual’s PET scan shows good accuracy in the 
striatal regions, using both anatomical and functional subdivisions. The alignment of 








Figure 4.1: Alignment of Striatal ROIs with an Individual’s PET Scan 
 
 
Striatal ROIs, defined using the Tziortzi Atlas (far left) and the functional subdivisions template, have been superimposed upon a 
[
18






 Figure 4.2: Alignment of Extrastriatal ROIs with an Individual’s PET Scan 
 
 
The reference region and extrastriatal ROIs, defined using the Anatomic Labelling Atlas and Tziortzi Atlas respectively, have been 
superimposed upon a [
18
F]fallypride image in standard MNI space. All images show transverse view. ITG = inferior temporal gyrus, 
MTG = middle temporal gyrus, OFC = orbitofrontal cortex, ACC = anterior cingulate cortex. 
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4.3.2 Regional Uptake of [
18
F]fallypride 
Time-activity curves for Method 1 (30 minute sampling times) are shown in Figures 
4.3-4.5 and represent the attenuation corrected (AC) filtered back projected (FBP) 
data on which the kinetic analysis was carried out. The curves show regions with 
high receptor concentration (caudate, putamen and striatal subdivisions), medium 
receptor concentration (amygdala and thalamus) and lower receptor concentration 
(hippocampus, temporal cortex, and frontal regions). Uptake in the striatal regions 
reached equilibrium at the start of the final scanning session (210-240 minutes), 
confirming that complete uptake of [
18
F]fallypride was achieved. The extrastriatal 
regions reached a plateau of binding prior to the final scanning session. The general 
uptake pattern of [
18
F]fallypride across the regions is similar to that of previous 
studies (Cropley et al., 2008; Mukherjee et al., 2002). 
 
Figure 4.3: Time-Activity Curves (Method 1) Representing [
18
F]fallypride Uptake in 






Figure 4.4: Time-Activity Curves (Method 1) Representing [
18
F]fallypride Uptake in 




Figure 4.5: Time-Activity Curves (Method 1) Representing [
18
F]fallypride Uptake in 









Test-retest variability and ICC values of regional [
18
F]fallypride binding for Method 
1 are presented in Table 4.1. All regions examined showed high reproducibility 
(<8% variability), with the exception of the orbitofrontal cortex (15.04% variability) 
and the anterior cingulate cortex (28.84% variability). The highest reproducibility 
was seen in the caudate, putamen, amygdala, and inferior temporal gyrus (<5% 
variability). The reliability was high in all regions, ranging from 0.80 in the limbic 
striatum to 0.99 in the middle and inferior temporal gyri. 
 
Method 2 
Mean percentage test-retest differences (% variability) and reliability (ICC) of 
regional [
18
F]fallypride binding for Method 2 (20 minute sampling times) are 
presented in Table 4.2. Reproducibility remained high (<8% variability) in all 
regions, with the exception of the limbic striatum (8.25%), and the prefrontal regions 
(orbitofrontal cortex = 17.45%; anterior cingulate cortex = 37.35%). In line with 
Method 1, the highest reproducibility was seen in the caudate, putamen, amygdala 
and inferior temporal gyrus (<5.68%). The reliability remained high (>0.80) in all 
regions, apart from the anterior cingulate cortex (0.79). The greatest reliability (0.99) 
was seen in the middle and inferior temporal gyri.  
 
Comparison of Method 1 and 2 
The mean percentage difference between the BPND values derived from Method 1 
compared to Method 2 was less than 2% in the striatal regions, amygdala, thalamus 
and hippocampus. The percentage difference between methods was <3.19% in the 
remaining regions, with the exception of the anterior cingulate cortex, which showed 
a difference of 14.47% between methods (Table 4.2). 
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1
BPND given as mean across subjects (SD); 
2
Absolute variance given as mean across subjects (SD) = 
[|test-retest|/(test+retest)/2] * 100; 
3
Intraclass Correlation Coefficient. 
 
Table 4.1: Test-Retest Reproducibility of Regional [
18
F]fallypride Binding Using 










Sensorimotor striatum 19.73 (2.66) 19.70 (2.06) 5.56 (2.69) 0.86 
Associative striatum 17.50 (2.39) 17.58 (1.77) 5.05 (5.33) 0.85 
Limbic striatum 16.90 (2.83) 17.04 (2.00) 7.12 (7.37) 0.80 
Putamen 21.19 (2.82) 21.50 (2.15) 4.99 (3.76) 0.88 
Caudate 16.57 (2.77) 16.71 (2.29) 3.44 (3.87) 0.96 
Amygdala 1.77 (0.41) 1.76 (0.38) 4.08 (4.64) 0.98 
Thalamus 1.48 (0.28) 1.47 (0.24) 6.10 (6.70) 0.90 
Hippocampus 0.82 (0.21) 0.79 (0.19) 7.35 (6.40) 0.95 
Inferior temporal gyrus 0.57 (0.21) 0.58 (0.20) 4.83 (7.61) 0.99 
Middle temporal gyrus 0.39 (0.17) 0.39 (0.17) 6.40 (9.45) 0.99 
Orbitofrontal cortex  0.21 (0.10) 0.23 (0.11)  15.04 (15.68) 0.92 







BPND given as mean across subjects (SD); 
2





Given as mean percentage difference between Method 1 and Method 2 test BPND (SD) = (|Method1_test-Method2_test|/Method1_test)*100. 
 
Table 4.2: Test-Retest Reproducibility of Regional [
18













Sensorimotor striatum 19.82 (3.04) 19.70 (2.06) 6.37   (3.70) 0.84 1.77   (1.13) 
Associative striatum 17.55 (2.64) 17.56 (1.84) 5.80   (5.91) 0.84 1.66   (0.93) 
Limbic striatum 16.94 (3.06) 16.99 (2.06) 8.25   (6.97) 0.80 1.56   (0.89) 
Putamen 21.27 (3.19) 21.49 (2.21) 5.68   (4.86) 0.86 1.69   (0.98) 
Caudate 16.62 (3.06) 16.68 (2.35) 4.43   (4.43) 0.95 1.72   (0.90) 
Amygdala 1.76 (0.42) 1.75 (0.38) 4.70   (5.30) 0.97 1.02   (0.74) 
Thalamus 1.47 (0.29) 1.46 (0.23) 6.60   (7.25) 0.89 1.13   (0.74) 
Hippocampus 0.81 (0.21) 0.79 (0.18) 7.67   (7.84) 0.94 1.38   (1.11) 
Inferior temporal gyrus 0.56 (0.21) 0.57 (0.20) 5.28   (9.96) 0.99 2.89   (2.60) 
Middle temporal gyrus 0.38 (0.18) 0.38 (0.17) 7.94 (10.47) 0.99 3.19   (2.76) 
Orbitofrontal cortex  0.21 (0.10) 0.22 (0.11) 17.45 (14.23) 0.92 2.70   (2.41) 
Anterior cingulate cortex 0.17 (0.11) 0.17 (0.09) 37.35 (54.16) 0.79 14.47 (20.50) 
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4.3.4 Reliability of Individual BPND Values 
Coefficient of Variation  
The COV was calculated for each subject’s BPND across the individual ROIs, and is 
presented in Table 4.3 as the mean % across subjects. The individual BPND values 
showed high reliability, with the COV less than 1% in both test and retest scans for 
Methods 1 and 2, in all regions apart from the hippocampus, temporal cortex and 
frontal regions. Using Method 1, the COV was <3% in the remaining regions, with 
the exception of the anterior cingulate cortex, which was 9.07% and 6.38% for the 
test and retest scans respectively. Using Method 2, the COV was slightly higher, at 
<4% in the remaining regions apart from the anterior cingulate cortex, which was 
20.47% and 8.44% for the test and retest scans. 
 
 
4.3.5 Regional Detectable Within-Subject % Change in [
18
F]fallypride Binding 
The results of a power analysis for a within-subject study design (N = 15, paired t-
test; α = 0.05, power = 0.8) are shown in Figure 4.6. The standard sample size of 15 
was chosen based on previous studies which have included samples of 10-25 
subjects (Narendran et al., 2009; Ray et al., 2012; Riccardi et al., 2006; Riccardi et 
Table 4.3: Mean COV Across Subjects for Individual ROIs 
Region COV % Method 1 COV % Method 2 
 Test Retest Test Retest 
Sensorimotor striatum 0.51 0.56   0.70 0.76 
Associative striatum 0.50 0.50   0.69 0.68 
Limbic striatum 0.56 0.55   0.75 0.71 
Putamen 0.45 0.49   0.63 0.68 
Caudate 0.44 0.49   0.62 0.67 
Thalamus  0.63 0.50   0.80 0.62 
Amygdala  0.86 0.82   1.09 1.02 
Hippocampus 1.18 1.11   1.47 1.38 
Inferior temporal gyrus  2.03 1.78   2.52 2.15 
Middle temporal gyrus 2.54 2.30   3.12 2.81 
Orbitofrontal cortex 2.43 2.71   3.09 3.36 
Anterior cingulate cortex  9.07 6.38 20.47 8.44 
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al., 2011; Slifstein et al., 2010). The results indicate that with an N of 15, Method 1 
would be sufficiently sensitive to detect changes of 5% or less in all regions apart 
from the limbic striatum (5.5%), hippocampus (5.7%), orbitofrontal cortex (11.7%) 
and anterior cingulate cortex (22.4%). Method 2 is marginally less sensitive to 
changes in [
18
F]fallypride binding, detecting changes of 5% or less across fewer 
regions than Method 1 (caudate, putamen, dorsal striatal subdivisions, inferior 
temporal gyrus and amygdala), and larger changes in the other regions; <6.5% in the 
limbic striatum, hippocampus and inferior temporal gyrus, and 13.6% and 29.1% in 
the orbitofrontal cortex and anterior cingulate cortex respectively. The lower 
sensitivity of Method 2 is emphasised in the frontal regions. Figure 4.6 shows the 
current protocol is most sensitive to detecting percentage changes in [
18
F]fallypride 
binding in the caudate, and least sensitive to detecting changes in the frontal regions 
(orbitofrontal cortex and anterior cingulate cortex).  
 
Figure 4.6: Regional Detectable % Change in [
18
F]fallypride Binding Using Method 
1 and Method 2  
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4.4 Discussion 
This study has shown high reproducibility of an adapted [
18
F]fallypride protocol 
across the striatum, consistent with previous test-retest studies using [
18
F]fallypride 
in young adults, which have used full modelling with arterial sampling (Mukherjee 
et al., 2002) or a simplified reference tissue approach (Cropley et al., 2008) to image 
analysis. High reproducibility (<8% variance) was also seen in the majority of 
extrastriatal regions; however not in the prefrontal regions, in particular the anterior 
cingulate cortex, where BPND differed by 28.84% between test and retest. These 
findings are consistent but more marked than those of Cropley et al. (2008) who 
similarly reported a high variability in the anterior cingulate cortex (21.8±3.8%) in 
healthy young adults. One reason for the increased variability in the frontal regions 
may be due to a relatively low signal to noise ratio of [
18
F]fallypride in this region, 
given the low D2 receptor density identified in these regions post mortem (Kessler et 
al., 1993). 
The second aim of this study was to identify whether sampling times could be 
further reduced to 20 minute sessions without affecting reliability. The present 
results show that individual scanning sessions of 20 minutes produced the same 
pattern of reproducibility across striatal and extrastriatal regions as the original 30 
minute protocol. The test-retest variability increased minimally (<3.2%) in all 
regions except the anterior cingulate cortex, where the increase was more substantial 
(14.47%).  
In order to establish the reliability of the individual BPND values in the current study, 
the COV across subjects was calculated, demonstrating high reliability in all striatal 
regions (<1% variance) and extrastriatal regions (<3.36% variance) bar the anterior 
cingulate cortex. The high variance observed in the individual BPND values in the 
anterior cingulate cortex may have contributed to the poor test-retest reliability in 
this region.  
 
4.4.1 Consideration of Age-Related Factors in D2/3 PET Imaging 
Several studies have reported a decline in D2 receptor binding with age in both 
striatal (reviewed by Reeves et al., 2002) and extrastriatal regions (Inoue et al., 2001; 
Kaasinen et al., 2000). The absolute BPND values in the caudate (16.57) and putamen 
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(21.19) reported in the current study are consistent with the eldest subject (aged 63 
years) in a previous [
18
F]fallypride test-retest study (caudate = 15.6, putamen = 
19.3), however are considerably lower than those reported in the youngest subject 
(aged 21 years) in the same study (caudate = 31.4, putamen = 36.3) (Mukherjee et 
al., 2002). This is consistent with studies which report a decrease in D2 receptor 
density in the caudate between 4.5% and 7.5% per decade (Rinne 1987; Rinne et al., 
1990; Severson et al., 1982), with similar reductions reported in the putamen (De 
Keyser et al., 1990; Morgan et al., 1987; Severson et al., 1982). Most relevant to the 
current finding of increased variability in the anterior cingulate and orbitofrontal 
cortices is the faster rate of D2/3 receptor decline seen in the frontal regions (Inoue 
et al., 2001). This is particularly prominent in the anterior cingulate cortex, where the 
D2/3 receptor density is reported to decline at a rate of 13% per decade, in contrast 
to 5% per decade in the thalamus (Kaasinen et al., 2000). This is consistent with 
Mukherjee et al. (2002) who reported the greatest decrease in binding per decade to 
occur in the frontal regions (15-20%). Such low receptor densities could result in a 
relatively low signal to noise ratio of [
18
F]fallypride in the frontal regions, therefore 
accounting for the poor reproducibility in these regions.  
In addition to age-related decreases in D2/3 receptor density, age-related volume loss 
has also been demonstrated by MRI studies, and is especially prominent in the 
frontal lobes (Coffey 1993; Cowell et al., 1994; Raz et al., 1997; Salat et al., 1999; 
Tisserand et al., 2002). Few studies have considered the different substructures 
within the prefrontal cortex, however two out of the three studies that have addressed 
this found the strongest age-associated volume loss to be in the anterior cingulate 
cortex, with the orbitofrontal cortex remaining fairly preserved (Salat et al., 1999; 
Tisserand et al., 2002). The liability of the anterior cingulate cortex to age-related 
volume loss could help to explain the poor reproducibility in this region; possibly 
due to enhanced partial volume effects (see Chapter 6, Section 6.2.3). 
 
4.4.2 Suitability for Occupancy Studies 
The primary aim of the current study was to adapt [
18
F]fallypride imaging to 
minimise the length of individual scanning sessions. The current protocol has 




F]fallypride studies (Cropley et al., 2008; Mukherjee et al., 2002). The shortened 
scan durations enhance the feasibility and accessibility of [
18
F]fallypride imaging for 
use across a range of neuropsychiatric disorders in which dopamine has been 
implicated, including patients with dementia, PD, movement disorders and disorders 
of impulsivity. Our main area of interest is to develop a scanning protocol suitable 
for use in D2/3 receptor occupancy studies in older and/or cognitively impaired 
patients. The current protocol is sufficiently sensitive to detect small percentage 
changes in all but the prefrontal regions, and therefore can be utilised to investigate 
the role of cortical vs. striatal D2/3 occupancy in response to antipsychotic treatment. 
Despite the urgent clinical need to optimise dosing regimens of antipsychotic 
medications in the elderly, this area of research has been largely neglected. The high 
reproducibility of the adapted [
18
F]fallypride imaging protocol suggests it is a 
reliable method for measuring D2/3 receptor occupancy in older adults, and the next 
stage of the research will be to optimise the protocol for use in patients with AD, 
following antipsychotic medication (Chapter 5). 
 
4.4.3 Suitability for Dopamine Release Studies 
In addition to receptor occupancy studies, the current study aimed to establish the 
sensitivity of the protocol to detect changes in endogenous dopamine following 
pharmacological or behavioural intervention. The past decade has demonstrated 
[
18
F]fallypride PET imaging to be a suitable method of measuring endogenous 
dopamine release in the striatum, using amphetamine displacement studies in both 
animals (Mukherjee et al., 1997; Slifstein et al., 2004) and humans (Cropley et al., 
2008; Riccardi et al., 2006). The same studies have also demonstrated a sufficiently 
robust effect across limbic (hippocampal, amygdala) regions. 
In contrast, the suitability of [
18
F]fallypride to measure changes in other cortical 
regions, in particular the frontal regions, is less well established. A finding of no 
significant change in [
18
F]fallypride binding in response to amphetamine in the 
frontal regions (dorsolateral prefrontal cortex, orbitofrontal cortex and medial 
orbitofrontal cortex), together with low baseline BPND values and high variability 
between baseline and post-challenge scans, led authors to conclude that 
[
18
F]fallypride is not a suitable tool for reliably measuring dopamine release in the 
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frontal regions (Slifstein et al., 2010). Support for this conclusion is provided by 




C]FLB-457 in terms of 
their ability to measure dopamine release in cortical regions in response to 
amphetamine. This study reported a significant effect of amphetamine in the cortex 
using [
11
C]FLB-457, but not [
18
F]fallypride (Narendran et al., 2009). Although, 
Cropley et al. (2008) reported a significant decrease in [
18
F]fallypride binding in the 
medial orbitofrontal cortex, the remaining frontal regions, including the anterior 
cingulate cortex, were not evaluated. This could again be due to the relatively low 
baseline BPND (< 0.5) and high variability of BPND (21.8%) between test and retest 
scans. 
Previous studies report mean displacements of [
18
F]fallypride between 5-16% in the 
striatal regions, and 4.4-15% in limbic regions (Cropley et al., 2008; Narendran et 
al., 2009; Riccardi et al., 2008; Riccardi et al., 2006; Slifstein et al., 2010). The 
power calculations carried out on the current results, using a standard sample size of 
15, indicates that Method 1 will be sufficiently sensitive to detect within-subject 
changes across the striatal and limbic regions, ranging from 2.7% in the caudate to 
5.7% in the hippocampus. Method 2 is slightly less sensitive, with detectable 
differences ranging from 3.4% in the caudate to 6.4% in the limbic striatum. Neither 
method is sufficiently sensitive to measure endogenous dopamine release in the 
frontal regions, consistent with previous literature mentioned above.  
The high sensitivity of the adapted [
18
F]fallypride imaging protocol supports its use 
in a two scan approach to detect minute differences in dopamine release in striatal 
and limbic regions. The shorter scanning times involved make dopamine release 
studies more feasible and accessible to a wider clinical population. It is not yet 
established whether these findings will generalise to cognitively or neurologically 
impaired populations, however given the fact that sensitivity to detect within-subject 
change is crucial for studies of this type, it may be advisable to collect data over the 
longer (30 minute) sampling times used in the original protocol, and to obtain a 
suitably large sample size. 
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4.4.4 Potential Limitations 
MRI and Partial Volume Effects 
In an attempt to increase the tolerability of the protocol, the current study did not use 
MRI data for co-registration with PET data. The templates used for co-registration 
originated from structural and functional imaging data on healthy young adults and 
this may have impacted upon the warping process. Visual inspection of the accuracy 
with which the ROIs aligned with individuals’ PET scans did not show any 
substantial misalignments, although small inaccuracies in the alignment of the 
orbitofrontal cortex may have contributed to the higher variability in this region (see 
Figure 4.2). In addition, partial volume effects, which are particularly relevant in 
older adults (Morris et al., 1999), are also likely to have affected the accuracy of 
tracer quantification in the current study. These factors are discussed in further detail 
in Chapter 6, Section 6.2.3. 
 
Sampling Times 
The sampling times used in the current study to quantify cortical and striatal BPND 
were based upon [
18
F]fallypride studies carried out in young adults (see Chapter 2, 
Section 2.5.3). The accuracy with which these timings are able to capture peak tracer 
binding in the elderly population is worth considering, given that the time taken to 
achieve peak tracer binding is dependent upon receptor density, and may be affected 
by age-related factors including peripheral clearance, regional cerebral blood flow 
and BBB transport. The possibility that the adapted protocol did not optimally 
capture peak tracer binding in all subjects can therefore not be excluded. Another 
consideration, given the lower density of D2/3 receptors in extrastriatal regions, is 
that equilibrium will have been achieved considerably earlier than the 240 minutes 
needed to achieve equilibrium in the striatum. The increased sampling time of 240 
minutes may have added unnecessary noise to the data, contributing to the high 
variability seen in the anterior cingulate cortex. However, given the fact that our 
findings are in line with previous test-retest data (Cropley et al., 2008), the low 
signal to noise ratio in the anterior cingulate cortex, combined with age-associated 
D2/3 receptor loss in this region, is likely to explain the findings without further 
exploring the modelling assumptions.  
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4.5 Conclusion 
We have successfully adapted [
18
F]fallypride imaging using an interrupted scanning 
protocol which considerably shortens the time spent in the scanner. The high 
reproducibility and reliability of the adapted protocol means that it can be applied 
not only to D2/3 receptor occupancy studies, but also to image endogenous 
neurotransmission in striatal and limbic regions. The shorter scanning times required 
in the adapted [
18
F]fallypride protocol could help to advance research across a range 




Chapter 5: Optimising [
18




A major translational achievement of PET neuroreceptor imaging has been its role in 
guiding and informing treatment strategies in schizophrenia, by establishing a 
‘therapeutic window’ of striatal D2/3 receptor occupancy by antipsychotic drugs. A 
threshold of 60-80% occupancy is required for therapeutic response, whereas 
occupancy above this increases the risk of developing EPS (Kapur 1998) (discussed 
in Chapter 1, Section 1.5.2). This research has been instrumental in guiding 
treatment strategies of schizophrenia in young adults. The ‘therapeutic window’ has 
also been used to guide the development and evaluation of new antipsychotics (de 
Greef et al., 2011). However, in contrast to the abundance of data on young adults, 
this area of research has been relatively neglected in older adults, particularly those 
with dementia, who are most vulnerable to antipsychotic treatment, and could 
potentially benefit most from the clinical application of imaging techniques. It is 
suggested that the limited research in this population may be due to the lengthy 
scanning times involved in imaging procedures. Chapter 4 describes an adapted 
imaging protocol, which minimises the time spent in the scanner, and could be the 
first step towards increasing research into the mechanisms of antipsychotic 
sensitivity in AD, and establishing a ‘therapeutic window’ of occupancy. The current 
chapter aims to further adapt the protocol for use in D2/3 receptor occupancy studies 
in the AD population. 
 
5.1.1 Antipsychotic Sensitivity in the Elderly: Mechanisms 
Antipsychotic drugs are used to treat behavioural (agitation/aggression) and 
psychotic (delusions/hallucinations) symptoms in AD, both of which are common 
causes of patient and carer distress, and have been associated with earlier 
institutionalisation (Steele et al., 1990). Current prescribing of antipsychotics in AD 
is associated with a high rate of side effects including: EPS, sedation, postural 
hypotension, falls, and increased mortality due to cerebrovascular events (Ballard & 
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Howard 2006). There is therefore an urgent clinical need to determine the underlying 
cause of such heightened sensitivity, in order to improve treatment, reduce 
morbidity, and improve quality of life. However, despite the need to understand the 
reasons for such sensitivity to the drugs, research in this field is sparse. The 
following theories have been proposed by one research group: (i) The peripheral 
pharmacokinetic hypothesis, (ii) The central pharmacokinetic hypothesis, and (iii) 
The pharmacodynamic hypothesis (Uchida et al., 2009b). Each of these theories 
relates to a different aspect of the drug pathway, from the injected dose to alterations 
at the target site (illustrated in Figure 5.1). 
 
Figure 5.1: Proposed Mechanisms of Antipsychotic Sensitivity  
 
 
(Uchida et al., 2009b) 
 
Peripheral Pharmacokinetic Theory  
The peripheral pharmacokinetic theory suggests an increased plasma level for a 
given dose of drug to be the cause of the age-related sensitivity to antipsychotics. 
Age-related changes in the metabolism and physiology of gastrointestinal, hepatic, 
renal, and cardiovascular systems are likely to contribute to this theory. However, 
there are several inconsistent findings concerning this theory. For example, age did 
not have an effect on the plasma level exposure of olanzapine in a study of patients 
with AD, and there was no relation between plasma levels and EPS in a different 
study with an elderly sample (Bigos et al., 2008; McCreadie 1992). In addition, 
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findings of a dissociation between the kinetics of plasma levels and D2/3 striatal 
occupancy suggests that the peripheral pharmacokinetic theory is unlikely to be the 
only factor responsible for the age-related heightened sensitivity to antipsychotic 
drugs (Tauscher et al., 2002). However, the possibility that peripheral 
pharmacokinetics may contribute to the overall increased sensitivity should not be 
excluded. 
 
Central Pharmacokinetic Theory  
The central pharmacokinetic hypothesis attributes the heightened sensitivity to 
increases in brain access and distribution for a given plasma level. Defects in the 
BBB could account for this, for example loosening of the tight junctions, or P-
glycoprotein dysfunction (Brenner & Klotz 2004). P-glycoprotein regulates central 
concentrations of drugs by pumping back into the peripheral circulation. In support 
of this theory, higher BBB access of (R)-[
11
C]verapamil (a substrate of P-
glycoprotein) was found in elderly compared to younger subjects (Toornvliet et al., 
2006). In addition, PET studies have demonstrated an age-related increase in 
radioactivity per given radiation dose, or plasma level, in the cerebellum; a region 
free of specific targets (Adams et al., 2004; Blin et al., 1993; Verhoeff et al., 2000). 
Age-related decline in endogenous dopamine levels have also been reported, 
including reduced levels of enzymes involved in the synthesis of dopamine (tyrosine 
hydroxylase and aromatic acid decarboxylase), and increased levels of enzymes 
involved in the catabolism of synaptic dopamine (MAO-B). A decline in endogenous 
dopamine removes competition for the receptor, resulting in increased binding for a 
given dose.  
 
Pharmacodynamic Theory 
The pharmacodynamic theory points towards an age-related decline in dopaminergic 
neurons (Cabello et al., 2002; Ma et al., 1999), and D2 receptors (Antonini et al., 
1993; Kaasinen et al., 2000; Seeman et al., 1987), as the underlying cause of the 
heightened sensitivity seen in the elderly. This theory is of particular relevance to the 
increased sensitivity to antipsychotic drugs seen in AD, given the increased decline 
in D2 receptors compared to healthy ageing (Joyce et al., 1993; Joyce et al., 1998). 
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This theory proposes that for a given D2 occupancy level, an elderly patient will be 
more susceptible to clinical/adverse effects. An explanation for this theory is given 
by reference to the absolute number of D2 receptors required for normal motor 
function. The magnitude of biological response (i.e. motor control) is dependent on 
the absolute number of receptors occupied by endogenous dopamine, and so when 
the receptor population declines, the percentage of the total number of receptors 
required for normal motor function will be higher. As a result, a lower percentage of 
antipsychotic occupancy will cause interference with normal motor function (Uchida 
et al., 2009b). 
 
5.1.2 Directly Assessing the Mechanisms of Heightened Sensitivity: Use of D2/3 
Occupancy Studies 
Although the literature suggests that the peripheral pharmacokinetic theory is 
unlikely to contribute independently to antipsychotic sensitivity in the elderly, the 
relevant contribution of the central pharmacokinetic and pharmacodynamic theories 
remains unclear. Only one study to date has directly assessed the relative 
contribution of each of these theories to antipsychotic sensitivity in the elderly 
(Uchida et al., 2009a). This study involved PET imaging and plasma sampling from 
13 subjects with schizophrenia, aged 50 years and over, receiving risperidone at the 
time of the study. The results demonstrated that the relationship between striatal 
D2/3 occupancy and plasma drug levels was similar to that reported in younger 
patients, and hence did not support the central pharmacokinetic hypothesis of 
increased brain access or diminished endogenous dopamine (Nyberg et al., 1999; 
Remington et al., 1998; Uchida et al., 2009a). However, EPS were observed in seven 
subjects at D2/3 receptor occupancies much lower (34-79%) than the 80% threshold 
seen in young adults (Kapur 1998). The greater functional effect (EPS) for a given 
occupancy was taken to support the pharmacodynamic theory of antipsychotic 
sensitivity. Based on these findings, Uchida et al. (2009) postulated a lower 
‘therapeutic window’ of D2/3 receptor occupancy in elderly schizophrenic patients, 
compared to the 60-80% reported in young adults (Kapur 1998). Preliminary data 
support this, whereby occupancies over 70% caused EPS and occupancies below 
52% caused a relapse of symptoms in two subjects (Uchida et al., 2012). However, 
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interpretation of these findings is limited by the absence of baseline data on D2/3 
receptor availability within the treated group; receptor occupancy was estimated 
using age-corrected measures from healthy older individuals. In addition, it is 
important that the range of psychotic disorders in the elderly receive individual 
consideration in terms of drug sensitivity. 
To date, there has been no research specifically concerning the mechanisms of the 
increased sensitivity to antipsychotic drugs in people with AD, and no attempts to 
define a ‘therapeutic window’ of antipsychotic drug occupancy for this population. 
Likewise, there have been no attempts to determine the clinical relevance of 
extrastriatal D2/3 receptors to antipsychotic response in AD. This may in part be due 
to the fact that imaging techniques have not been sufficiently adapted for use in 
cognitively and neurologically impaired populations. For example, current scanning 
protocols require prolonged periods of time inside the scanner, which is not tolerable 
for many clinical populations. Chapter 4 tested the reliability of an adapted 
[
18
F]fallypride protocol, which used an interrupted scanning procedure and reduced 
the length of individual scanning sessions to 30 minutes. The protocol was highly 
reproducible in healthy older subjects, and remained so after reducing the length of 
individual scanning sessions to 20 minutes. The current study now aims to establish 
whether the adapted protocol is feasible for use in patients with AD, and to further 
optimise the protocol for use in D2/3 occupancy studies.  
 
5.1.3 Aims 
(i) To assess the tolerability of the adapted (3 x 30 minute) protocol as a pre-
treatment (baseline) protocol in people with AD who were about to 
commence antipsychotic medication for the management of behavioural or 
psychotic symptoms.  
(ii) To further adapt and optimise a post-treatment imaging protocol, which 
would take into account the reduction in available dopamine D2/3 receptor 
sites as a result of drug occupancy.  
(iii) To establish whether sampling times could be further reduced to 20 minute 




A brief overview of the methodology involved in the recruitment/screening 
procedure, PET imaging, and clinical assessment of subjects is given in Chapter 2, 
Sections 2.6 & 2.7. The scanning protocols used for pre- and post-treatment scans 
are detailed below. 
 
5.2.1 Pre-Treatment Protocol 
Image data were collected using the adapted [
18
F]fallypride imaging protocol 
described in Chapter 2, Section 2.5.3. This consisted of three scanning sessions: 0-30 
minutes, 60-90 minutes, and 210-240 minutes. The initial 3 minutes of the first 
scanning session acquired frames with short duration (1 x 10 seconds, 10 x 5 
seconds, 6 x 10 seconds, and 3 x 20 seconds). The remaining 87 minutes of scanning 
were acquired using frame lengths of 1 minute.  
 
5.2.2 Post-Treatment Protocol 
The scanning times used are adapted from [
18
F]fallypride protocols used in 
occupancy studies carried out in young adults (Kegeles et al., 2008; Kessler et al., 
2006). The difference in timings between pre- and post-treatment protocols is to take 
into account the fact that occupancy of D2/3 receptors by antipsychotic medication 
lowers the number of available receptor sites, thus reducing the time taken to achieve 
equilibrium. The data was still collected during three scanning sessions, albeit at 
different time intervals: 0-20 minutes to provide an input function; 40-60 minutes to 
capture peak tracer binding in extrastriatal regions; and 110-150 minutes to capture 
peak binding within the striatum. The initial 3 minutes of the first scanning session 
acquired frames with short duration (1 x 10 seconds, 10 x 5 seconds, 6 x 10 seconds, 
and 3 x 20 seconds). The remaining 77 minutes of scanning were acquired using 
frame lengths of 1 minute.  
 
5.2.3 Optimising the Protocol 
In order to establish whether sampling times could be further reduced to 20 minute 
sessions in pre- and post-treatment protocols without affecting D2/3 occupancy 
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values, two sets of analyses were performed. Data were first analysed using the 
complete data set from three scanning sessions of 30 minutes, and then were 
reanalysed using only 20 minutes of data from each scanning session. The two 
analyses are referred to as follows: Method 1, pre-treatment (0-30, 60-90 and 210-
240 minutes), post-treatment (0-20, 40-60 and 110-150 minutes); and Method 2, pre-
treatment (0-20, 70-90 and 220-240 minutes), post-treatment (0-20, 40-60 and 130-
150 minutes). 
 
5.2.4 Defining ROIs 
The cerebellar reference region was defined using the Automated Anatomical 
Labelling atlas (Tzourio-Mazoyer et al., 2002), and the Tziortzi atlas was used to 
define the caudate, putamen, and extrastriatal regions; thalamus and inferior 
temporal cortex (Tziortzi et al., 2011). These regions were chosen to allow 
comparison with previous occupancy studies (Xiberas et al., 2001b), and studies 
investigating optimum scan durations (Vernaleken et al., 2011). The striatal 
subdivisions were defined using a template which was originally defined using the 
same anatomical landmarks as Mawlawi et al. (2001), described in Chapter 2, 
Section 2.7.4.  
 
5.2.5 Movement Correction 
Head movement was monitored by a video camera, which took still pictures of the 
patient’s head position at 1-second intervals. The images were converted into video 
format (avi) using PhotoLapse 3 software, and time compressed (15 frames per 
second). Time of head movement was recorded from the video and cross-referenced 
with the subject’s time-activity curves and dynamic PET images. Upon visual 
inspection, if movement from the video correlated with anomalies on the time-
activity curves or blurred dynamic images, the relevant 1-minute frames were 
deleted. This technique of movement correction was needed in addition to the frame-
to-frame realignment discussed in Chapter 2, in order to account for sudden 




The regional percentage change in [
18
F]fallypride BPND derived using Method 2 as 
opposed to Method 1 was calculated as follows: (|Method 1 – Method 2|/Method 
1)*100, and is expressed as the mean and SD across subjects, for both pre- and post-
treatment scans. Regional D2/3 receptor occupancy was determined by the following 
calculation: (|PreTreatment BPND – PostTreatment BPND|/PreTreatment BPND)*100, 
and was performed on data derived from Methods 1 and 2. The absolute difference 
between the calculated percentage occupancies from Methods 1 and 2 was 
determined by |Occupancy Method 1 – Occupancy Method 2| and expressed as the 
mean and SD across subjects. 
 
5.3 Results 
5.3.1 Clinical and Demographic 
Pre-Treatment Scan 
Eight subjects were recruited to the study, but two were unable to follow through 
with a baseline scan; one because of delusional preoccupation and a belief that 
research staff were colluding in this, and a second was withdrawn from the study 
because of deteriorating cardiorespiratory disease, which meant that he was not able 
to tolerate the scan or eligible to receive amisulpride. 
Of the remaining six subjects, all were able to tolerate the baseline scan, apart from 
one subject who failed to complete the final 30 minute scanning session (210-240 
minutes post-injection). This is likely due to a 90 minute delay in tracer delivery to 
the PET unit, which considerably extended the length of time that the subject spent 
in the department. For this subject, image data collected during the first two scanning 
sessions were used to determine BPND, and a bias correction (calculated from the 
five completed pre-treatment scans) was applied. The bias correction was determined 
by comparing BPND calculated using only the first two scanning sessions (2 x 30 
minutes) to the full dataset (3 x 30 minutes) (shown in Table 5.1). The bias corrected 





Original BPND with last scan missing (2x30mins); 
2
BPND corrected by average (minimum and 
maximum) % bias: % bias calculated as [(BPND (2x30) – BPND (3x30))/BPND (3x30)]*100 (Method 1) 
and [(BPND (2x20) – BPND (3x20))/BPND (3x20)]*100 (Method 2) using data from five completed pre-
treatment scans in the current study.  
 
Post-Treatment Scan 
Of the original six subjects, four returned for the post-treatment scan; one was unable 
to tolerate amisulpride because of an increased frequency of falls, and one was 
withdrawn because of unrelated physical health problems. The remaining four 
subjects responded well to 50mg amisulpride daily. The mean reduction in the three-
item NPI score was 62.6±22.9%, with a range between 36.4-100%. EPS were 
present in a single subject and were minimal (score of 0.2 on the SAS). Sedation was 
reported as a side effect in three subjects, two at a mild level (increased evening 
sleepiness) and one at a slightly more moderate level (sedation extended to the next 
day). The subject with moderate sedation received a reduction in the dose of 
amisulpride (50mg to 25mg) prior to the post-treatment scan. Of the four subjects, 
three were scanned after 28±7 days treatment with amisulpride 50mg, and the fourth 
was scanned after 47 days treatment (26 days at 50mg, followed by 21 days at 
25mg). The clinical and demographic data of the six subjects who had a baseline 
scan can be seen in Table 5.2. 
Table 5.1: Bias Corrected Pre-Treatment BPND    

















Caudate 10.60 12.37 (11.53-12.72)       9.74 11.98 (11.54-12.39) 
Putamen 14.78 17.75 (16.99-18.45)     13.86 17.46 (16.56-18.02) 
Limbic striatum 11.80 13.90 (12.76-14.85)     11.19 13.67 (12.30-14.40) 
Associative striatum 11.50 13.96 (13.49-14.67)     10.74 13.63 (12.90-14.25) 
Sensorimotor striatum 13.04 15.86 (15.10-16.72)     12.21 15.57 (14.80-16.24) 
Thalamus   1.35 1.31     (1.11-1.47)       1.32   1.30     (1.09-1.44) 






 100% response to 50mg nocte, but required dose reduction to 25mg nocte because of excessive sedation. The response was sustained at 25mg. 
Table 5.2: Clinical and Demographic data 
Age (years) 81  91 89  85 76 88 
Gender Male Female Male Female Male Female 
MMSE  15 14 13 18 19 17 
Sensory deficits Hearing and Vision Hearing and Vision Hearing and Vision -------- Vision -------- 
Impaired mobility  Yes  Yes Yes No No No 
Living arrangements Own home, with carer Own home, with carer Own home, formal 
live-in carer 
Care Home Lives alone Own home, 
with carer 
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No No Yes No No No 
Amisulpride dosage  at 
time of second scan 
– – 50mg 25mg  50mg 50mg 
Duration of treatment  
 
5 days – discontinued due 
to unrelated physical 
health problems 
Failed to tolerate 25mg 
stopped after 14 days 
due to increased falls 
28 days 26 days at 
50mg; 21 
days at 25mg 
35 days 21 days  
% reduction in total 
symptom score 
– – 36.4 
 
100 60 54.2 
SAS Score – – 0 0 0 0.2 
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Head Movement  
Head movement correction was required in all subjects, pre- and post-treatment, and 
is shown graphically in Figure 5.2. The Figure shows the time-activity curve for the 
caudate only, in subjects with pre- and post-treatment data.  
 
Pre-Treatment 
During the baseline scan, minimal frames were removed: 0-30 minutes, one 60-
second frame was removed in one subject; 60-90 minutes, a maximum of three 60-
second frames were removed; 210-240 minutes, a maximum of five 60-second 
frames were removed. 
 
Post-Treatment 
Head movement in the first two scanning sessions of the post-treatment scan was 
minimal, requiring the removal of a maximum of three 60-second frames across the 
four subjects. However, movement in the third scanning session was greater, 
requiring the removal of 26 60-second frames in one subject (85 years, female). The 
post-treatment scan for this subject was excluded from the analysis due to excessive 
movement. This is the same lady who reported moderate sedation and was given a 
reduced dose of amisulpride (25mg) prior to the post-treatment scan.  
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Figure 5.2: Time-Activity Curves for the Caudate, Showing 60-Second Frames 
Removed (blue) From Each Scanning Session (Method 1) 
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5.3.2 Regional D2/3 Receptor Binding 
Comparison of Methods 
Pre-Treatment 
Mean (SD) regional pre-treatment BPND (Method 1 and Method 2) is described and 
compared in Table 5.3. The mean percentage change in BPND between the two 
methods was <2.5% in all regions but the inferior temporal cortex, where the average 
percentage change was 3.51%. 
 
Post-Treatment 
Regional post-treatment BPND (Method 1 and Method 2) for the three subjects is 
presented in Table 5.4. Mean percentage variability in BPND across the two methods 




Pre-Treatment BPND given as mean across subjects (SD), mean includes bias corrected BPND for one 
subject; 
2
(|Method 1-Method 2|/Method 1)*100 
 
Table 5.3: Pre-Treatment Scan: Percentage Change in [
18
F]fallypride BPND  Between 
Method 1 (3 x 30 minutes) and Method 2 (3 x 20 minutes) 










15.66 (2.37) 15.62 (2.53) 2.20 (0.91) 
Putamen 
 
21.31 (2.47) 21.31 (2.48) 1.95 (0.52) 
Limbic striatum 
 
16.51 (1.98) 16.44 (2.06) 1.77 (0.87) 
Associative striatum 
 
17.22 (2.37) 17.20 (2.42) 1.99 (0.53) 
Sensorimotor striatum 
 
19.64 (2.69) 19.66 (2.80) 1.89 (0.50) 
Thalamus 
 
  1.39 (0.24)   1.39 (0.25) 1.41 (0.86) 
Inferior temporal gyrus 
 







(|Method 1-Method 2|/Method 1)*100 
 
Table 5.4: Post-Treatment Scan: Percentage Change in [
18
F]fallypride BPND Between Method 1 (20, 20, 40 minutes) and Method 2 (3 x 
20 minutes) 
Subject:(Age/gender)          1: 89/Male 2: 76/Male 3: 88/Female  




Mean (SD) %  
change (n = 3)
1
 
 Method 1 Method 2 Method 1 Method 2 Method 1 Method 2 
Caudate 
 




















0.32  0.32   0.82    0.82 0.37  0.37 0.93 (0.54) 
 
Inferior temporal gyrus 
 
0.23  0.24   0.53    0.54 0.23  0.24 4.31 (1.55) 
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5.3.3 Regional D2/3 Receptor Occupancy 
Figure 5.3 shows a parametric PET image of [
18
F]fallypride binding, before and after 
amisulpride treatment in one subject (88 years, female). The reduced colour 
intensity, from approximately 10 to 5 in the striatum and 1.5 to 0.5 in the 
extrastriatal regions, clearly illustrates a reduction in [
18
F]fallypride binding after 21 
days of 50mg amisulpride.  
 
Figure 5.3: Parametric Image of [
18




Regional D2/3 occupancy was calculated using pre- and post-treatment BPND for 
both Methods 1 and 2. Time-activity curves showing pre- and post-treatment data for 
Method 1 are shown in Figures 5.4, 5.5 and 5.6; representing the caudate and 
putamen, functional striatal subdivisions, and extrastriatal regions, respectively. The 
Figures illustrate the regional D2/3 occupancy in each of the three subjects with pre- 
and post-treatment data. Using the original protocol (Method 1), a higher striatal 
occupancy was seen in the caudate (46.66-72.39%), compared to the putamen 
(30.03-60.05%). The functional subdivisions of the striatum also showed a gradient 





















by the limbic striatum (34.55-60.05%) and sensorimotor striatum (31.83-60.14%). 
Amongst the extrastriatal regions, the thalamus showed a higher occupancy (53.80-
76.07%) than the inferior temporal gyrus (26.88-42.54%). The same pattern of 
occupancy was seen across both methods. The absolute difference in percentage 
occupancies between the two methods was <2% in all regions, apart from the 
inferior temporal gyrus, which showed an average difference of 6.11% between 
methods. A comparison of the two methods is shown in Table 5.5. Across the three 
subjects, subject one (89 years, male) showed the highest D2/3 receptor occupancy 
across all regions. The lowest occupancies were seen in subject two (76 years, male) 
across all regions, apart from the inferior temporal gyrus, which was lowest 
(26.88%) in subject three (88 years, female). 
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Figure 5.4: Time-Activity Curves Showing Striatal D2/3 Receptor Occupancy 
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Figure 5.5: Time-Activity Curves Showing Striatal Subdivisions D2/3 Receptor 
Occupancy 
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1
: Percentage Occupancy Method 1: ((PreTreatment 3x30minutes – PostTreatment 20, 20, 40minutes)/PreTreatment 3x30minutes)*100 
2
: Percentage Occupancy Method 2: ((PreTreatment 3x20minutes – PostTreatment 3x20minutes)/PreTreatment 3x20minutes)*100 
3
: Absolute difference between occupancies derived from Method 1 vs. Method 2: |Occupancy Method 1 – Occupancy Method 2| 
* Final 30 minutes of pre-treatment scan missing. The raw BPND values have been corrected using estimated % bias data (see Table 5.1) 
 
Table 5.5: Regional Dopamine D2/3 Receptor Occupancy During Treatment With Amisulpride 50mg Daily: Comparison of Method 1
 
and Method 2 







                                       Percentage occupancy of D2/3 receptors 
 





















69.97     68.50 46.66  47.00 66.09  62.25 1.88 (1.46) 
Putamen 
 
56.89     55.27 30.03 30.87 58.34  57.15 1.22 (0.32) 
Limbic striatum 
 
56.55     55.00 34.55  33.86 49.53  47.87 1.30 (0.43) 
Associative striatum 
 
63.39     62.00 39.28 40.01 62.97  61.95 1.05 (0.27) 
Sensorimotor striatum 
 
56.75     54.96 30.90  31.83 58.06  57.13 1.22 (0.41) 
Thalamus 
 
75.82     75.36 53.80  54.08 70.62  70.53 0.28 (0.15) 
Inferior temporal gyrus 
 
36.45     31.11 42.54  40.58 26.88  15.84 6.11 (3.75) 
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5.4 Discussion 
The first objective of the current study was to determine whether the recently 
adapted [
18
F]fallypride protocol (Chapter 4) was suitable for use in a clinically 
relevant population, and to assess the quality of the resulting image data. 
Generally, the protocol translated well for use with AD subjects, with only one of the 
six subjects failing to complete all three scanning sessions. For this scan, the tracer 
was delivered to the unit 90 minutes behind schedule, meaning the subject had an 
extended stay in the department. The waiting time appeared more problematic than 
the scan itself, which could have been due to several factors, such as: osteoarthritic 
pain, which caused discomfort when seated in the wheelchair for long periods of 
time; fatigue, due to several nights of disturbed sleep; and disorientation, caused by a 
combination of sensory and cognitive impairment. This patient was able to tolerate 
the first two scanning sessions with very little head movement, and so the image data 
was bias corrected and included in the analysis. 
A number of the patients in the present sample needed reassurance whilst in the 
scanner, and this created more head movement compared to that seen in the previous 
study with healthy adults (Chapter 4). However, movement was minimal in most 
cases, and image quality was preserved by performing frame-to-frame realignment 
and removing 60-second frames where motion had occurred. Nevertheless, the 
possibility that subtle head movements may have impacted on the quality of data 
should not be excluded.  
The second objective was to adapt and optimise a post-treatment [
18
F]fallypride 
imaging protocol to enable peak tracer binding in extrastriatal and striatal regions to 
be captured. The first two (20 minute) scanning sessions were generally well 
tolerated, with minimal head movement. However, the final (40 minute) session 
proved more difficult and produced poor quality data in one subject. The subject was 
unable to tolerate more than 15 minutes of the final scan, resulting in the post-
treatment scan being excluded from the analysis.  
The third aim of the study was to establish whether reducing the sampling times 
further, to 20 minute scanning sessions, would have an impact on the occupancy data 
collected. Reducing the duration of individual scanning sessions had minimal effect 
on pre- and post-treatment BPND in the striatal regions and thalamus (<2.5%), and 
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the inferior temporal gyrus (<5%). The impact of the reduced scan durations on the 
calculated occupancy values was also minimal (<2%) in all but the inferior temporal 
gyrus, where the discrepancy between methods ranged from 1.96% to 11.04%. The 
variability observed here could be due to a low signal to noise ratio of [
18
F]fallypride 
binding in the temporal cortex, and the additional impact of AD on D2/3 receptor 
density in this region (Joyce et al., 1998). 
 
5.4.1 Dose-Occupancy Relationships 
Amisulpride is a highly selective antagonist for D2/3 receptors, and in young adults 
achieves occupancies of 65% or above in striatal and extrastriatal regions, within the 
optimal clinical dose range (400-800mg daily) (Sparshatt et al., 2009). Occupancy 
data on very low dose amisulpride (50mg) is limited and varies considerably 
between studies. The first PET study to examine striatal D2/3 binding in response to 
amisulpride achieved occupancies ranging from 3-9%, using [
76
Br]bromolisuride 
(Martinot et al., 1996). The same group reported 0% striatal D2/3 receptor 
occupancy when using the high affinity radioligand [
76
Br]FLB-457 (Xiberas et al., 
2001a). In contrast to the low striatal occupancies reported in the above PET studies, 
research using SPECT techniques, and the [
123
I]IBZM radiotracer, reported 
occupancies of 40% in the striatum (la Fougère et al., 2005; Meisenzahl et al., 2008). 
These studies suggest that the discrepancies observed in occupancy data are due to 
differences in methodology, including the choice of radiotracer and imaging 
technique used. The timing of drug dose relative to the scan and treatment duration 
are also important methodological issues to consider when comparing occupancy 
data, particularly when plasma concentrations are not available (Meisenzahl et al., 
2008). 
Data on amisulpride D2/3 occupancy in extrastriatal regions consists of only one 
study using PET imaging, which reported occupancy values of 30-40% in the 
thalamus, and a range of 48-65% occupancy in the temporal cortex (Xiberas et al., 
2001b). 
In the present study, we observed the expected gradient of occupancy (caudate > 
putamen) in all three subjects (Stone et al., 2005; Vernaleken et al., 2004). In terms 
of specific occupancy values, striatal occupancy in one subject (76 year old male) 
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was within a similar range to that reported in the above literature in young adults. 
However, the occupancy values in the other two subjects (89 year old male, 88 year 
old female) are considerably higher. With regards to the extrastriatal regions, 
occupancy values in the thalamus exceeded those in young adults, whereas 
occupancies in the inferior temporal cortex were lower than expected, particularly so 
in one subject (26.88%).  
 
5.4.2 Methodological Issues 
Several methodological issues may have impacted on the accuracy of the current 
results. For example, additional noise was introduced to the data by the bias 
correction applied to the pre-treatment scan. Nevertheless, this method prevented the 
loss of data, and the fact that the bias was calculated based on pre-treatment scans 
from the same sample will have minimised the noise. It was not possible to apply a 
bias correction to the post-treatment scan as there was insufficient data to calculate 
an average bias. As a result, one post-treatment scan was excluded from analysis due 
to excessive head movement. Due to the small sample size, lack of information on 
plasma levels of amisulpride, and additional noise created by including bias 
corrected data, it is difficult to determine whether the higher striatal and thalamic 
occupancies seen in the two older subjects are due to changes in peripheral 
pharmacokinetics (i.e. an age-related increase in the plasma level of amisulpride), 
changes in central pharmacokinetics, or pharmacodynamic changes. It could, of 
course, be a combination of all three, and this will need to be explored in future 
studies with an adequate sample size to examine such relationships. However, the 
primary aim of this study was not to determine dose-occupancy relationships, but to 
establish the tolerability of the adapted [
18
F]fallypride protocol, and optimise it for 
use in future studies.  
Other methodological issues which should be considered include the lack of MRI, 
and partial volume effects. These factors are discussed in Chapter 6, Section 6.2.3. 
Partial volume effects are likely to have impacted most in regions where atrophy is 
more marked in AD, particularly the inferior temporal gyrus. Atrophy, together with 
low specific binding in this region, may have produced artefactually low occupancy 
values in the current study. The ability of the adapted [
18
F]fallypride protocol to 
 165 
image D2/3 receptors in the inferior temporal gyrus will need to be explored further, 
perhaps in different patient groups where atrophy in this region is less marked, for 
example in those with very late-onset schizophrenia-like psychosis.  
 
5.4.3 Accuracy of Post-Treatment Protocol 
A further consideration is the duration of the post-treatment scan, and the accuracy 
of the chosen sampling times in capturing peak [
18
F]fallypride binding in striatal and 
extrastriatal regions. This is an important consideration, as imaging before or after 
binding has reached a plateau in a particular region will result in inaccurate 
estimations of the BPND. This is particularly relevant to the striatal regions, where 
D2/3 receptor density is highest. Inaccuracies in BPND estimations, primarily caused 
by insufficient scan durations, can potentially influence the conclusions drawn from 
occupancy studies e.g. preferential extrastriatal binding of certain antipsychotic 
medication (Olsson & Farde 2001). 
The current post-treatment protocol was determined from previous studies which 
have measured D2/3 receptor occupancy following antipsychotic treatment. These 
studies have collected data over a period between 180-240 minutes (Kessler et al., 
2006), and during a single scanning session lasting 120 minutes (Kegeles et al., 
2008). A more recent study specifically investigated the effect of scan duration on 
occupancy values, using [
18
F]fallypride data on young adults (N = 50) who were 
treated with a range of antipsychotic drugs; clozapine, ziprasidone, quetiapine and 
olanzapine. The results of the study indicated that equilibrium is achieved within 70 
minutes post-injection in the extrastriatal regions (between 3.8 and 39.7 minutes in 
the thalamus; and 6.7 - 67 minutes in the inferior temporal cortex), and between 29.5 
and 167 minutes in the putamen (Vernaleken et al., 2011). 
Based on the findings of Vernaleken et al. (2011), it could be argued that the 
sampling times of the current study were too early to ensure peak tracer binding was 
captured. There is a possibility that this may have contributed to the lower 
occupancy values seen in the temporal cortex in all three subjects. However, it is 
unlikely to have had an effect on striatal values, as the antipsychotic drugs used in 
the above study have considerably lower striatal occupancies than is typically 
observed during amisulpride treatment (Kessler et al., 2005; Kessler et al., 2006; 
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Vernaleken et al., 2004), and would therefore result in a longer time for the tracer to 
achieve equilibrium in this region.  
 
5.5 Conclusion 
Overall, the current study has demonstrated the suitability of the adapted 
[
18
]fallypride protocol for use in D2/3 receptor occupancy studies in older adults with 
AD. The study also highlights the importance of avoiding unnecessary delays and re-
orienting subjects to their surroundings during scanning sessions, in order to 
maximise tolerability to the imaging procedure. However, after taking these factors 
into account, the protocol demonstrates tolerability in subjects who are both 
cognitively and behaviourally disturbed, and hence enables the advancement of 
research in this population. The next stage of the research will use the adapted 
protocol in a larger sample, including subjects with late-onset schizophrenia and 
those with AD, to determine the relationship between drug dose, plasma levels and 
regional occupancy. This research will aim to define the ‘therapeutic window’ of 
D2/3 occupancy in older adults, and will further explore the mechanisms involved in 
the heightened sensitivity to antipsychotic drugs observed in the elderly. Future work 
will also aim to refine the image analysis technique in relation to the inferior 




Chapter 6: Final Discussion  
This chapter summarises the main findings of the thesis, and the limitations involved 
in interpreting the results. The implications of the main findings will then be 
discussed, together with suggestions for future research. 
 
6.1 Summary of Main Findings 
6.1.1 Establishing the Neuropsychological Profile of Psychotic Symptoms in AD 
The first component of the thesis aimed to investigate the neuropsychological profile 
of psychotic symptoms in AD, and to establish if neuropsychological tests known to 
be associated with striatal D2/3 receptor function might act as ‘cognitive markers’ of 
psychotic symptoms in AD. 
The primary analysis addressed the hypothesis that tests which correlate with 
dopamine function would differ between psychotic and non-psychotic AD patients. 
This hypothesis was based on the finding that increased D2/3 receptor availability 
was associated with delusions in AD, as well as with poorer sustained attention 
(indexed by reduced accuracy of RVP performance) and increased motor speed 
(indexed by reduced latency on a motor screening test) in the same sample (Reeves 
et al., 2009; Reeves et al., 2010). Consistent with this hypothesis, RVP accuracy was 
reduced in the current psychotic group, after controlling for global cognition, years 
of education and age. Poorer sustained attention in the psychotic group could 
represent differential influences of the dopamine D1 receptors in the prefrontal 
cortex versus D2 receptors in the striatum; explained by fronto-striatal-thalamic 
circuitry (Chapter 1, Section 1.2.1) and the inverted U-shaped curve of dopaminergic 
function and cognitive performance (Arnsten 1997; Goldman-Rakic et al., 2000).  
In contrast, there was no significant between-group difference on the SRT task, 
which was chosen as a more robust measure of motor speed than the motor screening 
test (MOT). This finding could be due to the insensitivity of the SRT task to measure 
dopaminergic function (Pullman et al., 1990; Starkstein et al., 1989). However, the 
fact that motor latency did not differ between the two groups when measured by the 
MOT task either, suggests that motor speed may not be a sensitive marker of 
psychotic symptoms in AD. The lack of sensitivity of the motor tasks could be due 
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to age-related sensory deficits or osteoarthritis impacting on performance. 
Alternatively, the results could indicate that motor function and psychotic symptoms 
are predominantly controlled by different functional subdivisions of the striatum. 
Motor function is associated with dopaminergic function in the sensorimotor 
striatum (Graybiel et al., 1994; Reeves et al., 2010), whereas presynaptic 
dopaminergic function in the associative striatum has been implicated in delusions 
within the context of schizophrenia (Howes et al., 2007; Kegeles et al., 2010). 
Therefore, tasks linked to the associative striatum may be more sensitive cognitive 
markers of psychotic symptoms in AD.  
The present study also aimed to establish the neuropsychological profile of psychotic 
symptoms in AD, and included a neuropsychological test battery covering five 
cognitive domains: executive function, memory, language, constructional praxis and 
visuoperceptual function. After controlling for global cognition, years of education 
and age, significant between-groups differences were only observed on one task 
(Incomplete Letters), which was part of the visuoperceptual function domain. This 
finding remained significant after applying Bonferroni corrections for multiple 
comparisons. A trend-level significance (p = 0.053) was also observed for between-
group differences in Object Decision, a second task within the visuoperceptual 
function domain. Both the Incomplete Letters task and Object Decision task are 
measures of object perception, a process thought to be controlled by the ventral 
visual pathway (Mishkin et al., 1983). Therefore, the impaired performance in the 
psychotic group may be explained by a disruption to the above pathway. 
A secondary aim of the present thesis was to further explore significant between-
group differences in neuropsychological test performance in terms of paranoid 
(persecutory delusions) and misidentification (misidentification delusions and/or 
visual hallucinations) subtypes. The results demonstrate that the significant between-
group differences observed in the RVP and Incomplete Letters tasks were driven 
predominantly by the misidentification subgroup, who presented solely with 
misidentification delusions and hallucinations. The misidentification group 
performed significantly poorer than the non-psychotic group on the RVP task, and 
significantly worse than all the groups on the Incomplete Letters task. The fact that 
there was no significant difference between the individual delusional subtypes on the 
RVP task could indicate that D2/3 receptor availability is increased along a 
 169 
continuum, from subtle increases in the paranoid group, to more marked increases in 
the misidentification subgroup. The greater the increase in D2/3 receptor availability, 
the more impaired the performance on the RVP task. Hence the difference in 
performance between the misidentification subgroup and non-psychotic group 
reached statistical significance. However, the fact that the misidentification subgroup 
performed significantly worse than the paranoid group on the Incomplete Letters 
task could indicate that additional pathology is contributing to the observed 
perceptual deficits, which is distinct to the misidentification subgroup. A proposed 
neural framework for object-processing suggests that the ventral visual pathway is 
part of a highly interactive occipito-temporal network, which projects to multiple 
areas including limbic and frontal regions (Kravitz et al., 2013). The fact that more 
marked pathology is reported in the limbic structures (specifically the hippocampus 
and its projection zones - parahippocampal gyrus and transentorhinal cortex) of 
subjects with misidentification phenomena, but not persecutory delusions (Forstl et 
al., 1994; Mukaetova-Ladinska et al., 1993; Sweet et al., 2000) (reviewed by Reeves 
and colleagues 2012), and that hypometabolism has been observed in the frontal 
regions of AD subjects with misidentifications (Mentis et al., 1995), supports the 
suggestion of distinct ventral visual pathway disturbances in this group.  
A further secondary aim of the current study was to examine whether 
neuropsychological test performance can predict the odds of psychotic symptoms in 
AD patients. The RVP and Incomplete Letters tasks were thus entered into a logistic 
regression analysis to determine their ability to act as predictors of psychotic 
symptoms in AD. Whilst the Incomplete Letters task demonstrated a significant 
independent contribution to the presence of psychotic symptoms, the RVP did not 
(as shown by a non-significant effect of RVP when entered into the regression model 
with the Incomplete Letters task). This result suggests that group differences in the 
two tasks may be primarily underpinned by a visuoperceptual component. 
 
6.1.2 Establishing the Test-Retest Reliability of an Adapted [
18
F]fallypride 
Imaging Protocol for Use in Older People 
The second component of the present thesis aimed to adapt [
18
F]fallypride imaging 
for use in healthy older people, by using an interrupted scanning protocol which 
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considerably shortened the length of time spent in the scanner, so that individual 
sessions lasted only 30 minutes.  
The adapted protocol demonstrated high reproducibility and reliability across the 
striatum, consistent with previous test-retest studies using [
18
F]fallypride in young 
adults (Cropley et al., 2008; Mukherjee et al., 2002). Within extrastriatal regions, 
high reproducibility (<8% variance) was seen in all but the prefrontal regions 
(orbitofrontal and anterior cingulate cortices), in particular the anterior cingulate 
cortex, where BPND differed by 28.84% between test and retest scans.  
A secondary aim of Chapter 4 was to identify whether sampling times could be 
further reduced to 20 minute sessions without affecting the reliability of the method. 
The shorter scanning sessions produced the same pattern of reproducibility as the 
original 30 minute protocol, across striatal and extrastriatal regions. Test-retest 
variability increased minimally (<3.2%) in all regions except the anterior cingulate 




F]fallypride Imaging for D2/3 Occupancy Studies in AD 
The third component of the present thesis aimed to optimise the adapted 
[
18
F]fallypride imaging protocol for use in D2/3 occupancy studies in patients with 
AD. There were three specific aims to this study (Chapter 5).  
The first aim was to assess the tolerability of the adapted (3 x 30 minute) protocol as 
a pre-treatment (baseline) protocol in people with AD who were about to commence 
amisulpride for the management of behavioural and psychotic symptoms. The 
protocol translated well for use with AD subjects, with only one subject failing to 
complete all three scanning sessions, because of a long delay in tracer delivery as 
opposed to the scan itself.  
The second aim was to further adapt and optimise a post-treatment imaging protocol, 
taking into account the reduction in available dopamine D2/3 receptor sites as a 
result of drug occupancy. The post-treatment protocol involved three scanning 
sessions, two lasting 20 minutes and the final scan lasting 40 minutes. Whilst the 
first two scanning sessions were well tolerated, the final scan proved more difficult, 
and produced poor quality data in one subject due to excessive head movement.  
 171 
The final aim of the study was to establish whether sampling times could be further 
reduced to 20 minute sessions in pre- and post-treatment protocols without affecting 
D2/3 occupancy values. Reducing the sampling times had minimal effect on pre- and 
post-treatment BPND in the striatal regions and thalamus (<2.5%) and the inferior 
temporal gyrus (<5%). The impact of shorter scan durations on occupancy values 
was also minimal (<2%) in all but the inferior temporal gyrus (6.11%). The 
variability observed here probably reflects the low signal to noise ratio of 
[
18
F]fallypride binding in the temporal cortex and the additional impact of AD on 
D2/3 receptor density in this region (Joyce et al., 1998). The added effect of 
temporal volume loss is discussed below (see Limitations, Section 6.2.3). 
In summary, the adapted [
18
F]fallypride protocol, which uses interrupted scanning 
sessions, has shown high reproducibility and reliability in healthy older adults, and 
has proved tolerable in patients with AD. A post-treatment protocol has also been 
optimised, supporting the use of the adapted protocol for measuring D2/3 receptor 
occupancy in AD, and therefore fulfilling the aims of the current thesis. 
 
6.2 Limitations 
Specific limitations to each study are detailed in the relevant chapters, however 
several general limitations are discussed below. 
 
6.2.1 Sampling  
As with any research study, it is important to consider the sampling procedure, and 
the extent to which the study sample represents individuals with a particular 
condition within the general population. Selection bias did occur in Chapter 3, 
whereby the non-psychotic group were recruited from memory clinics, and the 
psychotic group from a mixture of memory clinics and community mental health 
teams. It is therefore possible that within the psychotic group, subjects differed in 
terms of global cognition and severity of psychotic symptoms, given that worsening 
of both infers referral to the community mental health teams. The purpose of this 
selection bias was to enhance recruitment of subjects experiencing psychotic 
symptoms and hence equalise group numbers. The recruitment procedure is unlikely 
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to have impacted on the current findings, given that MMSE was controlled for and 
all psychotic symptoms were below the threshold for antipsychotic treatment. 
Issues regarding diagnostic accuracy should also be considered. All AD patients in 
the current study (Chapters 3 and 5) met the diagnosis for ‘probable AD’ following 
the NINCDS-ADRDA criteria (McKhann et al., 1984), and were excluded from the 
study if they presented with any symptoms of DLB or EPS. Screening measures 
were carried out on all healthy controls (Chapter 4), including the MMSE and an 
MRI scan, in order to rule out cognitive impairment and pathology indicative of 
dementia. 
The sample size used in the neuropsychological testing component of the current 
thesis (Chapter 3) was based upon a power calculation, which took into account the 
results of a previous study where motor speed was found to be 11% higher in 
psychotic (n = 7) compared to non-psychotic (n = 16) subjects (Reeves et al., 2009). 
The power calculation demonstrated that a sample size of 50 in each group would be 
required to detect a between-group difference of 11% in mean motor speed, one of 
the hypothesis-driven tests. However, time restraints on the current study meant that 
a sample size of 34 in the psychotic and 36 in the non-psychotic group were 
recruited. The current sample size was large enough to detect a between-group 
difference of 13.6% in mean motor speed. A sample size of 34 in the psychotic 
group compares favourably with previous studies comparing psychotic and non-
psychotic patients with AD, in which 70% of studies had a sample size of <30 in the 
psychotic group (based on studies reviewed by Reeves et al. 2012). However, whilst 
the current sample was sufficiently large to compare neuropsychological test 
performance between psychotic and non-psychotic groups as a whole, the number of 
subjects in each delusional subgroup was not large enough to adequately determine 
whether the delusional subgroups had distinct neuropsychological profiles. In 
addition, due to the small sample size within each subgroup, the current study was 
unable to determine the ability of the Incomplete Letters and RVP tasks to predict 
the odds of delusional subtypes in AD. 
The sample size for the imaging components of the current thesis (N = 8) was 
comparable to a previous reliability study of [
18
F]fallypride carried out in healthy 
young adults (N = 6) (Mukherjee et al., 2002), and is a standard sample size used to 
establish the test-retest error of PET radiotracers. However, in the AD sample 
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(Chapter 5), only six baseline scans were obtained, and two of these were unable to 
return for the post-treatment scan due to unrelated health problems. A further post-
treatment scan was also removed from the analysis due to excessive head movement. 
This meant that data on only three post-treatment scans were available and used in 
the analysis. Therefore, the sample size was too small to determine meaningful D2/3 
occupancy data in AD, but can still be used to demonstrate the feasibility and 
tolerability of the protocol in this clinical population. Recruitment of the AD group 
for the scanning component of this study (Chapter 5) proved particularly challenging 
due to several changes to prescribing practices of antipsychotic drugs in dementia. In 
particular, the National Dementia Strategy, which aimed to significantly reduce 
antipsychotic prescribing, led to a change in prescribing practice, which meant that 
patients referred to the study were frailer and more cognitively impaired than was 
originally anticipated. This led to substantial amendments being made to the protocol 
(reduction in scanning times and approval to obtain consent from carers/relatives) in 
order to adapt for the more severely impaired sample. Disease severity and frailty are 
also likely to have impacted on drop-out rates and the quality of data obtained. 
 
6.2.2 Neuropsychological Test Measures 
The choice of the two hypothesis-driven tests was based on demonstrated and 
postulated links with dopaminergic function. Whilst the choice of the RVP was 
advantageous as it had been previously adapted for use in AD (Jones et al., 1992), 
the results of the current logistic regression analysis suggest that additional visual 
processing demands of the task may have reduced its sensitivity as a measure of 
sustained attention, and therefore dopaminergic function. This may explain the 
inability of the RVP to independently predict psychotic symptoms in AD (logistic 
regression analysis). Furthermore, the dopaminergic contribution to SRT task 
performance has been questioned (Pullman et al., 1990), with some postulating that 
additional attentional demands required by the task may have masked any between-
group differences in dopaminergic-controlled motor speed (Goodrich et al., 1989). 
Of the remaining tasks in the neuropsychological test battery, it is possible that some 
were too complex for the present AD sample. Specifically, nine subjects from the 
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psychotic group were unable to complete the Go/No-Go task. This may have been 
due to the speed of the task, or anxiety effects of using a computer. 
Chapter 3 of the current study included a large number of neuropsychological tests in 
order to establish the neuropsychological profile of psychotic symptoms in AD. The 
large test battery inevitably involved a large number of statistical comparisons, and 
may therefore have increased the chance of type 1 errors occurring. However, 
stringent correction criteria were applied to the results to correct for multiple 
comparisons, including Bonferroni and Fisher’s LSD adjustments, in addition to 
tests being grouped into cognitive domains to reduce the number of statistical 
comparisons. The logistic regression analysis is also not without limitations, and is 
particularly affected by high correlations among predictor variables. However, 
multicollinearity was assessed, and the highest correlation occurring between the 
predictor variables was <0.5 (Spearman’s rho), implying that such effects are 
unlikely to have significantly impacted on the reliability of the model (see Appendix 
7.4.6). In addition, the possibility that a third moderating variable may have affected 
the association between the independent variable and outcome variable cannot be 
excluded. For example, an unmeasured variable may have strengthened or weakened 
the relationship between the Incomplete Letters task and the psychotic group. 
However, the fact that age, years of education, and MMSE were controlled for in the 
current study will have reduced the effects of confounding variables on the present 
findings. 
The NPI rating scale was used to determine the presence of psychotic and 
behavioural symptoms in AD (Chapters 3 and 5). A major limitation of this scale is 
the fact that it relies on the subjective ratings of a carer/relative. The ratings are 
therefore likely to be influenced by a number of factors, including the frequency of 
contact between the patient and carer, and the knowledge of the informant as to the 
different manifestations of psychotic symptoms in AD. In order to control for these 
factors as far as possible, the carer/relative who had the most frequent contact with 
the patient was asked to complete the rating scale, and a detailed explanation of each 
symptom, together with relevant examples, was given to the informant to help them 
to recognise the symptoms. 
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6.2.3 Image Analysis: MRI and Partial Volume Effects 
In an attempt to further increase the feasibility of the protocol for use in cognitively 
impaired individuals, the current study chose not to utilise the subjects’ MRI data for 
co-registration with PET data. This decision was based upon previous experience of 
imaging older adults with AD (Reeves et al., 2009; Reeves et al., 2005), in whom a 
multi scan approach is more challenging, and tolerability to confined spaces is 
generally poor. Instead, PET images were co-registered to a [
18
F]fallypride PET 
template, and then warped to specific atlases with predefined ROIs. This process was 
carried out using an automated procedure, similar to the approach previously used to 
quantify [
11
C]raclopride BPND in people with AD (Reeves et al., 2009). This method 
has the advantage of removing any subjectivity in the placing of ROIs. However, the 
templates were derived from structural and functional imaging data on healthy young 
adults, and may therefore have led to inaccuracies in the warping process, 
particularly in the smaller, noisier regions, such as the anterior cingulate cortex 
(Chapter 4). However, the method of image analysis does not appear to have affected 
the pattern of reproducibility across other brain regions, as our findings are 
consistent with previously conducted test-retest studies which used the subject’s 
MRI (Cropley et al., 2008) or PET-MR co-registered images (Mukherjee et al., 
2002) to define ROIs. 
In addition, the relatively poor spatial resolution of PET has always been a limitation 
in quantitative studies. Limited resolution results in loss of signal from small ROIs 
and can also cause contamination of the signal due to spillover of activity from a 
neighbouring region. Partial volume effects are enhanced with ageing due to the 
reduction in size of certain brain regions (Morris et al., 1999). Given our sample, the 
accuracy of tracer quantification is likely to have been affected, and may have 
contributed to the high test-retest variability in the anterior cingulate cortex (Chapter 
4). In terms of the quantification of occupancy data, partial volume effects are likely 
to have impacted on values obtained from the inferior temporal gyrus (Chapter 5), 
given that atrophy is particularly marked in this region in AD (Scahill et al., 2002). 
These effects could have led to artefactually low occupancy values in this region. 
Therefore, the ability of the protocol to measure D2/3 occupancy in the inferior 
temporal gyrus in older people warrants further exploration, across different clinical 
populations.  
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The above methodological limitations are less important for within-subject study 
designs, but will need to be addressed to maximise the potential of the protocol for 
use in between-subject comparisons, or to correlate regional BPND with behavioural 
measures. 
 
6.3 Implications of Findings and Directions for Future Research 
6.3.1 Neuropsychological Test Battery 
The psychotic group in the current study experienced mild, transient symptoms, 
which caused minimal disruption to everyday activities, and therefore did not require 
antipsychotic medication. The fact that cognitive differences were found in patients 
presenting with such mild psychotic symptoms suggests that the RVP and 
Incomplete Letters tasks could potentially act as cognitive markers of psychosis-
proneness in AD. 
Whilst the sensitivity of the RVP is likely due to its association with striatal 
dopaminergic function (Reeves et al., 2010), this may not be the case for the 
Incomplete Letters task, which is more likely to reflect underlying pathology in the 
ventral visual pathway (Mishkin et al., 1983). This could be investigated further by 
including additional tasks of visuoperception, rather than focusing solely on tasks 
associated with striatal dopaminergic function. 
In fact, given that only one of the hypothesis-driven tasks in the current study was 
able to detect significant between-group differences (RVP not SRT), the suggestion 
that tasks linked to striatal dopaminergic function provide the most sensitive markers 
of psychosis in AD should be re-evaluated. One interpretation of the current findings 
is that cognitive tests associated with D2/3 receptor availability in the associative 
striatum (attention), rather than the sensorimotor striatum (motor function), may be 
more sensitive markers of psychosis in AD. This could be further explored by 
identifying tasks which are associated with D2/3 receptor availability in the 
associative striatum (caudate) and/or tasks associated with its functional connections 
- specifically the dorsolateral prefrontal cortex. Examples of such tasks include the 
Stroop Colour-Word Test (interference score) and Continuous Performance Test, 
respectively (Rezai et al., 1993; Volkow et al., 1998). 
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Another possible avenue for future research would be to explore whether paranoid 
and misidentification subtypes of delusions are underpinned by distinct 
neurochemical markers, or if the two groups have the same neurobiological 
underpinning, albeit with different intensities. Based on the present results, one 
hypothesis might be that both the paranoid and misidentification subtypes are 
underpinned by increases in striatal D2/3 receptor availability, with additional 
pathology in the ventral visual pathway in the misidentification subgroup. 
Cholinergic dysfunction has been implicated in visuoperceptual disturbances 
(reviewed by Collerton et al., 2005), and it could thus be argued that 
misidentification phenomena occur later in the AD course due to more marked 
cholinergic deficits. Dopaminergic dysfunction has also been reported to play a 
significant role in misidentification phenomena, but only in the presence of pre-
existing cholinergic deficits (Collerton et al., 2005). Therefore, it may be the case 
that D2/3 receptor availability is increased along a continuum from mild increases in 
the persecutory group, through to more marked increases in the misidentification 
group. The heightened cholinergic/dopaminergic imbalance in this group could 
underlie the attentional and perceptual deficits observed. To explore this further, 
future research could investigate differences in dopaminergic and cholinergic 
function between the delusional subgroups. In vivo imaging of both 
neurotransmitters in regions along the ventral visual pathway, and its projections 
(limbic and frontal regions), could identify specific neurochemical markers of the 
different subtypes of psychotic symptoms, which could potentially influence future 
treatments. More marked cholinergic deficits together with heightened D2/3 receptor 
availability in the misidentification group could indicate a role for combined therapy 
in the treatment of misidentification phenomena, as shown by a previous study 
which used this approach to reduce hallucinations in AD (Bergman et al., 2003). 
 
6.3.2 Imaging 
The shorter scanning times required for the adapted [
18
F]fallypride protocol could 
help to advance research across a range of cognitively and neurologically impaired 
populations in which dopamine has been implicated, including patients with 
dementia, PD, movement disorders, and disorders of impulsivity. 
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A direct application of the current research is the use of the adapted [
18
F]fallypride 
protocol in a study which aims to explore the mechanisms underlying antipsychotic 
sensitivity in the elderly by combining data on drug dosage, plasma kinetics, D2/3 
receptor occupancy, and symptom reduction in patients with AD and late-onset 
schizophrenia-like illness. The study aims to establish if there are disease-specific 
differences relating to pharmacokinetic and pharmacodynamic mechanisms of 
antipsychotic drug sensitivity within the two groups. Ultimately, the research could 
be used to inform and guide dosing strategies of the antipsychotic amisulpride, by 
establishing the minimal clinically effective dose of the drug, plus the optimal 
plasma levels and dose-occupancy range for response and avoidance of motor side 
effects. Subsequently, the work could be extended to other antipsychotic drugs and 
potentially in the development of new antipsychotics for use in the older population. 
This research, together with the work of Uchida et al. (2012) in older (but not late-
onset) patients with schizophrenia, could transform the current attitudes towards 
antipsychotic prescribing in the elderly, meaning more patients are successfully 
treated for their psychotic and behavioural symptoms, enabling a better quality of 
life for both the patient and carer. 
In addition to defining the ‘therapeutic window’ of striatal D2/3 occupancy, the 
protocol also has scope to explore the role of limbic D2/3 occupancy in antipsychotic 
response. Clinically relevant doses of amisulpride and other atypical antipsychotics 
have shown higher temporal and thalamic D2/3 receptor occupancy compared to 
striatal occupancy, and this limbic selectivity has been suggested to underpin the 
reduced side effect profile of the newer antipsychotics (Bressan et al., 2003; Xiberas 
et al., 2001b). Therefore the ability of the adapted [
18
F]fallypride protocol to image 
D2/3 receptor occupancy in these regions could advance the understanding of the 
therapeutic efficacy and low EPS profile of atypical antipsychotic drugs, and be 
influential to future drug development. However, it must be noted that the ability of 
the protocol to image D2/3 occupancy in the inferior temporal gyrus in AD warrants 
further exploration, given that occupancy values were very low in the current 
sample.  
The high reliability of the adapted [
18
F]fallypride protocol means that it can be 
applied not only to D2/3 receptor occupancy studies, but also to image endogenous 
neurotransmission in striatal and limbic regions. A potential use for this paradigm 
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would be to explore dopamine release in psychotic versus non-psychotic individuals 
with AD. At present, research has focused on post-synaptic indices of dopamine 
function using single scan measures, which reflect both receptor density and levels 
of endogenous dopamine, making interpretation of the measure difficult (Laruelle 
2000). Using the adapted [
18
F]fallypride protocol to measure dopamine release in 
psychotic compared to non-psychotic subjects, and in relation to specific 
neuropsychological tasks, could clarify the contribution of dopamine to psychosis 
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7.1 Leaflets, Information Sheets and Consent Forms  
(Font size 14 was used in the original documents) 
 




Are you between 55 and 95 years of age? Do you have a memory problem? Are you 
interested in taking part in research? 
 
We are looking to recruit 100 people who have memory problems to our study over 
the next 2 and a half years. Approximately half of the people we recruit will have 
had experiences that are difficult to explain - such as believing others have stolen 
from them - whereas the other half will not. We wish to find out whether tests known 
to be linked with a naturally produced brain chemical, dopamine, differ in people 
with memory problems who have unexplained experiences compared to those 
without.  
 
Dopamine is a chemical which is produced naturally within the brain. In people with 
Alzheimer’s disease, increased dopamine has been linked with unexplained 
experiences and has also been linked to both speed and the ability the maintain 
concentration.  
 
Taking part will involve:  
 
(i) You will be asked to carry out a series of tests 
(ii) Your carer will be asked about any symptoms you may have 
 
If differences in performance were found between people who have unexplained 
experiences and those who do not, this would help us to understand the underlying 
cause and develop a test battery to monitor the effects of drugs used to treat these 
symptoms, as such drugs act to reduce brain dopamine. 
 
If you think you might be interested in taking part, please contact me on: 
020 7848 0346 (office) 
07930 278 810 (mobile) 
Email: chloe.clark-papasavas@kcl.ac.uk 
 
Thank you for taking the time to read this, 
  




You are being invited to take part in a research study. Before you decide, it is 
important for you to understand why the research is being done and what it will 
involve. Please take time to read the following information carefully and discuss it 
with relatives, friends and your GP if you wish.  
 
Why me? 
You are aged between 55 and 95 years of age and have memory problems. Some of 
you will have been chosen because you have no other symptoms, and some of you 
will have had distressing experiences that are difficult to explain. For example, you 
may have wondered if things had been stolen from the house, or whether people 
were against you. You may have seen or heard things that no one else has, or you 
may not always recognise people that are familiar to you.  
 
What is the Purpose of the Study?  
This study will form the basis of a PhD student project and we are looking to recruit 
100 people who have memory problems to our study over the next 2 and a half years. 
We wish to find out whether people with memory problems who have ‘unexplained 
experiences’ find it more or less difficult to do particular tests compared to people 
who have no such symptoms. The tests that we will ask you to do have been shown 
to be linked with a naturally produced chemical in the brain, dopamine. You may 
have heard about dopamine in relation to Parkinson’s disease, in which ‘too little’ 
dopamine is available in the brain. In people with memory problems, we have 
previously shown that unexplained experiences are more likely in people who have 
higher levels of dopamine in their brain. We also found that higher dopamine was 
linked with faster movement, but more difficulties in concentrating over several 
minutes. There were not enough people in this study to directly compare people with 
unexplained experiences to those without. This study aims to recruit a larger group 
of people with memory problems, to allow a direct comparison between groups of 
performance on a range of tests known to be linked with brain dopamine.  
 
Why is it Important? 
If we find that there are differences between the two groups in their performance on 
tests that are linked with brain dopamine, this would help us to understand more 
about the underlying cause of troublesome, unexplained experiences in people with 
memory problems. Our findings could also be used to develop a series of tests – a 
test battery – that could be used to monitor the effects of drug treatments that aim to 
reduce the frequency of occurrence of these experiences, as the drugs act to reduce 
brain dopamine.  
 
Do I have to take part? 
It is up to you to decide whether or not to take part. Take your time, discuss things 
with your carer/relative/doctor and ask us if there is anything that is not clear or if 
you would like more information. If you decide not to take part your treatment will 
not be affected by your decision. You are free to withdraw at any time without 
explanation and your future treatment will not be affected. If you do decide to take 
part you and your carer/relative will each be given a copy of this information sheet to 
keep and asked to sign a consent form. If you decide to take part you are still free to 
 223 
withdraw at any time, without giving a reason, and this will not affect your future 
treatment. You will be given a copy of your signed consent form and we will inform 
your GP about your involvement in the project. 
 
What will happen to me if I take part? 
If you decide that you may want to take part in the study, one of the research team 
headed by Dr Suzanne Reeves will arrange a time to meet with you, to discuss the 
study in more detail and answer any questions you may have. Dr Reeves is a 
psychiatrist who specialises in treating older people with mental health and memory 
problems and, in addition to her research, she works as a Consultant Psychiatrist in 
North Southwark Community Mental Health Team for Older Adults. Chloe Clark-
Papasavas is a student who will be carrying out the majority of the testing and 
interviewing you. Taking part will involve being interviewed at home and being 
asked to carry out a series of tests, all of which are brief and some of which involve 
the use of a touch screen computer. You will be given plenty of time to familiarise 
yourself with the touch screen. The total time involved should be less than an hour. 
Your carer will also be asked some questions about your well-being and how you 
have been getting on in the past few weeks, to see if you have been experiencing any 
troublesome symptoms. 
 
What are the possible disadvantages and risks of taking part? 
There are no risks involved. Taking part will of course mean giving up your time to 
be interviewed and assessed.  
 
What are the possible benefits of taking part? 
There will be no direct benefits to yourself.  
 
What Happens When the Study Stops? 
A letter will be sent to your doctor to inform him/her that you are no longer involved 
in the study.  
 
What if something goes wrong? 
If you have any problems, concerns, complaints or other questions about the study, 
you should contact Dr Reeves in the first instance. In the unlikely event of 
participants experiencing any serious adverse effects due to participation in the 
study, there are facilities for compensation in place, via the Institute of Psychiatry 
Professional Liability Insurance.  
 
Will my taking part in this study be kept confidential? 
We will inform your GP of your participation in the study and may also need to ask 
him or her some questions about your medical history. All information that is 
collected about you during the course of the research will be kept strictly 
confidential. Aside from the possibility of passing on any relevant information to 
your GP, information about you which leaves the hospital will have your name and 
address removed so that you cannot be recognised from it.  
 
What will happen to the results of the research study? 
After the study has been completed, we would anticipate presenting the results and 
conclusions at scientific meetings (within months) and publishing them in a 
 224 
scientific journal (within a year). You will not be identified within these. If you wish, 
a copy of any published article or report will be sent to you. 
 
Who is organising and funding the research? 
Guys and St Thomas Charity are funding the project.  
 
Who has reviewed the study? 
The committee for Guys and St Thomas Charity have sent the project for external 
review. The study has also been reviewed by the Joint South London and Maudsley 
and the Institute of Psychiatry NHS Research Ethics Committee  
 
Contact for Further Information 
Chloe Clark-Papasavas, 
Department of Old Age Psychiatry, PO Box 070 
Institute of Psychiatry, De Crespigny Park 
London SE5 8AF    
 
 020 7848 0346;  
07930 278 810 (mobile) 
Email: chloe.clark-papasavas@kcl.ac.uk 
 
Many thanks for your interest in the study, 








The participant should complete the whole of this sheet him or herself. 
 
Place a  in each of the boxes if the statement applies to you: 
 
I have read the Information Sheet       
        
 
I have been given the opportunity to ask questions and 
discuss this study.        
 
I have received enough information about the study and satisfactory 
 answers to all my questions.     
 
I understand that a carer/relative will be asked to provide  
information about me  
 
I agree to disclosure of my medical records to researchers 
 
I understand that I am free to withdraw from 
the study at any time, without having to give a reason for 
withdrawing and without affecting future medical care.     
 
I agree to take part in the study 
 
I understand that my doctor will be informed if any of the results     
of the tests carried out as part of the research are important for my 
health.  
 





(NAME IN BLOCK 
CAPITALS).........................................................................................…………….. 
 
Investigator’s signature..............................................…Date: .............................. 
 
(NAME IN BLOCK 
CAPITALS).............................................................................……………………... 
 
Please inform my GP that I am taking part in this study          
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7.1.2 Establishing the Reliability of [
18





Are you between 55 and 95 years of age? Would you like to take part in research? 
We are looking to recruit 8 healthy volunteers to take part in a study. Our aim is to 
establish the reliability of a brain scanning technique that measures a naturally 
produced brain chemical, dopamine. You may have heard about dopamine in relation 
to Parkinson’s disease, where too little dopamine is produced. This type of brain 
scan is used in young people but involves long periods in the scanner (up to 2 hours 
at a stretch).  
Our study aims to use a technique for measuring brain dopamine that has been 
specifically adapted to reduce the length of time spent in the scanner and we wish to 
find out how reliable it is. The best way of establishing the reliability of a measure is 
to find out how much it varies in the same person, from one occasion to the next. 
The more reliable the measure, the less variation there is.  
Taking part will involve  
 
(i) Having an MRI scan 
(ii) Having 2 scans that measure dopamine in the brain 
 
Once we have established the degree of variation in our measure between the 2 
scanning sessions, we can use this to measure the action of drugs that act at 
dopamine sites in people with Alzheimer’s disease, with the aim of reducing drug 
side effects. 
If you think you might be interested in taking part, please contact me on 020 7848 
0548 (office), 07947036513 (mobile), or email suzanne.j.reeves@kcl.ac.uk 
 
Thank you for taking the time to read this, 
 




You are being invited to take part in a research study. Before you decide it is 
important for you to understand why the research is being done and what it will 
involve. Please take time to read the following information carefully and discuss it 
with relatives, friends and your GP if you wish.  
 
Why me? 
You are aged between 55 and 95 years of age and are healthy. 
 
What is the Purpose of the Study?  
We wish to establish the reliability of a brain imaging technique that measures a 
naturally produced brain chemical, dopamine. The term ‘reliability’ describes how 
stable a measure is over time, and the more reliable a measure is, the less fluctuation 
there is in the measure. The best way of establishing the reliability of a measure is to 
measure the degree (percentage) of variability in the measure in the same person, 
from one occasion to the next. In young people, the measure of brain dopamine 
obtained using a particular imaging method has been shown to vary between 5% and 
10%, depending upon the brain region examined. However, the method involves 
multiple and lengthy scanning sessions (up to 2 hours at a time over a total of 4 
hours). We have adapted this technique to make it more feasible for use in older 
people, by reducing the length of time spent in the scanner and wish to find out how 
reliable our method is at measuring dopamine in several brain regions. We plan to do 
this by asking participants to have 2 brain scans that measure dopamine, 4 weeks 
apart, to find out the percentage variation in the measure between the 2 scanning 
sessions.  
 
Why is it Important? 
In young people, this type of imaging has been used to measure the action of drugs at 
brain dopamine sites and has helped to optimise drug dosage and treatment 
strategies, with the aim of reducing side effects. This area of research has been 
neglected in older people, particularly in people with dementia. If we find that our 
adapted protocol is easy to tolerate and can provide a reliable measure of dopamine, 
we can then utilise this to investigate the reasons why older people are more 
vulnerable to developing side effects following the use of drugs that act at dopamine 
sites. If we know the degree of variation inherent in our technique, we can determine 
the number of participants we would need to carry out such a study. We use 
statistical programmes to do these calculations. In addition, an imaging technique 
that has been specifically adapted to reduce the time spent in the scanner could be 
used in a wide range of clinical and research settings.  
 
Do I have to take part? 
It is up to you to decide whether or not to take part. Take your time, discuss things 
with your carer/relative/doctor and ask us if there is anything that is not clear or if 
you would like more information. You are free to withdraw at any time without 
explanation. If you do decide to take part you will be given a copy of this 
information sheet to keep and asked to sign a consent form. If you decide to take part 
you are still free to withdraw at any time, without giving a reason. You will be given 
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a copy of your signed consent form and we will inform your GP about your 
involvement in the project. 
 
What will happen to me if I take part? 
If you decide that you may want to take part in the study, Dr Suzanne Reeves, or one 
of the research team who is carrying out the research, will arrange a time to meet 
with you, to discuss the study in more detail and answer any questions you may 
have. Dr Reeves is a psychiatrist who specialises in treating older people with mental 
health and memory problems and, in addition to her research, she works as a 
Consultant Psychiatrist in North Southwark Community Mental Health Team for 
Older Adults. She has been carrying out imaging research in older people since 2003 
and has been funded by the Guys and St Thomas’ Charity to carry out her current 
project. Taking part will involve having 2 brain scans that measure dopamine sites. 
 
1. First brain scan:  
 
What Happens During the Brain Scan?  
The brain scan will take place at St Thomas’ Hospital. The type of brain scan you 
will be having is a PET scan. PET stands for positron emission tomography and is a 
scan which allows us to measure the amount of dopamine in the brain. If you would 
like to visit the Centre prior to deciding whether or not you wish to take part in the 
study, this can be arranged. Otherwise, we have some photographs of the scanner 
that we can show you. On the day of each scan, you will be transported to the 
Imaging Sciences Centre at St Thomas’ Hospital in a minicab if you wish, or if you 
prefer you can make your own way there and we will reimburse your travel 
expenses. When you reach the unit, Dr Reeves or one of the research team will talk 
you through the scanning procedure, so that you can ask any questions. Before the 
scan a small tube (a cannula) will be placed into a vein in your arm, and a small 
amount of a chemical will be injected into the tube. This chemical allows us to 
measure dopamine in the brain. Once you are comfortable in the scanner, you will be 
asked to stay still for a 5 minute scan, to make sure you are positioned correctly. This 
will be followed by a series of scans lasting 30-40 minutes each with rest breaks in 
between, over a period of 4 hours. You will need to lie still in the scanner during 
each session, so that the pictures we take are not blurred. Your head will be 
supported by a moulded head-rest and a strap, to lessen the chance of your head 
moving without restricting it. The scanner is quiet and you can go to sleep if you 
wish. If you prefer to listen to music, there is a radio/cassette/CD player in the room. 
After 4 weeks, we will ask you to return for a second scan, which will be identical to 
the first one  
 
Will I Need to Have Any Other Tests? 
Yes, an MRI scan. We will arrange for you to have a scan that gives us a detailed 
picture of the structure of the brain. This will be performed at the Centre for 
Neuroimaging Sciences, based in Camberwell and jointly run by the Institute of 
Psychiatry and the South London and Maudsley NHS Foundation Trust. MRI stands 
for Magnetic Resonance Imaging and gives us a picture of your brain by using a 
powerful magnet. No radiation (X-Rays) is involved. You must not have a scan if 
you have received metal injuries to the eye, had metallic objects (including clips) 
inserted into your body at an operation, if you have received a shotgun or war injury, 
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or have a heart pacemaker. The radiographer will go through a list of possible risks 
with you before you go into the scanner. The scanner feels rather cramped inside and 
makes buzzing and whirring sounds, but will be over within around 15 minutes. This 
type of scan can help to diagnose memory problems that may be related to having 
had a stroke or a head injury. If we find out anything that is important for your 
doctor to know, we will pass this information on. 
 
What are the possible disadvantages and risks of taking part? 
PET scanning: This involves a small dose of radioactivity, which is given via an 
injection. Dr Reeves, or another suitably qualified practitioner will need to insert a 
small cannula into one of the veins in your arm to allow the injection to be given and 
this will be removed as soon as the scan is completed. To give you an idea about 
how much radiation you will get, we will make a comparison with an every-day 
situation. Everyone receives a small amount of unavoidable radiation each year and 
this varies depending upon where you live. This is referred to as background 
radiation. This research gives your body the equivalent of about 4 years of 
background radiation. The scans you will have if you take part in this study involve 
exposure to radiation. The additional amount of radiation involved is the same 
amount that everyone in the UK receives from natural sources over a period of about 
4 years. In the general population, the chance of anybody getting a fatal cancer 
during their lifetime is roughly 1 in 5. The additional risk associated with the 
radiation in this study is up to approximately 1 in 2300. Taking part in this study will 
therefore increase your chance of getting a fatal cancer from an existing 1 in 5 up to 
at most 1 in 4.99. 
During the study, you should let us know if you need to start any new treatments. 
Before each of the PET scans, you should not drink any alcohol for 24 hours. On the 
morning (or afternoon) of the PET scan, you should limit caffeine intake. If you have 
been exposed to radiation in the past year, either from medical investigations, or 
taking part in other research projects, you should not take part in the study. You will 
be given as much time as you need to discuss this with Dr Reeves.  
 
What are the possible benefits of taking part? 
There will be no direct benefits to yourself, but if we establish that the imaging 
technique is a reliable one – in other words if the measure varies little (< 20%) 
between the two scanning sessions - we will apply this protocol to a clinical setting, 
to examine the action of drugs that act at dopamine sites. We do reimburse you for 
your time with £40 per visit to the unit. We will of course provide transport and 
lunch or soft drinks that you may require. If you do not wish to accept payment for 
yourself, we would ask you to take the money and use it to benefit a charity of your 
choice. We can give you a picture of your PET scan at a later date if you would like 
this. 
What Happens When the Study Stops? 
A letter will be sent to your doctor to inform him/her that you are no longer involved 
in the study. 
 
What if something goes wrong? 
If you have any problems, concerns, complaints or other questions about the study, 
you should contact Dr Reeves in the first instance. In the unlikely event of 
participants experiencing any serious adverse effects due to participation in the 
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study, there are facilities for compensation in place, via the Institute of Psychiatry 
Professional Liability Insurance.  
 
Will my taking part in this study be kept confidential? 
We will inform your GP of your participation in the study and may also need to ask 
him or her some questions about your medical history. All information that is 
collected about you during the course of the research will be kept strictly 
confidential. Aside from the possibility of passing on any relevant information to 
your GP, information about you which leaves the hospital will have your name and 
address removed so that you cannot be recognised from it.  
 
What will happen to the results of the research study? 
After the study has been completed, we would anticipate presenting the results and 
conclusions at scientific meetings (within months) and publishing them in a 
scientific journal (within a year). You will not be identified within these. If you wish, 
a copy of any published article or report will be sent to you. 
 
Who is organising and funding the research? 
Guys and St Thomas Charity are funding the project for 2 years.  
 
Who has reviewed the study? 
The committee for Guys and St Thomas Charity have sent the project for external 
review. The study has also been reviewed by the Joint South London and Maudsley 
and the Institute of Psychiatry NHS Research Ethics Committee 
Contact for Further Information 
Dr Suzanne Reeves, 
Department of Old Age Psychiatry, PO Box 070 
Institute of Psychiatry, De Crespigny Park 
London SE5 8AF    
 020 7848 0548/0550, Fax 020 7848 0632 07947 036 513 (mobile) 
 
Many thanks for your interest in the study, Dr Suzanne Reeves, Professor Robert 








The participant should complete the whole of this sheet him or herself. 
 
Place a  in each of the boxes if the statement applies to you: 
 
I have read the Information Sheet       
        
 
I have been given the opportunity to ask questions and 
discuss this study.        
 
I have received enough information about the study and satisfactory  
answers to all my questions.     
 
I understand that I am free to withdraw from 
the study at any time, without having to give a reason for 
withdrawing and without affecting future medical care.     
 
I agree to disclosure of my medical records to researchers 
 
I agree to take part in the study 
 
I understand that my doctor will be informed if any of the results     
of the tests carried out as part of the research are important for my 
health.  
 














Please inform my GP that I am taking part in this study          
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7.1.3 Imaging Dopamine Receptor Occupancy During Antipsychotic Treatment 




Are you between 55 and 95 years of age? Have you been prescribed a medication to 
help with troublesome or distressing symptoms? 
 
We are looking to recruit 8 people who have memory problems and who have been 
prescribed the drug amisulpride. We want find out which effects of the drug are 
linked with its action on a naturally produced brain chemical dopamine.  
 
Dopamine is a chemical that helps to focus attention and co-ordinate movements. 
Amisulpride acts to reduce dopamine and, for this reason, may affect concentration 
or speed of movement.  
 
In young people, brain scans have been used to find out the lowest possible dose of 
drugs like amisulpride that can be used to reduce symptoms without causing side 
effects and we would like to do the same in people with memory problems. 
 
Taking part will involve: 
(i) Both you and your carer will be asked some questions before and after 
you begin drug treatment. 
(ii) Having 2 brain scans that measure dopamine sites in the brain – one 
before and one after 2-8 weeks of treatment.  
 
If you think you might be interested in taking part, please contact me on 020 7848 
0548 (office), 07947036513 (mobile), or email suzanne.j.reeves@kcl.ac.uk 
 
Thank you for taking the time to read this, 
  




You are being invited to take part in a research study. Before you decide it is 
important for you to understand why the research is being done and what it will 
involve. Please take time to read the following information carefully and discuss it 
with relatives, friends and your GP if you wish.  
 
Why me? 
Your doctor wishes to start you on medication to help with some of your symptoms. 
The name of the drug is amisulpride (Solian). Overall 8 people who are about to start 
this drug will be taking part in the study, which should take about a year to complete.  
 
What is the Purpose of the Study?  
We wish to find out more about the action of amisulpride in the brain, using a type 
of scan that measures a naturally produced chemical, dopamine. Dopamine is 
important in the brain as it helps us to co-ordinate movements and to concentrate on 
day to day events. You may have heard of it in relation to Parkinson’s ddisease 
where people have too little available dopamine. Drugs like amisulpride act to 
reduce dopamine levels in the brain and are used because they can reduce 
troublesome or distressing symptoms in people with memory problems. By reducing 
dopamine they can however cause side effects, including stiffness of movement or 
tremor. In young people, brain scanning methods have been used to find out the 
lowest possible doses of drugs like amisulpride that can be used to treat symptoms 
without causing side effects. We would like to carry out a similar study in people 
with memory problems who are taking amisulpride. We want to see whether or not 
changes in dopamine that occur as a result of your treatment are linked with changes 
in the symptoms you experience, your ability to concentrate and side effects. The 
study will also form part of a PhD student project. 
 
Why is it Important? 
The research will provide us with valuable information about whether the effects of 
drugs like amisulpride are linked with their action on brain dopamine and will be 
used to inform a wider study that aims to investigate the reasons why older people 
are more sensitive to drug side effects than younger ones.  
 
Do I have to take part? 
It is up to you to decide whether or not to take part. Take your time, discuss things 
with your carer/relative/doctor and ask us about anything that is not clear or if you 
would like more information. If you decide not to take part your treatment will not 
be affected by your decision. You are free to withdraw at any time without 
explanation and your subsequent treatment will not be affected. If you do decide to 
take part you and your carer/relative will each be given a copy of this information 
sheet to keep and asked to sign a consent form. If you decide to take part you are still 
free to withdraw at any time, without giving a reason, and this will not affect your 
subsequent treatment. You will be given a copy of your signed consent form and we 
will inform your GP about your involvement in the project. 
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What will happen to me if I take part? 
If you decide that you may want to take part in the study, Dr Suzanne Reeves, or one 
of the research team who is carrying out the research, will arrange a time to meet 
with you and your carer, to discuss the study in more detail and answer any 
questions you may have. Dr Reeves is a psychiatrist who specialises in treating older 
people with mental health and memory problems and, in addition to her research, she 
works as a Consultant Psychiatrist in North Southwark Community Mental Health 
Team for Older Adults. She has been funded by the Guys and St Thomas’ Charity to 
carry out the research. She will not be prescribing your treatment, but will be in close 
contact with the doctor and/or team who are responsible for your clinical care and 
may need to access to your medical notes, for the purposes of her research. Taking 
part will involve several stages: 
The research will involve both you and your carer being interviewed before and after 
starting amisulpride, so that we can see how effective the medication has been and 
monitor any side effects that you may experience. We will also ask you to have 2 
brain scans, which will allow us to measure the action of amisulpride at dopamine 
sites. 
 
1. First Assessment: Dr Reeves or one of her team will review your symptoms and 
check for any side effects. Your carer will be asked how you have been getting 
on in the past few weeks, to see if there have been any symptoms that are 
distressing you. 
2. First brain scan: This will happen at St Thomas’ Hospital before you start taking 
amisulpride medication. Dr Reeves will organise this as soon as possible after 
meeting with you, so that your treatment will not be delayed by you agreeing to 
take part in the study. 
 
What Happens During the Brain Scan?  
The type of brain scan you will be having is a PET scan. PET stands for positron 
emission tomography and is a scan which allows us to measure the amount of 
dopamine in the brain. By scanning you before and after treatment with amisulpride, 
we can see how much dopamine activity is reduced by the drug in different areas of 
the brain. This type of scan does not provide a detailed picture of the brain and will 
not help us to find out the cause of your memory problems. If you would like to visit 
the Centre prior to deciding whether or not you wish to take part in the study, this 
can be arranged. Otherwise, we have some photographs of the scanner that we can 
show you. 
On the day of each scan, you and your carer will be transported to the Imaging 
Sciences Centre at St Thomas’ Hospital in a minicab. When you reach the unit, Dr 
Reeves or one of the research team will talk you through the scanning procedure, so 
that you can ask any questions. Before the scan a small tube (a cannula) will be 
placed into a vein in your arm, and a small amount of a chemical will be injected into 
the tube. This chemical allows us to measure dopamine in the brain. Once you are 
comfortable in the scanner, you will be asked to stay still for a 5 minute scan, to 
make sure you are positioned correctly. This will be followed by a series of scans 
lasting 30 minutes each with rest breaks in between, over a period of 4 hours. You 
will need to lie still in the scanner during each session, so that the pictures we take 
are not blurred. Your head will be supported by a moulded head-rest and a strap, to 
lessen the chance of your head moving without restricting it. The scanner is quiet 
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and you can go to sleep if you wish. If you prefer to listen to music, there is a 
radio/cassette/CD player in the room. 
 
3. Second brain scan: This will happen around 4 weeks after the first scan, and will 
follow a similar procedure. This time, there will be three scans with rest breaks in 
between, lasting a total of 2 and a half hours. The first two scans will last 20 
minutes each, and the final scan will last 40minutes.  
 
What are the possible disadvantages and risks of taking part? 
PET scanning: This involves a small dose of radioactivity, which is given via an 
injection. Dr Reeves, or another suitably qualified practitioner will need to insert a 
small cannula into one of the veins in your arm to allow the injection to be given and 
this will be removed as soon as the scan is completed. To give you an idea about 
how much radiation you will get, we will make a comparison with an every-day 
situation. Everyone receives a small amount of unavoidable radiation each year and 
this varies depending upon where you live. This is referred to as background 
radiation. This research gives your body the equivalent of about 4 years of 
background radiation. The scans you will have if you take part in this study involve 
exposure to radiation. The additional amount of radiation involved is the same 
amount that everyone in the UK receives from natural sources over a period of about 
4 years. In the general population, the chance of anybody getting a fatal cancer 
during their lifetime is roughly 1 in 5. The additional risk associated with the 
radiation in this study is up to approximately 1 in 2300. Taking part in this study will 
therefore increase your chance of getting a fatal cancer from an existing 1 in 5 up to 
at most 1 in 4.99  
During the study, you should let us know if you need to start any new treatments. 
Before each of the PET scans, you should not drink any alcohol for 24 hours. On the 
morning (or afternoon) of the PET scan, you should limit caffeine intake. If you have 
been exposed to radiation in the past year, either from medical investigations, or 
taking part in other research projects, you should not take part in the study. You will 
be given as much time as you need to discuss this with Dr Reeves or one of her 
research team.  
 
What are the possible benefits of taking part? 
There will be no direct benefits to yourself, but the knowledge gained will be put to 
use to inform a wider study that aims to investigate the causes of antipsychotic drug 
sensitivity in older people.  
We do reimburse you for your time with £40 per visit to the unit. We will of course 
provide transport and lunch or soft drinks that you may require. If you do not wish to 
accept payment for yourself, we would ask you to take the money and use it to 
benefit a charity of your choice. We can give you a picture of your PET scan at a 
later date if you would like this. 
 
What Happens When the Study Stops? 
Dr Reeves will not be involved in your treatment at any stage of the study, but will 
be in close contact with the doctor who is prescribing your medication. When the 
final assessment has been carried out, a letter will be sent to your doctor to inform 
him/her that you are no longer involved in the study.  
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What if something goes wrong? 
If you have any problems, concerns, complaints or other questions about the study, 
you should contact Dr Reeves in the first instance. In the unlikely event of 
participants experiencing any serious adverse effects due to participation in the 
study, there are facilities for compensation in place, via the Institute of Psychiatry 
Professional Liability Insurance  
 
Will my taking part in this study be kept confidential? 
We will inform your GP of your participation in the study and may also need to ask 
him or her some questions about your medical history. All information that is 
collected about you during the course of the research will be kept strictly 
confidential. Aside from the possibility of passing on any relevant information to 
your GP, information about you which leaves the hospital will have your name and 
address removed so that you cannot be recognised from it.  
 
What will happen to the results of the research study? 
After the study has been completed, we would anticipate presenting the results and 
conclusions at scientific meetings (within months) and publishing them in a 
scientific journal (within a year). You will not be identified within these. If you wish, 
a copy of any published article or report will be sent to you. 
 
Who is organising and funding the research? 
Guys and St Thomas Charity are funding the project for 2 years.  
 
Who has reviewed the study? 
The committee for Guys and St Thomas Charity have sent the project for external 
review. The study has also been reviewed by the Joint South London and Maudsley 
and the Institute of Psychiatry NHS Research Ethics Committee  
 
Contact for Further Information 
Dr Suzanne Reeves, 
Department of Old Age Psychiatry, PO Box 070 
Institute of Psychiatry, De Crespigny Park 
London SE5 8AF    
 
 020 7848 0548/0550, Fax 020 7848 0632 07947 036 513 (mobile) 
 
Many thanks for your interest in the study, 









The participant should complete the whole of this sheet him or herself. 
 
Place a  in each of the boxes if the statement applies to you: 
 
I have read the Information Sheet       
        
 
I have been given the opportunity to ask questions and 
discuss this study        
 
I have received enough information about the study and satisfactory  
answers to all my questions     
 
I understand that a carer/relative will be asked to provide  
information about me 
 
I agree to disclosure of my medical records to researchers 
 
I understand that I am free to withdraw from 
the study at any time, without having to give a reason for 
withdrawing and without affecting future medical care     
 
I agree to take part in the study 
 
I understand that my doctor will be informed if any of the results     
of the tests carried out as part of the research are important for my 
health  
 





(NAME IN BLOCK 
CAPITALS).............................................................................................…………….. 
 
Investigator’s signature....................................................…Date: .............................. 
 




Please inform my GP that I am taking part in this study         
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7.3 Modified version of the NPI 
 
NPI rated by professional care                        NPI rated by friend/relative  
 
"I am now going to ask you some questions designed to evaluate [subject's] behaviour. 
They can usually be answered 'yes' or 'no'." 
 
A. Delusions 
"Has [subject] had beliefs that you know are not true? For example, insisting that people 
are trying to harm him/her or steal from him/her. Has he/she said that family members 
are not who they say they are or that the house is not their home? I’m not asking about 
mere suspiciousness. I am interested if the patient is convinced that these things are 
happening to him/her."        
  Yes       No  If ‘Yes’ proceed to sub-questions,  
     If ‘No’ proceed to next screening question 
 
         Yes      No 
          
1. Does the patient believe that he/she is in danger - or 
 that others are planning to hurt him/her? 
 
2. Does the patient believe that others are stealing from him/her? 
 
3. Does the patient believe that his/her spouse is having an affair? 
 
4. Does the patient believe that unwelcome guests are 
 living in his/her house? 
 
5. Does the patient believe that his/her spouse or others  
 are not who they claim to be? 
 
6. Does the patient believe that his/her house is not his/her home? 
 
7. Does the patient believe that family members  
 plan to abandon him/her? 
 
8. Does the patient believe that television or magazine  
 figures are actually present in the home?  
 (Does he/she try to talk or interact with them?) 
 
9. Does the patient believe any other  
 unusual things that I haven’t asked about? 
 
 "When were these behaviours at their worst?" 
 
 In the last month / Now as bad as ever   
   1-6 months ago 
   6 months-1 year ago 
   1 year - 3 years ago 
   More than 3 years ago  
  Yes No 
"Do they still occur?" 
“If  no, when did they last  
occur?” (in months) 
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If the screening question is confirmed, determine the frequency and severity of the 
delusions. 
 
"Now I want to find out how often these things {define using the description of the 
behaviour} occur. When they were at their worst, would you say that they occurred less 




 1. Occasionally - less than once per week                                       
 
 2. Often - about once per week 
 
 3. Frequently - several times per week but less than every day 
 
 4. Very frequently - once or more per day 
 
"Now I would like to find out how severe these things are. By severity I mean how 
disabling they are to the patient. When they were at their worst would you say they were 




1. Mild  Delusions present but seem harmless  
  and produce little distress in the patient 
  
2. Moderate  Delusions are distressing and disruptive 
 
3. Marked Delusions are very disruptive and are a major  
  source of behavioural disruption.  
  (If PRN medications are prescribed, their use  
  signals that the delusions are of marked severity.) 
 
If applicable and rated, please enter the score (frequency x severity) 
 
 
"How emotionally distressing do you find this behaviour / did you find this behaviour 
when it was at its worst?" 
 
   0. Not at all…………………………………………… 
 
   1. Minimally………………………………………… 
   
   2. Mildly……………………………………………… 
 
   3. Moderately………………………………………… 
 
   4. Severely……………………………………………. 
 
   5. Very severely or extremely………………………… 
 
 




“Has [subject] had hallucinations such as false visions or voices? Has he/she seemed to 
see, hear or experience things that are not present? By this question we do not mean just 
mistaken beliefs such as stating that someone who has died is still alive, rather we are 
asking if the patient actually has abnormal experiences of sounds or visions" 
 
  Yes       No   If ‘Yes’ proceed to sub-questions,  
      If ‘No’ proceed to next screening question 
 
            Yes         No 
1. Does the patient describe hearing voices  
 or act as if he/she hears voices? 
 
2. Does the patient talk to people who are not there? 
 
3.  Does the patient describe seeing things not seen  
     by others or behave as if he/she is seeing things  
 not seen by others (people, animals, lights, etc.)? 
 
4.   Does the patient report smelling odours not smelled by others? 
 
5.  Does the patient describe feeling things on his/her skin  
 or otherwise appear to be feeling things  
 crawling or touching him/her? 
 
6.   Does the patient describe tastes that are without 
 any known cause? 
 
7.  Does the patient describe any other  
 unusual sensory experiences?  
  
 
"When were these behaviours at their worst?" 
 
 In the last month / Now as bad as ever 
   1-6 months ago 
   6 months-1 year ago 
   1 year - 3 years ago 







  "Do they still occur?" 
“If no, when did they last  
occur?” (in months) 
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If the screening question is confirmed, determine the frequency and severity of the 
hallucinations. 
 
"Now I want to find out how often these things {define using the description of the 
behaviour} occur. When they were at their worst, would you say that they occurred less 




 1. Occasionally - less than once per week 
 
 2. Often - about once per week 
 
 3. Frequently - several times per week but less than every day 
 
 4. Very frequently - once or more per day 
 
"Now I would like to find out how severe these things are. By severity I mean how 
disabling they are to the patient. When they were at their worst would you say they were 




1. Mild  Hallucinations present but seem harmless  
  and produce little distress in the patient 
  
2. Moderate  Hallucinations are distressing and disruptive 
 
3. Marked Hallucinations are very disruptive and are a major  
  source of behavioural disruption.  
  (PRN medications may be prescribed to control them) 
 
If applicable and rated, please enter the score (frequency x severity) 
 
 
"How emotionally distressing do you find this behaviour / did you find this behaviour 
when it was at its worst?" 
 
   0. Not at all…………………………………………… 
 
   1. Minimally………………………………………… 
   
   2. Mildly……………………………………………… 
 
   3. Moderately………………………………………… 
 
   4. Severely……………………………………………. 
 







"Has the patient had periods when he/she refused to co-operate or wouldn’t let people 
help him/her? Has he/she been hard to handle?" 
 
  Yes       No   If ‘Yes’ proceed to sub-questions,  
      If ‘No’ proceed to next screening question 
 
            Yes      No 
 
1.  Does the patient get upset with those trying to 
 care for him/her or resist activities such as bathing  
 or changing clothes? 
 
2.  Is the patient stubborn, having to have things his/her way? 
 
3.  Is the patient uncooperative, resistive to help from others? 
 
4.  Does the patient have any other behaviours  
 that make him hard to handle? 
 
5.  Does the patient shout or curse angrily? 
 
6.  Does the patient slam doors, kick furniture, throw things? 
 
7.  Does the patient attempt to hurt or hit others? 
 
8.  Does the patient have any other aggressive 
 or agitated behaviours?  
 
 
 "When were these behaviours at their worst?" 
 
 In the last month/ Now as bad as ever 
    
   1-6 months ago 
    
   6 months-1 year ago 
    
   1 year - 3 years ago 
    
   More than 3 years ago  
 
Yes No 
"Do they still occur?" 
“If  no, when did they last  
occur?” (in months) 
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If the screening question is confirmed, determine the frequency and severity of the 
agitation/aggression. 
 
"Now I want to find out how often these things {define using the description of the 
behaviour} occur. When they were at their worst, would you say that they occurred less 




 1. Occasionally - less than once per week 
   
 2. Often - about once per week 
 
 3. Frequently - several times per week but less than every day 
 
 4. Very frequently - once or more per day 
 
"Now I would like to find out how severe these things are. By severity I mean how 
disabling they are to the patient. When they were at their worst, would you say they were 




1. Mild  Behaviour is disruptive but can be  
  managed with redirection or reassurance   
 
2. Moderate  Behaviours disruptive and difficult to redirect or control 
 
3. Marked Agitation is very disruptive and a major source  
  of difficulty; there may be a threat of  
  personal harm. Medications are often required 
 
If applicable and rated, please enter the score (frequency x severity) 
 
 
"How emotionally distressing do you find this behaviour / did you find this behaviour 
when it was at its worst?" 
 
   0. Not at all…………………………………………… 
 
   1. Minimally………………………………………… 
   
   2. Mildly……………………………………………… 
 
   3. Moderately………………………………………… 
 
   4. Severely……………………………………………. 
 
   5. Very severely or extremely………………………… 
 




"Has the patient seemed sad or depressed? Has he/she said that he/she felt sad or 
depressed?" 
 
  Yes       No   If ‘Yes’ proceed to sub-questions,  
      If ‘No’ proceed to next screening question 
 
         Yes       No 
1. Does the patient have periods of tearfulness or  
 sobbing that seems to indicate sadness? 
 
2. Does the patient say or act as if he/she is sad or in low spirits? 
 
3. Does the patient put him/herself down or say that  
 he/she feels like a failure? 
 
4. Does the patient say that he/she is a bad person or 
 deserves to be punished? 
 
5. Does the patient seem very discouraged or say  
 that he/she has no future? 
 
6. Does the patient say that he/she is a burden to the family 
 or that the family would be better off without him/her? 
 
7. Does the patient express a wish for death or talk  
 about killing him/herself? 
 
8. Does the patient show any other signs of depression or sadness? 
 
 "When were these behaviours at their worst?" 
 
 In the last month / Now as bad as ever 
    
   1-6 months ago 
    
   6 months-1 year ago 
    
   1 year - 3 years ago 
    
   More than 3 years ago   
Yes No 
"Do they still occur?" 
“If no, when did they last  
occur?” (in months) 
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If the screening question is confirmed, determine the frequency and severity of the 
depression. 
 
"Now I want to find out how often these things {define using the description of the 
behaviour} occur. When they were at their worst, would you say that they occurred less 





 1. Occasionally - less than once per week 
 
 2. Often - about once per week 
 
 3. Frequently - several times per week but less than every day 
 
 4. Very frequently - once or more per day 
 
"Now I would like to find out how severe these things are. By severity I mean how 
disabling they are to the patient. When they were at their worst, would you say they were 




1. Mild  Depression is distressing but usually responds  
  to redirection or reassurance  
 
2. Moderate  Depression is distressing, depressive symptoms  
  are spontaneously voiced by the patient and  
  difficult to alleviate 
 
3. Marked Depression is very distressing and a major source of  
  suffering for the patient 
 
If applicable and rated, please enter the score (frequency x severity) 
 
 
"How emotionally distressing do you find this behaviour / did you find this behaviour 
when it was at its worst?" 
   
   0. Not at all…………………………………………… 
 
   1. Minimally………………………………………… 
   
   2. Mildly……………………………………………… 
 
   3. Moderately………………………………………… 
 
   4. Severely……………………………………………. 
 
   5. Very severely or extremely………………………… 
 
 




"Has the patient been very nervous, worried or frightened for no apparent reason? Has 
he/she seemed very tense or fidgety? Has the patient been afraid to be apart from you?" 
 
  Yes       No   If ‘Yes’ proceed to sub-questions,  
      If ‘No’ proceed to next screening question 
 
                Yes         No 
 
1. Does the patient say that he/she is worried about planned events? 
 
2. Does the patient have periods of feeling shaky, unable  
 to relax, or feeling excessively tense? 
 
3. Does the patient have periods of (or complain of)  
 shortness of breath, gasping, or sighing for  
 no apparent reason other than nervousness? 
 
4. Does the patient complain of butterflies in his/her stomach,  
 or of racing or pounding of the heart in association with  
 nervousness? (Symptoms not explained by ill health). 
 
5. Does the patient avoid certain places or situations  
 that makes him/her more nervous such as riding in the car,  
 meeting with friends, or being in crowds? 
 
6. Does the patient become nervous and upset when  
 separated from you (or his/her caregiver)?  
 (Does he/she cling to you to stop you being separated?) 
 
7. Does the patient show any other signs of anxiety?  
 
 
"When were these behaviours at their worst?" 
 
 In the last month /Now as bad as ever 
    
   1-6 months ago 
    
   6 months-1 year ago 
    
   1 year - 3 years ago 
    
   More than 3 years ago  
Yes No 
"Do they still occur?" 
“If no, when did they last  
occur?” (in months) 
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If the screening question is confirmed, determine the frequency and severity of the anxiety. 
 
"Now I want to find out how often these things {define using the description of the 
behaviour} occur. When they were at their worst would you say that they occurred less 





 1. Occasionally - less than once per week 
 
 2. Often - about once per week 
 
 3. Frequently - several times per week but less than every day 
 
 4. Very frequently - once or more per day 
 
"Now I would like to find out how severe these things are. By severity I mean how 
disabling they are to the patient. When they were at their worst would you say they were 




1. Mild  Anxiety is distressing but usually responds  
  to redirection or reassurance  
 
2. Moderate  Anxiety is distressing, anxiety symptoms  
  are spontaneously voiced by the patient and  
  difficult to alleviate 
 
3. Marked Anxiety is very distressing and a major source of  
  suffering for the patient 
 
If applicable and rated, please enter the score (frequency x severity) 
 
 
"How emotionally distressing do you find this behaviour / did you find this behaviour 
when it was at its worst?" 
 
   0. Not at all…………………………………………… 
 
   1. Minimally………………………………………… 
   
   2. Mildly……………………………………………… 
 
   3. Moderately………………………………………… 
 
   4. Severely……………………………………………. 
 
   5. Very severely or extremely………………………… 
 
 




"Has the patient seemed too cheerful or too happy for no reason? I don’t mean the 
normal happiness that comes from seeing friends, receiving presents or spending time 
with family members. I am asking if the patient has a persistent and abnormally good 
mood or finds humour where others do not." 
 
  Yes       No   If ‘Yes’ proceed to sub-questions,  
      If ‘No’ proceed to next screening question 
 
               Yes        No 
 
1. Does the patient appear to feel too good or to be too 
  happy, different from his/her usual self? 
 
2. Does the patient find humour and laugh at  
 things that others do not find funny? 
 
3. Does the patient seem to have a childish sense of humour 
  with a tendency to giggle or laugh inappropriately  
 (such as when something unfortunate happened to others)? 
 
4. Does the patient tell jokes or make remarks that  
 have little humour for others but seem funny to him/her? 
 
5. Does he/she play childish pranks such as pinching or  
 playing “hide and seek” for the fun of it? 
 
6. Does the patient “talk big” or claim to have more abilities  
 or wealth than is true? 
 
7. Does the patient show any other signs of feeling too  
 good or being too happy? 
 
 "When were these behaviours at their worst?" 
 
 In the last month / Now as bad as ever 
    
   1-6 months ago 
    
   6 months-1 year ago 
    
   1 year - 3 years ago 
    
   More than 3 years ago 
Yes No 
"Do they still occur?" 
“If no, when did they last  
occur?” (in months) 
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If the screening question is confirmed, determine the frequency and severity of the elation / 
euphoria. 
 
"Now I want to find out how often these things {define using the description of the 
behaviour} occur. When they were at their worst, would you say that they occurred less 





 1. Occasionally - less than once per week 
 
 2. Often - about once per week 
 
 3. Frequently - several times per week but less than every day 
 
 4. Very frequently - once or more per day 
 
"Now I would like to find out how severe these things are. By severity I mean how 
disabling they are to the patient. When they were at their worst, would you say they were 




1. Mild  Elation is notable to friends and family  
  but is not disruptive 
  
2. Moderate Elation is notably abnormal 
 
3. Marked Elation is very pronounced, patient 
  is euphoric and finds nearly everything to be humorous 
 
If applicable and rated, please enter the score (frequency x severity) 
 
 
"How emotionally distressing do you find this behaviour / did you find this behaviour 
when it was at its worst?" 
 
   0. Not at all…………………………………………… 
 
   1. Minimally………………………………………… 
   
   2. Mildly……………………………………………… 
 
   3. Moderately………………………………………… 
 
   4. Severely……………………………………………. 
 
   5. Very severely or extremely………………………… 
 
 




"Has the patient lost interest in the world around him/her? Has he/she lost interest in 
doing things or lack motivation for starting new activities? Has he/she been more difficult 




  Yes       No   If ‘Yes’ proceed to sub-questions,  
      If ‘No’ proceed to next screening question 
 
                  Yes      No 
 
1. Does the patient seem less spontaneous and less active than usual? 
 
2. Is the patient less likely to initiate a conversation? 
 
3. Is the patient less affectionate or lacking in emotions when  
 compared to his/her usual self? 
 
4. Does the patient contribute less to household chores? 
 
5. Does the patient seem less interested in the activities and  
 plans of others? 
 
6. Has the patient lost interest in friends and family members? 
 
7. Is the patient less enthusiastic about his/her usual interests? 
 
8. Does the patient show any other signs that he/she  
 doesn’t care about doing new things? 
 
 "When were these behaviours at their worst?" 
 
 In the last month / Now as bad as ever 
    
   1-6 months ago 
    
   6 months-1 year ago 
    
   1 year - 3 years ago 
    
   More than 3 years ago   
Yes No 
"Do they still occur?" 
“If no, when did they last  
occur?” (in months) 
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If the screening question is confirmed, determine the frequency and severity of the 
apathy/indifference. 
 
"Now I want to find out how often these things {define using the description of the 
behaviour} occur. When they were at their worst, would you say that they occurred less 




 1. Occasionally - less than once per week 
 
 2. Often - about once per week 
 
 3. Frequently - several times per week but less than every day 
 
 4. Very frequently - once or more per day 
 
"Now I would like to find out how severe these things are. By severity I mean how 
disabling they are to the patient. When they were at their worst, would you say they were 




1. Mild apathy is notable but produces little interference  
  with daily routines; only mildly different from  
  patient’s usual behaviour; patient responds  
  to suggestions to engage in activities 
 
2. Moderate  apathy is very evident; may be overcome by  
  the caregiver with coaxing and encouragement;  
  responds spontaneously only to powerful events  
  such as visits from close relatives or family members 
 
3. Marked apathy is very evident and usually fails to respond  
  to any encouragement or external events 
 
If applicable and rated, please enter the score (frequency x severity) 
 
"How emotionally distressing do you find this behaviour / did you find this behaviour 
when it was at its worst?" 
   0. Not at all…………………………………………… 
 
   1. Minimally………………………………………… 
   
   2. Mildly……………………………………………… 
 
   3. Moderately………………………………………… 
 
   4. Severely……………………………………………. 
 
   5. Very severely or extremely………………………… 





"Has the patient seemed to act impulsively without thinking? Has he/she said or done 
things that are not usually done or said in public? Has he/she done things that were 
embarrassing to you or others?" 
 
  Yes       No   If ‘Yes’ proceed to sub-questions,  
      If ‘No’ proceed to next screening question 
              
         Yes       No 
 
1. Does the patient act impulsively without appearing to  
 consider the consequences? 
 
2. Does the patient talk to total strangers as if he/she knew them? 
 
3. Does the patient say things to people that are insensitive  
 or hurt their feelings? 
 
4. Does the patient say crude things or make sexual remarks 
 that they would not usually have said? 
 
5. Does the patient talk openly about very personal or  
 private matters not usually discussed in public? 
 
6. Does the patient take liberties or touch or hug others that is  
 out of character for him/her? 
 
7. Does the patient show any other sign of loss of control  
 of his/her impulses? 
 
"When were these behaviours at their worst?" 
 
 In the last month / Now as bad as ever 
    
   1-6 months ago 
    
   6 months-1 year ago 
    
   1 year - 3 years ago 
    
   More than 3 years ago   
Yes No 
"Do they still occur?" 
“If no, when did they last  
occur?” (in months) 
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If the screening question is confirmed, determine the frequency and severity of the 
disinhibition. 
 
"Now I want to find out how often these things {define using the description of the 
behaviour} occur. When they were at their worst, would you say that they occurred less 





 1. Occasionally - less than once per week 
 
 2. Often - about once per week 
 
 3. Frequently - several times per week but less than every day 
 
 4. Very frequently - once or more per day 
 
"Now I would like to find out how severe these things are. By severity I mean how 
disabling they are to the patient. When they were at their worst, would you say they were 




1.  Mild          Disinhibition is notable but usually responds to  
  redirection and guidance 
 
2.  Moderate  Disinhibition is very evident and difficult to  
  overcome by the caregiver 
 
3.  Marked Disinhibition usually fails to respond to any  
  intervention by the caregiver, and is a  
  source of embarrassment or social distress 
 
If applicable and rated, please enter the score (frequency x severity) 
 
"How emotionally distressing do you find this behaviour / did you find this behaviour 
when it was at its worst?" 
   0. Not at all…………………………………………… 
 
   1. Minimally………………………………………… 
   
   2. Mildly……………………………………………… 
 
   3. Moderately………………………………………… 
 
   4. Severely……………………………………………. 
 
   5. Very severely or extremely………………………… 
 




"Has the patient got irritated and easily disturbed? Have his/her moods been very 
changeable? Has he/she been abnormally impatient? We do not mean frustration over 
memory loss or inability to perform usual tasks; we are interested to know if the patient 
has had abnormal irritability, impatience, or rapid emotional changes different from 
his/her usual self." 
 
  Yes       No   If ‘Yes’ proceed to sub-questions,  
      If ‘No’ proceed to next screening question 
 
         Yes      No 
 
1. Does the patient have a bad temper, flying “off the handle”  
 easily over little things? 
 
2. Does the patient rapidly change moods from one to the  
 other, being fine one minute and angry the next? 
 
3. Does the patient have sudden flashes of anger? 
 
4. Is the patient impatient, having trouble coping with  
 delays or waiting for planned activities? 
 
5. Is the patient cranky and irritable? 
 
6. Is the patient argumentative and difficult to get along with? 
 
7. Does the patient show any other signs of irritability? 
 
 
 "When were these behaviours at their worst?" 
 
 In the last month / Now as bad as ever 
    
   1-6 months ago 
    
   6 months-1 year ago 
    
   1 year - 3 years ago 
    
   More than 3 years ago  
Yes No 
"Do they still occur?" 
“If no, when did they last  
occur?” (in months) 
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If the screening question is confirmed, determine the frequency and severity of the 
irritability. 
 
"Now I want to find out how often these things {define using the description of the 
behaviour} occur. When they were at their worst, would you say that they occurred less 





 1. Occasionally - less than once per week 
 
 2. Often - about once per week 
 
 3. Frequently - several times per week but less than every day 
 
 4. Very frequently - once or more per day 
 
"Now I would like to find out how severe these things are. By severity I mean how 
disabling they are to the patient. When they were at their worst would you say they were 




1.  Mild Irritability or lability is notable but usually  
  responds to redirection and guidance 
 
2.  Moderate  Irritability and lability are very evident and  
  difficult to overcome by the caregiver 
 
3.  Marked Irritability and lability are very evident, they usually  
  fail to respond to any intervention by the caregiver and 
  they are a major source of distress 
 
If applicable and rated, please enter the score (frequency x severity) 
 
"How emotionally distressing do you find this behaviour / did you find this behaviour 
when it was at its worst?" 
 
   0. Not at all…………………………………………… 
 
   1. Minimally………………………………………… 
   
   2. Mildly……………………………………………… 
 
   3. Moderately………………………………………… 
 
   4. Severely……………………………………………. 
 
   5. Very severely or extremely………………………… 
 
 
Caregiver distress score 
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J. Aberrant Motor Behaviour 
 
"Has the patient been pacing, doing things over and over such as opening closets or 
drawers, or been repeatedly picking at things or winding string or threads?" 
 
  Yes       No   If ‘Yes’ proceed to sub-questions,  
      If ‘No’ proceed to next screening question 
 
              Yes      No 
 
1. Does the patient pace around the house without 
 apparent purpose? 
 
2. Does the patient rummage around opening and  
 unpacking drawers or closets? 
 
3. Does the patient repeatedly put on and take off clothing? 
 
4. Does the patient have repetitive activities or “habits” 
 that he/she performs over and over? 
 
5. Does the patient engage in repetitive activities such as  
 handling buttons, picking, wrapping string etc.? 
 
6. Does the patient fidget excessively, seem unable to sit still,  
 or bounce his/her feet or tap his/her fingers a lot? 
 
7. Does the patient do any other activities over and over? 
 
 
"When were these behaviours at their worst?" 
 
 In the last month / Now as bad as ever 
    
   1-6 months ago 
    
   6 months-1 year ago 
    
   1 year - 3 years ago 
    
   More than 3 years ago  
Yes No 
"Do they still occur?" 
“If no, when did they last  
occur?” (in months) 
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If the screening question is confirmed, determine the frequency and severity of the motor 
behaviours. 
 
"Now I want to find out how often these things {define using the description of the 
behaviour} occur. When they were at their worst, would you say that they occurred less 





 1. Occasionally - less than once per week 
 
 2. Often - about once per week 
 
 3. Frequently - several times per week but less than every day 
 
 4. Very frequently - once or more per day 
 
"Now I would like to find out how severe these things are. By severity I mean how 
disabling they are to the patient. When they were at their worst, would you say they were 




1. Mild  Abnormal motor activity is notable but produces little 
  interference with daily routines 
 
2. Moderate Abnormal motor activity 
 
3. Marked Abnormal motor activity is very evident, 
  it usually fails to respond to any intervention  
  by the caregiver and is a major source of distress 
 
If applicable and rated, please enter the score (frequency x severity) 
 
"How emotionally distressing do you find this behaviour/ did you find this behaviour 
when it was at its worst?" 
 
   0. Not at all…………………………………………… 
 
   1. Minimally………………………………………… 
   
   2. Mildly……………………………………………… 
 
   3. Moderately………………………………………… 
 
   4. Severely……………………………………………. 
 
   5. Very severely or extremely………………………… 
 
 




"Has the patient had difficulty sleeping (do not count as present if the patient simply gets 
up once or twice per night only to go to the bathroom and falls back asleep immediately)? 
Has he/she been up at night? Has he/she wandered at night, got dressed or disturbed your 
sleep?" 
 
  Yes       No   If ‘Yes’ proceed to sub-questions,  
      If ‘No’ proceed to next screening question 
 
               Yes        No 
1. Does the patient have difficulty falling asleep? 
 
2. Does the patient get up during the night  
 (do not count if the patient gets up once or twice per  
 night only to go to the bathroom and falls back asleep 
 immediately)? 
 
3. Does the patient wander, pace or get involved 
  in inappropriate activities at night? 
 
4. Does the patient awaken you during the night? 
 
5. Does the patient awaken at night, dress, and plan to  
 go out thinking that it is morning and time to start the day? 
 
6. Does the patient awaken too early in the morning 
 (earlier than was his/her habit)? 
 
7. Does the patient sleep excessively during the day? 
 
8. Does the patient have any other night-time  
 behaviours that bother you that we haven’t talked about? 
 
 
 "When were these behaviours at their worst?" 
 
 In the last month / Now as bad as ever 
    
   1-6 months ago 
    
   6 months-1 year ago 
    
   1 year - 3 years ago 
    
   More than 3 years ago  
Yes No 
"Do they still occur?" 
“If no, when did they last  
occur?” (in months) 
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If the screening question is confirmed, determine the frequency and severity of the 
sleeplessness. 
 
"Now I want to find out how often these things {define using the description of the 
behaviour} occur. When they were at their worst would you say that they occurred less 




 1. Occasionally - less than once per week 
 
 2. Often - about once per week 
 
 3. Frequently - several times per week but less than every day 
 
 4. Very frequently - once or more per day 
 
"Now I would like to find out how severe these things are. By severity I mean how 
disabling they are to the patient. When they were at their worst would you say they were 




1.  Mild  Night-time behaviours occur but they are  
  not particularly disruptive 
 
2.  Moderate  Night-time behaviours occur and disturb the patient  
  and the sleep of the caregiver, more than one type of  
  night-time behaviour may be present 
 
3.  Marked Night-time behaviours occur; several types of night-time  
  behaviour may be present; the patient is very distressed 
  during the night and the caregiver’s sleep is markedly disturbed 
 
If applicable and rated, please enter the score (frequency x severity) 
 
"How emotionally distressing do you find this behaviour/ did you find this behaviour 
when it was at its worst?" 
   0. Not at all…………………………………………… 
 
   1. Minimally…………………………………………… 
   
   2. Mildly……………………………………………… 
 
   3. Moderately………………………………………… 
 
   4. Severely……………………………………………. 
 
   5. Very severely or extremely………………………… 
 
Caregiver distress score 
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L. Appetite and Eating Disorders 
 
"Has he/she had any change in appetite, weight or eating habits (count as ‘No applicable’ 
if the patient is incapacitated and has to be fed)? Has there been any change in type of 
food he/she prefers?" 
 
  Yes       No   If ‘Yes’ proceed to sub-questions,  
      If ‘No’ proceed to next screening question 
 
                Yes      No 
 
1. Has he/she had a loss of appetite? 
 
2. Has he/she had an increase in appetite? 
 
3. Has he/she had a loss of weight? 
 
4. Has he/she gained weight? 
 
5. Has he/she had a change in eating behaviour such  
 as putting too much food in his/her mouth at once? 
 
6. Has he/she had a change in the kind of food  
 he/she likes such as eating too many sweets or other  
 specific types of food? 
 
7. Has he/she developed eating behaviours such as  
 eating exactly the same types of food each day or 
 eating the food in exactly the same order? 
 
8. Have there been any other changes in appetite  
 or eating that I haven’t asked about? 
 
"When were these behaviours at their worst?" 
 
 In the last month / Now as bad as ever 
    
   1-6 months ago 
    
   6 months-1 year ago 
    
   1 year - 3 years ago 
    
   More than 3 years ago  
Yes No 
"Do they still occur?" 
“If no, when did they last  
occur?” (in months) 
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If the screening question is confirmed, determine the frequency and severity of the changes 
in eating habits or appetite. 
 
"Now I want to find out how often these things {define using the description of the 
behaviour} occur. When they were at their worst, would you say that they occurred less 




1. Occasionally - less than once per week 
 
2. Often - about once per week 
 
3. Frequently - several times per week but less than every day 
 
4. Very frequently - once or more per day 
 
"Now I would like to find out how severe these things are. By severity I mean how 
disabling they are to the patient. When they were at their worst would you say they were 




1.  Mild  Changes in appetite or eating are present  
  but have not led to changes in weight and are not disturbing 
 
2.  Moderate  Changes in appetite or eating are present and  
  cause minor fluctuations in weight. 
 
3.  Marked Obvious changes in appetite or eating are present  
  and cause fluctuations in weight, are embarrassing or  
  otherwise disturb the patient. 
 
If applicable and rated, please enter the score (frequency x severity) 
 
"How emotionally distressing do you find this behaviour / did you find this behaviour 
when it was at its worst?" 
   0. Not at all…………………………………………… 
 
   1. Minimally………………………………………… 
   
   2. Mildly……………………………………………… 
 
   3. Moderately………………………………………… 
 
   4. Severely……………………………………………. 
 
   5. Very severely or extremely………………………… 
 




7.4 Additional Analysis 




Adjusted mean with constant covariates - age, transformed MMSE and years of education. T = 
Transformed (MMSE = x
4
, Delayed Visual Recall = Log10(x+1), Incomplete Letters = x
2,
) used in 




7.4.2 Statistical Analysis After Removing 6 Subjects Not Experiencing Psychotic 
Symptoms at the Time of Assessment 
Note: 
a
Adjusted mean with constant covariates - age, transformed MMSE and years of education. n = 




Adjusted mean with constant covariates - transformed MMSE and years of education. n = 24 in 
psychotic group as four subjects were unable to complete the task, and n = 34 in non-psychotic group 
as two subjects were unable to complete this task. 
*
Significant main effect at p<0.05.  
Appendix Table 1: Mean and SE Values of Neuropsychological Tests in 
Transformed Scale 































































Appendix Table 2: Motor Speed 
Test Group Mean SE F-ratio P-value ηp
2
 












1.87 0.18 0.03 
Appendix Table 3: Sustained Attention 





Rapid Visual Processing 


















Adjusted mean with constant covariates - transformed MMSE and ears of education. n = 20 in 
psychotic group as eight subjects were unable to complete at least one of the tasks from this cognitive 





Adjusted mean with constant covariates - age, transformed MMSE and years of education. 
t




Appendix Table 4: Executive Function 



































































Hayling total errors 



























Appendix Table 5: Memory   





















0.68 0.64 0.06 
 
Delayed Verbal Recall 





































































Adjusted mean with constant covariates - age, transformed MMSE and years of education. n = 
35 in non-psychotic group as 1 subject from each group was unable to complete at least 1 of the tasks 




Adjusted mean with constant covariates - age, transformed MMSE and years of education. n = 
27 in psychotic group as one subject was unable to complete at least one of the tasks in this domain.
*
 
Significant main effect at p<0.025 as Levene's test was significant (p<0.001) for Incomplete Letters. 
 
t




Appendix Table 6: Language 
Test Group Mean SE F-ratio P-value ηp
2
 
Boston Naming Test 











0.73 0.40 0.01 
Appendix Table 7: Constructional Praxis 





Total Praxis score 












1.24 0.30 0.04 
Clock Drawing Task 














Appendix Table 8: Visuoperceptual Function 





















3.65       0.01
*
        0.21 
Object Decision 












   
Number Location 





























Data transformed to fit normality assumption. 
*
Significant at Bonferroni adjusted alpha level, 
p<0.0125. 
 
7.4.3 ANCOVA to Assess Between-Group Differences in Motor Latency, as 
Measured by the Motor Screening Task From the CANTAB 
Note: 
a
Adjusted mean with constant covariates - age, transformed MMSE and years of education. 
 




Adjusted mean with constant covariates - age, transformed MMSE and years of education. 
Appendix Table 9: Visuoperceptual Function - Posthoc Pairwise Comparisons 











(maximum = 20) 
 
4.16 0.046 0.07 
Number Location 
(maximum = 10) 
 
1.16 0.29 0.02 
Cube Analysis 
(maximum = 10) 
0.10 0.76 0.002 
Appendix Table 10: Motor Latency (MOT) 




















0.02 0.89 <0.001 
Appendix Table 11: VOSP Screening (out of 20) 

























2.70 0.053 0.11 
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7.4.5 ANCOVA to Assess Between-Group Differences on Incomplete Letters Task, with 
VOSP Screening Task as a Covariate 
Note: 
a
Adjusted mean with constant covariates - age, transformed MMSE, years of education and 
VOSP Screening Task. 
*




Significant mean difference at p<0.05. Multiple comparisons corrected for using Fisher’s LSD.  
 
7.4.6 Multicollinearity of variables in Logistic Regression Model 
Appendix Table 14: Multicollinearity of Independent Variables  
Independent variable Age Years of 
Education 
MMSE RVP Incomplete 
Letters 
Age  -0.06 -0.18 -0.14 -0.25 
Years of Education    0.09  0.09  0.07 
MMSE     0.49  0.36 
RVP      0.37 
Incomplete Letters      
Note: Spearman’s rho presented as MMSE and Incomplete Letters violate assumptions for Pearson’s 
correlation. Shaded cells represent values already presented within the table, or where the correlation 
is equal to 1. 
Appendix Table 12: Incomplete Letters Task 























9.95 <0.001* 0.33 
Appendix Table 13: Incomplete Letters Task – Pairwise Comparisons 



















  0.24 
<0.001 










  0.002 
  0.10 
Misidentification Paranoid & 
Misidentification 
-5.73* 1.24 <0.001 
